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ABSTRACT 
 
The implementation of a pharmaceutical care tool to guide community pharmacy 
interventions in osteoporosis 
 
Introduction Osteoporosis is a systematic skeletal disease characterized by low bone density 
resulting in enhanced risk for fractures. Osteoporosis often remains undiagnosed. 
ObjectiveTo test an audit tool for use in evaluation of level of adherence to osteoporosis 
guidelines in three practicesused for application to a database of patient records. To validate a 
potential community pharmacy based service for osteoporosis detection and management. 
SettingPatient records from a general medical practitioner database (GPASS®) in three general 
medical practices; A (n=154), B (n=62)  and C (n=103) sampling .  
Method Retrospective survey with the application of a tool specifically designed for medication 
assessment in this field (19 criteria, each representing a separate guideline recommendation). 
Key findings The testing of the application of the medication assessment tool (MAT) by two 
independent raters showed 99.1% agreement  (Total agreement 15/21 criteria; range (%) 89.6-
100) for applicability, 99.6% agreement  (Total agreement 18/21 criteria; range (%) 99.6-100) 
for yes-results, 100% agreement  (Total agreement 21/21 criteria; range (%) 100-100) for 
justified non-adherence, 99.9% agreement  (Total agreement 19/21 criteria; range (%) 98.5-
100) for unjustified non-adherence. Overall adherence was 60.4% (95% CI 58.1, 62.7; n=3234 
criteria applied in 154 patients) for researcher 1 and 60.7% (95% CI 58.0, 63.4; n=3234 applied 
criteriain 154 patients) for researcher 2 in practice A and 47.1% (95% CI 43.8, 51.2; n=1302 
criteriaapplied in 62 patients) in practice B. Comparison showed adherence was 56.3% (95% CI 
53.4, 58) in  practice A (n= 4536 applied criteriain 216 patients) for researcher 1 and 53.9% 
(95% CI 51.5, 56.3) in  practice A (n= 4536 applied criteriain 216 patients) for researcher 2. The 
tool identified 13/21 (61.9%) of criteria where adherence was <70% in both settings and. The 
tool identified 6/21 (28.6%) criteria where adherence was different between practices.  
Conclusion The tool offers a systematic and reliable audit method using a database search 
facility to enable large scale audit of medication use in osteoporosis. The identification of a 
mean of 16.7% for non-adherences per criterion to clinical guidelines represents a first stage in 
addressing pharmaceutical care issues prior to informed discussion between pharmacist 
prescribing advisor and general medical practitioners. A potential community pharmacy based 
service for detection and management of osteoporosis is considered as useful and feasible. 
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1- INTRODUCTION 
1.1. Osteoporosis 
1.1.1. Definiton and classification 
1.1.1.1. Definition 
Osteoporosis is the most common bone disease in both men and women (Mauck and 
Clarke 2006). The World Health Organisation (WHO) defines osteoporosis as a 
‘disease characterized by low bone mass and structural deterioration of bone tissue, 
leading to bone fragility and an increased susceptibility to fractures’. Osteoporotic 
fractures especially occur at the hip, spine and wrist (WHO 2003). Osteoporosis is a 
systematic skeletal disease; hence fractures can occur at any site of the skeleton 
(SIGN 2003).  
Before 1994, Osteoporosis was diagnosed on the basis of low-impact or fragility 
fractures. In 1994, the WHO established definitions for osteoporosis and osteopenia, 
which represents the pre-stage of osteoporosis(Mauck and Clarke 2006). These 
definitions and categorizations allow an early diagnosis of the disease as well as a 
prediction of fracture risk. Osteoporosis is defined as bone mineral density (BMD) more 
than 2.5 standard deviations below the young normal mean (T-score <-2.5). The T- 
score represents the number of standard deviations by which the patient's BMD differs 
from the mean peak BMD for young normal subjects of the same gender (SIGN 2003). 
BMD is usually measured via dual-energy X-ray absorptiometry (DXA) (Copeland and 
Worsley 2009). 
The following table shows the categorisation of bone mineral density and related 
conditions set up by the World Health organization (Copeland and Worsley 2009): 
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Table 1 WHO bone mineral density scale 
 
1.1.1.2. Classification 
In young human beings the rate of bone formation is bigger than the rate of bone 
resorption (NICE 2008). Peak bone mass is reached between 30 and 40 years of age 
(Copeland and Worsley 2009). By the third decade of life there is a gradual loss of 
bone mass(NICE 2008) since bone remodelling continues, but cannot outweigh the 
damages done to the skeleton by everyday life’s activities (Copeland and Worsley 
2009). Osteoporosis therefore usually represents a disease related with age (NICE 
2008) but can also occur in younger individuals due to impaired development of peak 
bone mass (e.g. due to delayed puberty or undernutrition) or excessive bone loss 
during adulthood (e.g. due to oestrogen deficiency in women, undernutrition, or 
corticosteriod use)(Copeland and Worsley 2009). Osteoporosis cantherefore be 
classified as either primary or secondary osteoporosis (Mauck and Clarke 2006). 
1.1.1.2.1. Primary osteoporosis 
95% of osteoporotic patients, mainly women, are suffering from primary osteoporosis, 
also termed idiopathic, postmenopausal or pre-senile osteoporosis (Siegenthaler et al. 
1992). The main reason in female patients with primary osteoporosis is deficiency in 
production of oestrogens. Oestrogens reduce the effect of parathyroid hormone on 
Category Description T- Score 
Normal A value of BMD within 1 standard deviation of 
the young adult reference mean 
" -1 
Low bone mass 
(osteopenia) 
A value of BMD more than 1 standard deviation 
below the young adult mean, but less than 2.5 
standard deviations below this value 
< -1 and > -2.5 
Osteoporosis A value of BMD 2.5 standard deviations or more 
below the young adult mean 
# - 2.5 
Severe 
osteoporosis  
A value of BMD 2.5 standard deviations or more 
below the young adult mean in the presence of 
one or more fragility fractures 
# - 2.5  
(+ fragility fracture) 
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mobilization of calcium from the skeleton (Hettenkofer 1998). Primary osteoporosis 
occurs as a normal result of bone loss during the aging process in both sexes (Mauck 
and Clarke 2006). Deficiency in sex hormones represents the principal cause for 
primary osteoporosis in both men and women (Copeland and Worsley 2009). 
1.1.1.2.2. Secondary Osteoporosis 
In secondary osteoporosis bone loss is associated with several chronic medical 
conditions, medications and nutritional deficiencies(Mauck and Clarke 2006).These 
conditions and medications represent the actual cause for the development of the 
disease. Decreased calcium and vitamin D levels caused by poor diet and/or 
insufficient exposure to sunlight contribute to the development of osteoporosis 
(Copeland and Worsley 2009; Hettenkofer 1998; Schettler and Greten 1998). 
Endocrine disorders such as hyperthyroidism,diabetes mellitus, Cushing’s syndrome, 
hyperparathyroidism and hypogonadism can attribute to the development of secondary 
osteoporosis (Siegenthaler et al. 1992).Furthermore anorexia nervosa, chronic liver 
disease, renal disease, rheumatoid arthritis, inflammatory bowel disease and certain 
types of cancerrepresent conditions associated with secondary osteoporosis 
(Copeland and Worsley 2009; Schettler and Greten 1998; Siegenthaler et al. 1992; 
SIGN 2003). Some medications such as oral glucocorticoids is a main reason for 
secondary osteoporosis (Schettler and Greten 1998). Oral administration of 7.5 mg 
prednisolone or equivalents for 3 months and more should be accompanied by certain 
measures for prevention of osteoporosis (SIGN 2003). Drugs like phenobarbitone or 
phenytoin induce the production of certain enzymes activating the production of 
metabolites of vitamin D other than the active one (25-OH-vitamin D3) (Schettler and 
Greten 1998). Furthermore immobilization can cause secondary osteoporosis. 4 to 6 
weeks of bed rest have been shown to induce demineralisation of bone of up to 18% 
(Siegenthaler et al. 1992). 
1.1.2. Epidemiology 
The prevalence of osteoporosis increases with age (SIGN 2003). One in three women 
and one in twelve men over the age of 50 are affected by osteoporosis (NHS 2006). 
The disease is particularly common in postmenopausal, white women(NICE 2008; 
SIGN 2003). After the menopause, the prevalence of osteoporosis increases massively 
with age, from approximately 2% at 50 years to more than 25% at 80 years. In women 
aged over 50 years, the lifetime risk to sustain a vertebral fracture is estimated to be 
one in three, and that of hip fracture one in five which is higher than the one in nine risk 
of developing breast cancer (Cummings and Melton 2002; NICE 2008).Patients, who 
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have already sustained a fracture, are at greater risk of subsequent fractures (NICE 
2008). 
In Scotland one in three women over the age of 50 will suffer an osteoporotic fracture. 
Despite the significantly high prevalence in women, osteoporosis also affects men. 
One in twelve men over 50 will suffer an osteoporotic fracture.This makes around 
200,000 women and 40,000 men affected. Approximately 20,000 osteoporotic fractures 
occur annually in Scotland (SIGN 2003). Presumably 70% of all fractures in persons 
aged 45 or over occur as a result of osteoporosis (Cummings and Melton 2002). 
Since the proportion of elderly people among populations worldwide is greatly 
expanding, the number of patients suffering from osteoporosis and/or sustaining 
osteoporotic fractures is predicted to increase (Mauck and Clarke 2006). The sedentary 
lifestyle followed by more and more people nowadays, also contributes to the increase 
in osteoporotic fractures (SIGN 2003). 
Barrett-Connor et al. reported in 2005 that the prevalence of osteoporosis varies 
between different ethnic groups. Studies showed that Afro-American women have 
greater bone mass than white women and are less affected by osteoporosis. On the 
other hand bone mass among Hispanics is more similar to whites. Still the fracture risk 
among whites is higher than among women with Hispanic origins, so the bone mineral 
density does not necessarily correlate with the fracture risk. Furthermore studies were 
conducted showing that fracture risk among Asian women is smaller than among white 
women (Barrett-Connor et al. 2005). 
Besides variation between different ethnic groups, there is also variation among each 
individual ethnic group. Among European countries rates vary more than seven fold 
with an especially high rate in Scandinavia. Similar variations have been shown for the 
USA and Asia. Studies revealed that rates of hip fractures are higher in urban areas 
than in rural areas of the same country, which is mainly attributed to a decrease in 
physical activity (Cummings and Melton 2002). 
1.1.3. Socioeconomic impact 
Osteoporosis represents a major health issue and has enormous societal and 
economical implications(Faulkner 2005).Osteoporosis and osteoporotic fractures are 
associated with high mortality, morbidity and high cost of medical care (Mauck and 
Clarke 2006). Fractures tremendously diminish the quality of living of sufferers 
(Faulkner 2005) since they are associated with chronic pain, reduced mobility, disability 
and increasing degree of dependence (NICE 2008). 10% to 20% of patients who have 
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sustained a hip fracture die within the subsequent six months. 50% of these patients 
will not be able to walk without assistance and 25% will loose the ability to live 
independently (NICE 2008). In Scotland, patients who have sustained a hip fracture 
take up more than 20% of orthopaedic bed days. In the UK, osteoporotic fractures 
cause a cost of 1.7 billion British Pounds annually (SIGN 2003). 
Although there is effective treatment available, osteoporosis still often remains 
undiagnosed until fractures occur. In addition, patients representing osteoporotic 
fractures are often not identified as being osteoporotic and might sustain a subsequent 
fracture (Mauck and Clarke 2006).Mortality, morbidity as well as costs could be 
reduced via identification and appropriate treatment of people who are at high risk of 
osteoporosis (Reginster 2007). 
1.1.4. Bone metabolism 
The human skeleton is capable of repairing the damages caused by daily use on basis 
of the interplay of bone formation and resorption. This balance between formation and 
resorption of bone is termed ‘remodelling’ (Copeland and Worsley 2009). Three types 
of cells are to be found in bone, osteoblasts, osteoclasts and osteocytes (Compston 
2001). Osteoblasts are responsible for the formation and mineralisation of bone, 
osteoclasts for the resorption (Copeland and Worsley 2009). Osteocytes are believed 
to play an important role in the response to mechanical stimuli, initiating the 
appropriate action, formation or resorption (Compston 2001). Osteoblasts are derived 
from pluripotent mesenchymal stem cells, which can also differentiate into e.g. 
adipocytes. The osteoblast phenotype is achieved by the osteoblast stimulating factor 
2 (Osf 2).  
 
Osteoblast differentiation requires further components such as fibroblastic growth 
factors  (FGFs), bone morphogenetic factors (BMPs), glucocorticoids and vitamin D. 
Osteoblasts produce type I collagen, alkaline phosphatase, osteopontin and 
osteocalcin (Aktories et al. 2005). Osteoclasts are derived from haematopoietic 
precursors of monocytes respectively macrophages. Osteoclastic differentiation and 
activation is stimulated via binding of receptor activator of NF!B ligand (RANKL), a 
member of the tumor necrosis factor (TNF) ligand family, to its transmembrane 
receptor RANK expressed by osteocytes (Compston 2001). Osteoprotegerin (OPG), a 
member of the TNF receptor family, represents a soluble receptor for RANKL and 
prevents its binding to and activation of osteoclasts (Aktories et al. 2005). Bone 
modelling takes place during growth, as response to mechanical stimuli or during 
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fracture healing, but the capacity decreases with increasing age. Bone modelling 
consists of both bone formation and resorption, while formation clearly exceeds 
resorption. In bone remodelling on the other hand, amounts of formed and resorbed 
bone are similar and the two processes are coupled, a removal of bone via osteoclast 
activity is followed by subsequent formation via osteoblasts. Remodelling allows 
maintenance of stability of the human skeleton and calcium and phosphate release 
from the latter. Bone remodelling is regulated via several factors including mechanical 
stresses, systemic hormones like sex steroids, parathyroid hormone (PTH), thyroid 
hormones, growth hormone and glucocorticoids.  
 
Locally produced factors like cytokines and growth factors play an important role in 
bone remodelling, Interleukin (IL)-1$ and -1% are stimulators of resorption, as well as 
IL-6. Furthermore TNFs, Epidermal growth factor (EGF), Platelet-derived growth factor 
(PDGF), Fibroblast growth factors (FGFs), Macrophage-colony stimulating factor (M-
CSF) and Granulocyte/macrophage-colony stimulating factor (GM-CSF) are stimulators 
of bone resorption. Among stimulators of bone formation are Insulin-like growth factors 
(IGFs), Transforming growth factor % (TGF-%), Fibroblast growth factors (FGFs) and 
bone morphogenetic proteins (BMPs). Interleukin 4 and Interferon & represent inhibitors 
of bone resorption (Aktories et al. 2005; Compston 2001). In osteoporosis, an increase 
in activation of remodelling units is resulting in an increased resorption rate. This is 
called ‘high bone turnover’ (Compston 2001; Hettenkofer 1998). The second possible 
mechanism underlying osteoporosis is that the amount of bone formed is less than the 
amount resorbed. In many cases both mechanisms coexist in osteoporosis, high burn 
turnover and remodelling imbalance, resulting in bone loss, changes in bone 
architecture and subsequent decrease in bone strength (Compston 2001). 
1.1.5. Symptoms and diagnosis of osteoporosis 
Preclinical osteoporosis is painless and unaccompanied by any symptoms, whereas 
clinically manifest osteoporosis, which is associated with occurrence of fractures 
results in severe pain, mainly of the back. This backache, which is very common in 
osteoporotic patients results from deformations and fractures of vertebral bodies 
(Siegenthaler et al. 1992). Osteoporotic deformations of the vertebra very often result 
in hyperkyphosis, also known as ‘dowager’s hump’, relating to the curvature of the 
thoracic region of the spine (NOS 2009; Schettler and Greten 1998). Another very 
common symptom in patients suffering from osteoporosis is hyperlordosis (inward 
curvature of the spine) leading to the characteristic loss of height in osteoporotic 
The implementation of a pharmaceutical care tool to guide community pharmacy interventions in osteoporosis 
! 7 
patients of up to 20cm (Bitsch 1997; Hettenkofer 1998; Siegenthaler et al. 1992). 
Deformation and fractures of vertebral bodies are associated with acute pain, resulting 
from bleeding, decompensation of statics of the vertebra or compression of nerves. 
Furthermore occurrence of chronic pain is very common in osteoporosis, resulting from 
impaired statics of the vertebra leading to muscle fatigue of the trunk, especially in the 
afternoon and after a period of walking or standing upright (Hettenkofer 1998; 
Siegenthaler et al. 1992). 
Osteoporosis is usually diagnosed via dual- energy X-ray absorptiometry (DXA) which 
represents the goldstandard for the assessment of bone mineral density since it 
provides very accurate and reliable results (Copeland and Worsley 2009). The dose of 
radiation the patient is exposed to is relatively small - approximately 30 micro Sievert 
(micro Sv) which is comparable to the radiation dose of a single transatlantic 
flight.Although the purchase of a scan is high, the costs for the scans are low (SIGN 
2003). As mentioned before, the result given by DXA scan is the T-score. The 
calculation of the T- score is defined as the difference between a measured bone 
density (BMD) and the expected young normal value (YN) divided by the population 
standard deviation (SD): 
T- score = (BMD – YN) / SD (Reginster 2007). 
There is no unit for the T- score since it is a ratio of two numbers with the same 
units(Faulkner 2005).Another value of BMD is the Z-score, which represents the 
number of standard deviations by which the patient's BMD differs from the mean BMD 
for subjects of the same age(SIGN 2003).  
However, there are several other techniques available which serve the purpose of 
measuring BMD.  Among these are radiography, quantitative ultrasound (QUS), 
quantitative computed tomography (QCT) and peripheral methods (SIGN 2003). 
 
Radiography 
Assessment via radiography might be of interest since it is simple to use and 
available. The disadvantage of radiographic images is that the three- dimensional 
micro- architecture of bone is not visible in a two- dimensional image (Kazakia and 
Majumdar 2006). Stillosteoporosis can often be diagnosed via radiographs, 
although with low sensitivity(Kanis 2002). Only massive bone loss can be detected 
by the radiograph (Faulkner 2005). Furthermore interpretation of radiographic is 
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likely to depend on the individual observer(SIGN 2003).Treatment might be started 
unnecessarily while patients who indeed suffer from osteoporosis might be missed. 
Therefore radiography should not be implemented in the assessment o bone 
mineral density(Cummings and Melton 2002).A possible advantage of radiographic 
images is that vertebral deformities that might have remained undiagnosed might 
be discovered on a radiograph(NICE 2008). 
 
Quantitative ultrasound (QUS) 
Most ultrasound systems measure speed of sound (SOS) and broad- band 
ultrasound attenuation (BUA) of the calcaneus. Different systems produce different 
values and are therefore not comparable (Cummings and Melton 2002).Hence QUS 
is not an appropriate technique for diagnosis of osteoporosis(NICE 2008).However 
QUS of the heel can predict the risk of spine and hip fracture(Cummings and 
Melton 2002), so it might be used for the assessment of fracture risk in elderly 
women(NICE 2008). 
 
Quantitative computed tomography (QCT) 
QCT has been widely used to measure BMD, especially in the spine (Cummings 
and Melton 2002). X- rays pass through the object determined for examination 
towards a detector (Faulkner 2005). Source and detector rotate about the object 
and attenuation of X-rays is measured. The important advantage of QCT over 
DEXA and QUS is that it provides three- dimensional spatial resolution (Faulkner 
2005), which allows assessment of true volumetric density (NICE 2008) as well as 
of macro- architecture(Faulkner 2005). This might help to understand the individual 
underlying pathology as well as to monitor the effect of drug therapy (Faulkner 
2005).DXA on the other hand only provides area- adjusted results(NICE 2008). 
Another advantage of QCT is its capability to measure cortical and trabecular bone 
separately(Cummings and Melton 2002).  Trabecular bone is crucial for the stability 
of the vertebra due to its active metabolism and a separate assessment without 
interference caused by cortical bone is valuable in the detection of vertebral loss 
(Faulkner 2005). Furthermore QCT can differentiate between degenerative disease 
of the spine and osteoporosis, via DEXA scan this differentiation is not 
possible(NICE 2008). Disadvantages of QCT in comparison to DEXA are the higher 
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radiation dose, higher costs and the limited availability of equipment(Faulkner 
2005). 
Peripheral Methods 
Peripheral methods are: peripheral quantitative computed tomography (pQCT), 
peripheral DEXA, single- energy x- ray absorptiometry (SXA) and radiographic 
absorptiometry (RA). Advantages of these methods compared to DEXA are the 
lower costs and the portability of the equipment. They are often used as screening 
methods for patients requiring a DEXA scan. (Cummings and Melton 2002) 
1.1.6. Risk factors for osteoporosis 
There are several risk factors that are significantly related to the prevalence of 
osteoporosis (Snelling et al. 2001). Risk factors for the development of osteoporosis 
can be subdivided into modifiable and non- modifiable factors(SIGN 2003). Among 
non-modifiable risk factors are advanced age, female sex, heredity and ethnicity. 
Weight, smoking, alcohol consumption, physical activity and diet represent modifiable 
risk factors whose avoidance could have a positive impact o bone health (Snelling et 
al. 2001). 
1.1.6.1. Non- modifiable risk factors 
1.1.6.1.1. Age 
Since bone mineral density decreases with age, the prevalence of osteoporosis 
increases with advancing age (SIGN 2003). The NHANES III study indicated a two fold 
higher risk for women of the age 60 to 69 and a four fold higher risk for women aged 70 
years or older relative to women in their fifth decade of life (Hirschhorn and Gennari 
2008). 90% of hip fractures occur in women over the age of 50 years suggesting that 
age is a very strong predictor for the prevalence of osteoporosis (Hirschhorn and 
Gennari 2008).  
1.1.6.1.2. Gender 
Women are at higher risk of osteoporosis than men since they have smaller bones and 
therefore a lower total bone mass (SIGN 2003). Furthermore the larger bone size in 
men represents a biomechanical advantage, which results in a lower rate of fragility 
fractures (Compston 2001). In addition, the rapid decrease in oestrogen levels after the 
onset of the menopause further contributes to this increased risk (SIGN 2003). The 
Framingham Osteoporosis Study revealed that the rate of bone loss in women is bigger 
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than in men with an annual rate of 0.86% to 1.21% in women versus 0.04% to 0.96% in 
men (SIGN 2003). Secondary osteoporosis is more common in men with a proportion 
of up to 40% of the cases (SIGN 2003). 
1.1.6.1.3. Heredity and genetics 
A family history of osteoporosis represents an important risk factor for osteoporosis 
(Hirschhorn and Gennari 2008). In patients presenting a family history of osteoporosis, 
kyphosis and low impact fractures, bone mass has been proven to be lower, depending 
on how many family members are affected by osteoporosis (SIGN 2003). Contrarily a 
study conducted by Snelling et al indicated that women whose mothers never suffered 
from osteoporosis are at lower risk to develop osteoporosis. It revealed 40% reduction 
in risk in offspring of mothers who have never been osteoporotic (Snelling et al. 2001).  
Osteoporosis has a strong genetic component (Hirschhorn and Gennari 2008). Genetic 
variations in genes associated with bone mineral density result in different bone 
phenotypes (Styrkarsdottir et al. 2008). Single nucleotide polymorphisms (SNPs) have 
been identified on 5 different loci. For these loci there is strong evidence that they are 
associated with BMD (Styrkarsdottir et al. 2008). Three of them are close to or within 
genes which have previously been shown to play an important role in bone 
homeostasis: the estrogen receptor 1 gene (ESR 1), OPG and the receptor activator of 
nuclear factor !B ligand gene RANKL. ESR 1, OPG and RANKL are crucial regulators 
in bone metabolism (Styrkarsdottir et al. 2008). RANKL, its receptor RANK and OPG 
represent major regulators of osteoclast activity and bone resorption. Consequently 
abnormalities within this system lead to subsequent bone abnormalities. Furthermore a 
decreased oestrogen sensitivity, which might be due to a defect oestrogen receptor, 
can result in disorder in bone homeostasis (Hirschhorn and Gennari 2008). See also 
chapter ‘Bone metabolism’ for OPG and RANKL. 
 
 Styrkarsdottir et al discovered 2 other sites that are strongly associated with bone 
mineral density, on 1p36 close to the zinc finger and BTB domain and on 6p21 near to 
the major histocompatibiltity complex (MHC). It is not possible to predict fracture risk 
via these variations, but knowledge about them provides insight into biochemical 
pathways that result in the development of osteoporosis (Styrkarsdottir et al. 2008). 
Furthermore they represent possible drug targets for the development of treatment and 
prevention strategies (Hirschhorn and Gennari 2008).  
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1.1.6.1.4.Ethnicity 
Ethnic origins serve as a predictor of fracture risk, at least as concerns the comparison 
of white and black (Snelling et al. 2001). White Caucasian women are at highest risk of 
osteoporosis, similarly to white women of Hispanic or Asian origins. Afro- American 
women on the other hand are at a significantly lower risk of developing osteoporosis 
which is most likely to the fact that bone mass is higher among them (Barrett-Connor et 
al. 2005). In Afro- American women skeletal calcium and potassium contents are 
higher and they have been shown to have a higher muscle mass which probably 
further contributes (Snelling et al. 2001). In comparison to white women Afro-American 
women are at a 2.5 fold lower risk of osteoporosis (SIGN 2003).  
1.1.6.2.Modifiable risk factors 
Whereas there can be nothing done about non- modifiable risk factors, engagement in 
behavioural towards modifiable risk factors can have a significant impact on reducing 
the risk of developing osteoporosis or delay the onset of the disease (Snelling et al. 
2001).  
1.1.6.2.1. Weight 
There is strong evidence that low body weight, mainly expressed as low body mass 
index (BMI), is a major risk factor for osteoporosis (SIGN 2003). Excess body weight 
on the other hand apparently represents a protecting factor due to increased skeletal 
loading, which enhances bone maintenance. Furthermore an increase in body fat mass 
induces a subsequently higher oestrogen production. Contrarily low body weight 
significantly increases the risk of developing osteoporosis, which might be due to lower 
calcium levels resulting from dieting as well as to decreased skeletal load. It has to be 
mentioned, that overweight represents a major risk factor for coronary heart disease, 
cancer, diabetes and other chronic conditions and the disadvantages definitely 
outweigh the advantages (Snelling et al. 2001). 
1.1.6.2.2. Smoking 
Smoking represents a further risk factor for osteoporosis since it is associated with a 
greater rate of bone loss. Bone loss due to smoking especially occurs in the hip 
(Kenneth and Klesges 2001). Studies revealed that smoking increases the lifetime risk 
to sustain a hip fracture by about half from estimated 12% to 19% in women aged up to 
85 years and from 22% to 37% to 90 years of age. Of all hip fractures, 1 in eight is 
attributable to smoking (Law and Hackshaw 1997). In vitro tests showed the toxicity of 
nicotine and other components of cigarette smoke on bone cells. Smoking causes a 
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decrease in intestinal calcium absorption and either increases the metabolism of 
oestrogen or decreases production of the latter (Hoidrup et al. 2000). Levels of cortisol 
are raised in smokers, which has been proven to reduce bone mineral density (Law 
and Hackshaw 1997). The prevalence of falls is higher among smokers due to poorer 
balance and physical performance resulting from deleterious effects of smoking on the 
neurovascular and peripheral vascular system (Hoidrup et al. 2000). However, there 
has been no significant effect of tobacco consumption on bone detected in individuals 
younger than 40 years (Kenneth and Klesges 2001).  
 
The deleterious effect of smoking on bone health increases cumulative with age. It has 
been shown that in postmenopausal women who are smoking there is an additional 
bone loss of 0.2% of the average annual bone loss per year. By the age of 80 the 
accumulated additional bone loss will result in a 71% higher risk of sustaining a hip 
fracture. Contrarily to previous beliefs, there appears to be no gender-related 
differences, so male smokers are most likely at the same risk of suffering additional 
bone loss due to smoking as women, and not at higher risk (Law and Hackshaw 1997). 
1.1.6.2.3. Alcohol 
The chronic consumption of alcohol is associated with an increased incidence in 
fractures from falls and delays in fracture healing. The so-called ‘Alcohol induced bone 
disease’ results from a dose-dependent toxic effect of alcohol on osteoblasts since it 
represses osteoblastic differentiation of bone marrow cells. Furthermore alcohol leads 
to impaired fracture healing resulting from an inhibition of cell proliferation in repair 
tissue (Chakkalakal 2005).   
1.1.6.1.4. Physical activity 
Studies have indicated that people who participate regularly in weight bearing exercise 
have a higher bone mass than inactive individuals (Snelling et al. 2001). Weight 
bearing exercise has been shown to effectively slow down or even stop bone loss 
(Korpelainen et al. 2006). Unfortunately this effect might be site- specific, with an 
impact mainly on the hip (Snelling et al. 2001). There is evidence that the incidence of 
fractures related with falls is smaller among people who exercise regularly (Korpelainen 
et al. 2006). Weight bearing exercise represents an effective and appropriate non- 
pharmacological approach to maintaining bone health (Snelling et al. 2001). 
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1.1.6.1.5. Diet 
Decreased calcium and vitamin D levels caused by poor diet or and/or insufficient 
exposure to sunlight contribute to the development of osteoporosis (Copeland and 
Worsley 2009). 
1.1.6.1.6. Reproductive factors 
Reproductive factors play a central role in bone health in both men and women. Sex 
steroids are crucial for bone growth, attainment of peak bone mass and maintenance 
of bone mass. Late menarche and premenopausal amenorrhea resulting from anorexia 
nervosa are associated with low bone mass (Compston 2001; Siegenthaler et al. 
1992). Consequently an early onset of menopause represents a major disadvantage in 
the bone health whereas a late menopause is associated with a higher bone mass 
(Compston 2001; SIGN 2003). Similarly in male individuals, androgen deficiency due to 
hypogonadotropic hypogonadism results in low bone mass (Schettler and Greten 
1998). 
1.1.6.1.7. Diseases and conditions associated with secondary osteoporosis 
Endocrine disorders such as hyperthyroidism,hyperparathyroidism, diabetes mellitus or 
Cushing’s syndromeare associated with secondary osteoporosis (Copeland and 
Worsley 2009; Siegenthaler et al. 1992).As mentioned in the section before, 
amenorrhoea resulting from anorexia nervosa and (mainly male) hypogonadism are a 
main risk factor for secondary osteoporosis (Schettler and Greten 1998; Siegenthaler 
et al. 1992). Furthermore chronic liver disease, renal disease, rheumatoid arthritis, 
inflammatory bowel disease, and certain tumours are associated with secondary 
osteoporosis (Siegenthaler et al. 1992). 
Hyperthyroidism 
Both bone resorption and formation are stimulated by thyroid hormone, but osteoclasts 
are more sensitive to the latter then osteoblasts. Consequently the higher stimulation of 
rate of bone resorption outweighs the stimulation of bone formation (Hettenkofer 1998; 
Siegenthaler et al. 1992). 
Hyperparathyroidism 
High levels of parathyroid hormone activate the mobilization of calcium from the bone, 
which represents the pathological impact of PTH on bone (Schettler and Greten 1998). 
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Diabetes mellitus 
Diabetes mellitus and subsequent development of secondary osteoporosis are very 
common in younger patients treated with insulin (Siegenthaler et al. 1992).  
Cushing’s Syndrome 
Cushing’s syndrome is characterized by high blood levels of cortisole and therefore 
correlates with glucocorticoid-induced osteoporosis (Siegenthaler et al. 1992). 
Chronic liver disease 
Diseases of the parenchyma of the liver can result in impaired 25- hydroxylation of 
vitamin D3, which represents the active metabolite of vitamin D (Schettler and Greten 
1998). 
Chronic kidney disease 
Chronic kidney disease can induce secondary osteoporosis due to impaired renal 
production of 1,25-OH-vitamin D3 and decreased intestinal resorption of calcium and 
subsequent ‘renal hyperparathyroidism’ induced by hypocalcaemia (Schettler and 
Greten 1998). 
Rheumatoid arthritis 
Impaired physical activity, inflammatory processes and intake of steroids represent the 
connection between rheumatoid arthritis and secondary osteoporosis (Hettenkofer 
1998). 
Inflammatory bowel disease 
Crohn’s disease is highly associated with malabsorption, especially of calcium 
(Siegenthaler et al. 1992). 
1.1.6.1.8. Glucocorticoids 
Glucocorticoids are important drugs but unfortunately produce severe adverse effects 
(Tamura et al. 2004). Long-term oral use of these drugs represents the most common 
cause for secondary osteoporosis (Migliaccio et al. 2009). Fractures occur in 30% of 
people taking glucocorticoids on a long- term basis (Reid 2008). A daily oral intake of 
more than 5 mg prednisolone or equivalent increases the fracture risk within the first 
three to six months of treatment (Tamura et al. 2004). Glucocortiocoids cause a 
decrease in bone formation due to apoptosis of osteoblasts and an increase in bone 
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resorption resulting from prolonged lifespan of osteoclasts (Migliaccio et al. 2009). 
Furthermore reductions in intestinal calcium absorption and calcium absorption from 
the renal tubule contribute to bone loss resulting from the destabilised balance 
between bone formation and resorption (Reid 2008). Long- term oral steroid use result 
can in hypogonadism, mainly in men, which further explains the deleterious effects on 
bone health (Reid 2008). High dose inhaled glucocorticoids may also increase the risk 
of developing secondary osteoporosis (Tamura et al. 2004). Therefore patients 
receiving long- term oral and probably also inhaled glucocorticoid therapy should be 
prescribed preventive treatment (Tamura et al. 2004). 
1.1.6.2. Risk assesment 
Osteoporosis remains often undiagnosed until fractures occur (WHO 2003). Studies 
revealed that one in two women is at risk of osteoporosis, but only one in five receives 
assessment of bone mineral density (Law and Shapiro 2005). Information about bone 
mineral density is not sufficient for the estimation of fracture risk. Many patients 
suffering from osteoporosis do not meet the definition respectively criteria for being 
osteoporotic set up in 1994 by the WHO. Therefore it is necessary to include other 
factors in addition to information about BMD. These factors are termed ‘clinical risk 
factors’ and their integration enables the calculation of a 10- year absolute risk or 
probability of fracture. The implementation of clinical risk factors allowed to move away 
from an intervention threshold based BMD to a threshold based on absolute risk of 
fracture (Silverman 2009). 
FRAX®- fracture risk assessment tool 
FRAX® is a WHO tool to predict fracture risk in men and women (Kanis et al. 2008a). It 
represents algorithms to predict age-specific 10-year probability of fracture one the 
basis of clinical risk factors (CRF) with or without measurement of BMD at the femur 
(Kanis et al. 2008b).  FRAX® was published in 2008 and is accessible free of charge 
on the Internet (www.shef.ac.uk/FRAX) (Roux and Thomas 2008). The algorithms are 
based on a series of meta- analyses using the primary data from population-based 
cohorts that have identified several CRFs for fracture (Kanis et al. 2008b).  As 
mentioned before, low bone mineral density does not explain all fractures, even if it is 
strongly related with many of them.  About 40% of women with fractures have normal 
BMD values. In some cases, the reason might be poor sensitivity of BMD 
measurements, but there are other factors, CRFs, contributing to the decrease in bone 
strength (Roux and Thomas 2008). These clinical risk factors are more or less 
independent from BMD (Kanis et al. 2008a). Clinical risk factors are  
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• Body mass index (BMI) 
• A prior history of fracture 
• A parental history of hip fracture 
• Use of oral glucocorticoids 
• Rheumatoid arthritis and other secondary causes of osteoporosis 
• Current smoking 
• Alcohol intake 3 or more units daily (Kanis et al. 2008a) 
Nowadays the combined use of BMD and CRFs is strongly recommended in the 
evaluation of fracture risk. The FRAX® tool is very easy to use. BMD at the femur is 
indicated as e.g. ‘- 2.5’. As mentioned before, the probability of fracture can also be 
obtained without BMD, on the basis of exclusively CRFs. The FRAX® algorithms give 
the 10-year probability of hip fracture and the 10-year probability of a major 
osteoporotic fracture, such as hip, shoulder, forearm or clinically manifest spine 
fracture. FRAX® can only be implemented in countries that have provided 
epidemiological data in order to identify the risk profile. Seven European countries did 
not provide this data. Risk profiles differ among countries (Roux and Thomas 2008).    
The FRAX® tool has two major limitations. First, several risk factors can only be 
indicated as being present or absent, hence there can only be a ‘no’- or ‘yes’- answer 
given. For glucocorticoid use or presence of vertebral fracture, a ‘yes’- or ‘no’- answer 
might not provide sufficient information to assess fracture probability. In glucocorticoid 
therapy, dose and duration significantly influence the fracture risk. In vertebral 
fractures, number, severity and site strongly affect the risk of subsequent fractures. 
Second, only femoral BMD is taken into account by the FRAX® tool. The reason for 
this is, that only BMD in this site was available in all study cohorts that were assessed 
in order to establish the tool (Roux and Thomas 2008). 
However, FRAX® represents a useful tool in the finding of decisions in osteoporosis 
management, if used optimally in the awareness of these limitations mentioned before. 
So far, decisions whether to initiate osteoporosis therapy or not were based on the 
presence or absence of fractures and on a T-Score of # -2.5 SD. As mentioned before, 
40% of women with fractures have normal BMD; so fractures might have been avoided 
by initiating pharmacological osteoporosis treatment, which would not have been 
possible previously to the occurrence of fractures since the prevalence of osteoporosis 
The implementation of a pharmaceutical care tool to guide community pharmacy interventions in osteoporosis 
!17 
would not have been identified in the absence of fractures. It can also be used for 
patient education to highlight how additional risk factors can increase the initial risk. In 
women of the age between 50 and 60 decisions regarding whether to start treatment or 
not is particularly difficult and studies indicated that the fracture probability estimated by 
FRAX® might be lower than the observed fracture risk. In this group, the FRAX® might 
solely be used in patients with low fracture probability in order to convince them that 
treatment is unnecessary. Nevertheless the goal of prediction of fracture probability is 
to enable the decision making whether to start treatment or not. For this purpose, 
studies were conducted in order to establish fracture risk cut-offs or intervention 
thresholds.  
 
The studies have suggested that treatment is cost-effective in patients at any age 
presenting a 10-year risk of major osteoporotic fracture higher than 7%(Roux and 
Thomas 2008). The intervention threshold or cut-off is dependent on age. The 
intervention threshold at the age of 50 is suggested to be a 10-year probability of major 
osteoporotic fracture of 7.5%, rising up to 30% at the age of 80 (see table) (Kanis et al. 
2008b). Besides intervention thresholds, assessment thresholds were established. 
There are two different assessment thresholds, the lower and the higher assessment 
threshold. The lower assessment threshold represents the fracture probability below 
which neither BMD assessment nor treatment is recommended. Above the higher 
assessment threshold treatment could be initiated without a previous assessment of 
bone mineral density. The range between the upper and the lower threshold includes 
cases in which measurement of BMD is indicated (Kanis et al. 2008b). 
Table 2 Intervention threshold 
Age (years) Major fracture Hip fracture 
50 7.5 1.0 
55 10 1.5 
60 12.5 2.4 
65 15 3.6 
70 20 5.6 
75 25 8.4 
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80 30 12 
 
1.1.7. Treatment and prevention of osteoporosis 
1.1.7.1. Non- pharmacological measures to maintain bone health 
1.1.7.1.1. Falls prevention 
Falls, fractures and osteoporosis are closely linked since falls often result in fractures, 
especially in osteoporotic patients (Lowrie 2008). It is estimated that a third to one half 
of people of the age over 65 who live in the community fall every year.  In Glasgow this 
results in 45 000 to 68 000 people falling each year. Many people fall more than once 
and the prevalence of falls increases with age. It is estimated that 12 000 falls occur 
annually among inhabitants of care homes (NHS 2006). The National Institute for 
Clinical Excellence (NICE) has issued a guideline for the assessment and the 
prevention of falls in elderly people. Elderly people who are in contact with healthcare 
professionals should be asked routinely whether they have fallen in the past year as 
well as about frequency, context and characteristics of the fall. Elderly people who 
report a fall or are considered to be at risk of falling should be observed for balance 
and gait deficits and considered to participate in interventions to improve strength and 
balance(NICE 2004). For patients identified as being at risk of falling, multifactorial falls 
risk assessment should be conducted, including  
• assessment of gait, balance, mobility and muscle weakness   
• assessment of osteoporosis risk   
• assessment of the older person’s perceived functional ability and fear relating to 
falling   
• assessment of visual impairment  
• assessment of cognitive impairment and neurological examination   
• assessment of urinary incontinence   
• assessment of home hazards and  
• cardiovascular examination and medication review (NICE 2004) 
Certain medications can increase the risk of falling, especially if a patient takes four or 
more at the same time (polypharmacy) (Lowrie 2008). The drug group mainly 
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associated with an increase in risk of falling are drugs acting on the central nervous 
system like psychotropics such as benzodiazepines, antidepressants and 
antipsychotics (Hartikainen et al. 2007). Antiepileptics and drugs that lower blood 
pressure are also, but only weakly associated with an increase in falls (Hartikainen et 
al. 2007). An increase in risk of falling resulting from certain drugs who are known to 
increase risk of falls and/or polypharmacy might be avoided by the conduction of a 
clinical medication review via e.g. a GP or a pharmacist. Drugs that increase risk of 
falling might be withdrawn or doses reduced (Lowrie 2008). 
1.1.7.1.2. Calcium and vitamin D 
Calcium is a crucial component of the skeleton since the inorganic phase of bone is 
mainly composed of calcium hydroxyapatite (Compston 2001). Vitamin D improves the 
absorption of calcium from the gastrointestinal tract (Copeland and Worsley 2009). It 
can be found in the literature that calcium and vitamin D are regarded as drugs capable 
of reducing bone resorption, so called ‘antiresorptive’ drugs (Reid 2008). However, 
there is no evidence that the supplementation of calcium and vitamin D alone 
represents an efficient preventive measure; therefore they are mentioned apart from 
antiresorptive treatment in this context.  
Supplementation of calcium and vitamin D is recommended in all patients receiving 
‘bone treatment’ (Copeland and Worsley 2009). The daily calcium intake should be 
1000mg, which represents the calcium contained in two slices of cheese and a glass of 
milk. In case of balanced nutritional uptake, supplementation of calcium does not 
appear to be necessary. Supplementation should not exceed a daily dose of 1500 mg. 
Vitamin D deficiency decreases the intestinal calcium intakes as well as muscular 
balance. A daily exposure to sunlight of the face and arms for 30 minutes on a daily 
basis provides a sufficient vitamin D production. Since this might be difficult to be 
achieved in central respectively northern European countries, vitamin D substitution 
might be necessary, especially in people living in nursing homes or housebound 
patients. The daily dosage of vitamin D supplementation should comprise 800 to 2000 
I.U. vitamin D3 (Jehle and Pfeilschifter 2009). 
1.1.7.2. Pharmacological managment of osteoporosis 
Pharmacological treatment of osteoporosis is indicated if a patient’s 10 year- fracture 
probability is exceeding 30% (Jehle and Pfeilschifter 2009). 
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1.1.7.2.1. Antiresorptive treatment 
Antiresorptive agents inhibit bone resorption by osteoclasts (Reid 2008). Potential 
antiresorptive drugs such as bisphosphonates can reduce the risk of vertebral fracture 
by approximately 50% and the risk of non-vertebral fractures by 25% (Li et al. 2009b). 
Although mechanisms of action differ among different antiresorptive drugs, the effect 
on increasing bone strength and decreasing risk of fragility fractures represents a result 
from an increase in bone mineral content and reduction in bone turnover (Miller 2008). 
Antiresorptive drugs are bisphosphonates, estrogen whose supplementation in terms 
of hormone replacement therapy (HRT) has to be mentioned very critically because of 
the risks the latter, selective estrogen receptor modulators (SERMs) like raloxifene and 
calcitonin (Reid 2008). Strontium ranelate as well represents a potential antiresorptive 
drug but will be mentioned separately due to its additional, dual mechanism of action 
(Jehle and Pfeilschifter 2009). 
1.1.7.2.1.1. Bisphosphonates 
Bisphosphonates are first line treatment for both primary and secondary prevention of 
osteoporosis (Copeland and Worsley 2009). Bisphosphonates that are most common 
in use for the management of osteoporosis are alendronate, risedronate, etidronate, 
ibandronate and zoledronic acid (Jehle and Pfeilschifter 2009). It has to be mentioned 
that the bisphosphonates ibandronate and zoledronic acid, which have to be 
administered intravenously, are not explicitly recommended by current guidelines, but 
since they are licensed for the treatment of osteoporosis and recommended by the 
British National Formulary (BNF), they are mentioned in this context (BNF 2009). The 
decision whether to prescribe alendronate, risedronate, etidronate, ibandronate or 
zoledronic acid should be taken according to the guideline-recommended order of 
choice: 1. Alendronate, 2. alternatively risedronate or 3. etidronate (SIGN 2003). The 
‘i.v. bisphospohantes’ ibandronate or zoledronic acid should be considered for use in 
patients who are unable to comply with the instructions for administration for 
bisphosphonates or have severe gastrointestinal side effects which are very common 
in bisphosphonate use and can be avoided by intravenous administration (Li et al. 
2009b; Reid 2008). Furthermore the dosing intervals (once every three months in 
ibandronate and once a year in zoledronic acid) may represent a major advantage for 
patients who are unable to comply with daily or weekly uptake of medication like e.g. 
patients with cognitive impairment (Jehle and Pfeilschifter 2009). 
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Alendronate, risedronate and etidronate are the only drugs that have a license for both 
primary and secondary prevention of glucocorticoid- induced osteoporosis (BNF 2009; 
NICE 2008; SIGN 2003). 
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Table 3 Bisphosphonates in the management of osteoporosis, brand names and dosages 
Agent Brand names  Dosages 
Alendronate Fosamax®, Fosavance® 
(+5600 I.E. vitamin D) 
10 mg daily or 70 mg weekly 
Risedronate Actonel®, Actonel plus® 
(+calcium and vitamin D) 
5 mg daily or 35 mg weekly 
Etidronate Didronel® Administered in a 90 day cycle, 
each cycle consisting of 400 mg 
etidronate daily for 14 days 
followed by 1.25 mg calcium- 
carbonate daily for the remaining 
76 days 
Ibandronate Bonviva® 150 mg p.o. monthly or 3 mg i.v. 
every 3 months 
Zoledronic acid Aclasta® 5 mg i.v. every 12 months 
 
1.1.7.2.1.1.1. Alendronate 
Alendronate is recommended by guidelines for the primary prevention of fragility 
fractures in  
• Women at or over the age of 70 who are diagnosed with osteoporosis and have 
an independent clinical risk factor for fracture (see) or an indicator of low BMD 
(see). In women over the age of 75 who present two or more independent 
clinical risk factors or indicators of low BMD, a DXA scan may not be required if 
it is considered to be infeasible or inappropriate by the clinician. 
• Women at the age of 65 to 69 who are diagnosed with osteoporosis and 
presenting an independent clinical risk factor 
• Postmenopausal women diagnosed with osteoporosis who are younger than 65 
and presenting an independent clinical risk factor and at least one indicator of 
low BMD 
as well as for the secondary prevention of osteoporosis (NICE 2008). 
Alendronate is the only agent that is licensed for primary prevention in men (BNF 2009; 
NICE 2008; SIGN 2003). 
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1.1.7.2.1.1.2. Risedronate and etidronate 
Risedronate and etidronate are recommended as alternative treatment options for 
patients who are unable to comply with the instructions of use for alendronate or have 
a contraindication to alendronate (NICE 2008). 
1.1.7.2.1.1.3. Side effects and administration of bisphosphonates 
Side effects associated with bisphosphonates as well as the complicated instructions 
for use represent major disadvantages of bisphosphonates. Common adverse drug 
caused by bisphosphonates are dyspepsia, abdominal pain, gastritis and oesophagitis 
(Peters et al. 2001). The most severe side effect resulting from bisphosphonate is 
osteonecrosis of the jaw (Lewiecki 2009a). Bisphosponates present a very low 
bioavailabilty. Hence compliance with the instructions of use is very important. These 
instructions include the intake with plain water on an empty stomach after an overnight 
fasting- period at least one hour before the intake of food, liquids or other medications. 
Patients must remain upright for 30 to 60 minutes after intake in order to avoid side 
effects within the oesophagus (Peters et al. 2001; SIGN 2003). This complexity of the 
oral administration of bisphosphonates explains the advantages of the intravenous 
administrable bisphosphonates  ibandronate and zoledronic acid whose three months- 
respectively 12 months- dosing interval clearly are able to improve the quality of living 
in patients (Lewiecki 2009a). 
 
1.1.7.2.1.1.4 Mechanism of action of bisphosphonates 
All bisposphonates mentioned before are nitrogenous bisphosphonates, meaning that 
they contain nitrogen. They influence bone metabolism via binding and blocking the 
enzyme farnesyl diphosphat synthase (FPPS) in the HMG-CoA reductase pathway, 
which is also known as the mevalonate pathway. Disruption of the mevalonate pathway 
at the level of FPPS prevents the production of two metabolites, farnesol and 
geranylgeraniol, which are crucial for the connection of some small proteins to the cell 
membrane, a process termed ‘prenylation’. The inhibition of protein prenylation via 
bisphosponates particularly affects proteins in osteoclasts that play a central role in 
osteoclastogenis, cell survival and cytoskelelet dynamics (Aktories et al. 2005). This 
mechanism underlies the inhibition of bone resorption promoted by bisphosphonates 
(Reid 2008).  
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1.1.7.2.1.2. Selective Estrogen Receptor Modulators (SERMS): Raloxifene 
Raloxifene is a selective estrogen receptor modulator (SERM) and is recommended as 
a treatment option for the primary and secondary prevention of osteoporosis in 
postmenopausal women (NICE 2008). Raloxifene has been shown to reduce the risk of 
vertebral fracture by 30 to 50%, but there is no evidence that it reduces the risk of hip- 
or other non-vertebral fractures (Lewiecki 2009a). Raloxifene provides the beneficial 
effects of estrogen on bone, but without the negative proliferative effects of oestrogen 
on breast and endometrium(Rey et al. 2009). Among these beneficial effects of 
estrogens are an increased DNA synthesis and proliferation of osteoblasts and bone 
matrix protein production. Furthermore oestrogen represses the number and activity of 
osteoclasts (Compston 2001). A disadvantage of raloxifene is the increased risk of 
thromboembolic events (Sontag et al. 2009). Hence raloxifene is not indicated in 
women with previous or recent thromboembolic events, in women who are at risk for 
stroke. Furthermore it is contraindicated in pregnant women. Common side effects are 
leg cramps and hot flashes. Due to the increase in thromboembolic events raloxifene 
represents a second line agent, which should only be prescribed in patients who are 
not or poorly tolerating first line therapy (Lewiecki 2009a). Recent studies have 
indicated that cessation of raloxifene therapy results in accelerated bone loss. Bone 
loss following cessation of raloxifene therapy at 96 weeks was greater than in the 
control group. The beneficial effect on bone metabolism of 96 weeks of raloxifene was 
lost 6 months after cessation of treatment(Naylor et al. 2009). 
1.1.7.2.1.3. Calcitonin 
Calcitonin is a naturally occurring polypeptide hormone playing a central role in the 
calcium and bone metabolism (Blahos 2007). Like other antiresorptive drugs it 
performs its effect on bone health via decreasing bone resorption resulting in an 
increase in bone mineral density and bone strength (Karsdal et al. 2008). Contrarily to 
other antiresorptive agents calcitonin shows an additional analgetic effect on bone pain 
(Blahos 2007). Therefore it can be used to lower pain associated with fractures 
(Morgan and Kitchin 2008). It appears to target the most active osteoclasts, but unlike 
other antiresorptive drugs it does not reduce the number of osteoclasts. Calcitonin is 
available for nasal and subcutaneous application (Karsdal et al. 2008). The usual dose 
regimen is 200 IU intranasally per day. This dose evidently reduces the incidence of 
vertebral fractures, but the effect seems to be independent from the dose administered: 
neither 100 nor 400 IU were associated with a change of incidence of fractures (SIGN 
2003). The PROOF- study (Prevent Recurrent of Osteoporotic Fractures) revealed a 
reduction of 36% in the relative risk of sustaining a new fracture (Blahos 2007). 
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However, calcitonin has not been shown to reduce the incidence of non- vertebral 
fractures (SIGN 2003). Recently there have been attempts to find an optimal oral 
formulation (Karsdal et al. 2008). Calcitonin is licensed for the secondary prevention of 
osteoporotic fractures in both men and women (BNF 2009; NICE 2008; SIGN 2003). 
Reported nasal side effects of calcitonin have been found to occur only locally and to 
be transient and mild (Chatziavramidis et al. 2008). 
1.1.7.2.1.4. Strontium ranelate 
Strontium ranelate represents an exceptional position since it provides a dual effect of 
both reducing bone resorption and increasing bone formation (Jehle and Pfeilschifter 
2009). It evidently provides efficacy in reducing vertebral, non- vertebral and hip 
fracture (Li et al. 2009a). Strontium ranelate is licensed for the treatment of 
osteoporosis in postemenopausal women to reduce the risk of vertebral and hip 
fracture (NICE 2008). It has a marketing authorisation for both primary and secondary 
prevention in women, but not for men and not for the treatment of glucocorticoid 
induced osteoporosis (NICE 2008; SIGN 2003). It is prescribed in patients who can not 
tolerate or have a contraindication to alendronate and either risedronate or etidronate 
(NICE 2008). The mechanism of action underlying the effects promoted by strontium 
ranelate consists on the synthesis of strontium-calcium-hydroxyapatite via strontium 
substitution on the calcium site in hydroxyapatite (Li et al. 2009a). Strontium ralenate is 
available as Protelos® 2g sachets which is administered as a suspension in water 
(NICE 2008). Common side effects are nausea and diarrhoea (Lewiecki 2009a). 
1.1.7.2.2. Anabolics 
1.1.7.2.2.1. Teriparatide 
‘Teriparatide’ is the term for the polypeptide sequence 1 to 34 in human recombinant 
parathyroid hormone. Administered subcutaneously on a daily basis it stimulates bone 
formation. Teriparatide is the only agent not showing antiresorptive activity but 
solemnly anabolic effect on bone (Lewiecki 2009a). Therefore it represents a separate 
category, namely the one of ‘Anabolics’. The effect wanes with continued application. 
However the beneficial effect on bone strength was shown for all sites of the skeleton 
and to continue up to 30 months. Hence there could be strategies implemented which 
combine the use of teriparatide followed by an antiresorptive drug (Blahos 2007). Long- 
term treatment with teriparatide, meaning more than two years, is not recommended 
since its safety has not yet been proven beyond this point (Morgan and Kitchin 2008). 
Teriparatide is only prescribed in very few cases due to its high costs and the special 
requirements that have to be met in order to justify its prescription (NICE 2008). 
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Teriparatide is recommended as an alternative treatment option for the secondary 
prevention of osteoporotic fragility fractures in those postmenopausal women who  
- are unable to take alendronate and either risedronate or etidronate, or have a 
contraindication to or are intolerant ofalendronate and either risedronate or 
etidronate  
- have a contraindication to, or are intolerant of strontium ranelate 
- have had an unsatisfactory response to treatment with alendronate, 
risedronate or etidronate and 
are 65 years or older and have a T-score of –4.0 SD or below, or a T-
score of –3.5 SD or below plus more than two fractures, or who are 
aged 55–64 years and have a T-score of –4 SD or below plus more than 
two fractures(SIGN 2003). 
Furthermore teriparatide is licensed for the secondary prevention of osteoporosis in 
men (BNF 2009; NICE 2008; SIGN 2003).  
1.1.7.2.3. Hormone replacement therapy (HRT) 
Oestrogen monotherapy or combined estrogen/progesterone therapy was shown to 
efficiently reduce risk of hip, vertebral and other fractures in postmenopausal women 
(Lewiecki 2009a). Due to the risks of hormone replacement therapy, it should only be 
implemented very critically (NICE 2008). Oestrogen substitution increases the risk for 
stroke, thromboembolic events and breast cancer. The FDA recommends the use of 
HRT only in women at high risk of osteoporosis for whom non-oestrogen medications 
are considered to be inappropriate (Lewiecki 2009a). 
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1.2. Pharmaceutical care 
Pharmaceutical care is defined as the responsible provision of drug therapy for the 
purpose of achieving definite outcomes that improve a patient’s quality of life (Hepler 
and Strand 1990). These outcomes are:  
• cure of a disease 
• elimination or reduction of a patient’s symptomatology 
• arresting or slowing of a disease process 
• arresting a disease or symptomatology (Hepler and Strand 1990) 
Pharmaceutical care is described as a ‘patient-centred practice in which the practitioner 
assumes responsibility for a patient’s need’ (Cipolle et al. 2004). 
By the beginning of the 20th century, the pharmacist’s role mainly consisted on 
preparing and selling medicinal drugs, a service that was gradually taken over by the 
pharmaceutical industry. The profession was reduced to the distribution of drugs. By 
the mid 60’s, drugs of higher complexity emerged. Drug-to-drug interactions and 
adverse drug reactions brought up the needs for clinical pharmacists whose 
appropriate knowledge and skills enabled the assurance of optimally safe and efficient 
drug use. In 1987 the United States Food and Drug Administration (FDA) reported 
12,000 deaths and 15,000 hospital admissions due to adverse reactions in prescribed 
drugs. This number is estimated to be only 10% of the actual number of cases (Strand 
et al. 1991). The need for pharmaceutical care results from multiple practitioners 
prescribing for one patient and a large number of drugs and related information 
available for the patient (Cipolle et al. 2004). 
Cipolle et al define key concepts of pharmaceutical care as optimizing a patients drug 
therapy by using drug therapy appropriately for each medical condition, using the most 
effective and safest drug, reassuring that the patient is willing and able to take a 
medications as intended to and identifying as well as resolving drug related problems. 
Pharmaceutical care can be applied in all settings, community pharmacy, hospital, long 
term care and clinic for all kinds of patients with all kinds of diseases and all kinds of 
drug therapy (Cipolle et al. 2004).  
Cipolle et al described the stages of a patient care process to be: 
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• assessment of the patient: patient data (demographic information, medication 
experience) ,disease data (current medical condition, medical history, nutritional 
status) as well as drug data (current medications, past medications, allergies, 
alerts) are assessed in order to understand a patient’s medical problems to 
make decisions regarding therapy with him or her 
• care plan development: to negotiate and agree upon endpoints and timeframe 
for pharmacotherapies, to establish goals. The appropriate therapeutic 
intervention has to be selected by considering alternative treatment options, 
selecting patient-specific drug therapy, taking into account non-drug 
interventions and educating the patient. 
• follow up evaluation: To evaluate effectiveness of pharmacotherapy and safety 
of the latter, to determine a patient’s compliance. To judge the clinical condition 
of a patient while being treated and to identify new drug related problems and 
their cause. To provide continous care.(Cipolle et al. 2004) 
Nevertheless several barriers for the implementation of pharmaceutical care exist 
which vary between different countries and include education, skills, resources and 
environment. Though, different studies indicate the value of the provision of 
pharmaceutical care in patients with diabetes, asthma, hypertension, chronic pain, 
psychiatric disorders as well as in polymedicated patients (Berenguer et al. 2004).   
As mentioned before, provision of patient-specific drug therapy as well as development 
and implementation of plans of care designed to provide the highest benefit for the 
patient are crucial aspects of pharmaceutical care (Strand et al. 1991). Nonetheless 
there are other aspects. The major link between pharmaceutical care and osteoporosis 
represents the need for increased screening and awareness of the risk of osteoporosis 
in order to prevent fractures and related mortality, morbidity and costs. Awareness 
programmes performed by pharmacists in the community setting can engage more 
people to refer themselves for a DXA scan and diagnosis. Pharmaceutical care in the 
field of osteoporosis consists on screening patients to identify those who are at high 
risk of osteoporosis and create awareness among patients. Furthermore the provision 
of relevant recommendations concerning lifestyle modifications and support with drug 
compliance are crucial aspects in the pharmaceutical care of osteoporosis (Law and 
Shapiro 2005). In Scotland there are strategies to prevent people from falling and 
sustaining fractures performed by pharmacists (Lowrie 2008). All these aspects 
represent pharmaceutical care. 
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1.2.1. A model of care for the management of osteoporosis 
A model of care for osteoporosis was designed by Anton Luf in 2009 to enable a better 
detection and management of osteoporosis. Within this potential service the community 
pharmacy plays a central role. Men above the age of 50 and postmenopausal women 
presenting a prescription for chronic medication in a community pharmacy are invited 
to a screening process consisting of a questionnaire. The questionnaire includes age, 
weight, height, fractures resulting from mild falls, parental history of hip fracture, 
smoking status and alcohol intake. An entry in the patient’s Pharmacy Medication 
Record (PMR) is made in order to document the patient has been recruited. Besides 
the questionnaire a questionnaire for the pharmacist exists. The pharmacist completes 
the questionnaire via accessing patient data from the PCR and asking the patient 
directly. The pharmacist questionnaire consists of questions like gender, diagnosis of 
osteoporosis, rheumatoid arthritis and diabetes mellitus type 1.  
 
Patients who have a reported diagnosis of osteoporosis are recordedfor evaluation 
using GPASS data. For patients without a recorded diagnosis of osteoporosis the risk 
of osteoporosis is interpreted. 10 year fracture probability is calculated by applying 
patient information retrieved from both questionnaires to the FRAX® tool. The action 
required by the FRAX® is identified and the patient is informed during his or her next 
visit. Patients with a fracture probability in the amber or red zone (this means their 
fracture probability exceeds the assessment threshold) are referred to the GP for a 
DEXA scan. Patients in the green zone (which means that their fracture risk is below 
the assessment threshold) are verified to be at low risk. Patients with a recorded 
diagnosis of osteoporosis, rheumatoid arthritis or diabetes mellitus type 1 are verified 
as candidates for MAT-assessment via GPASS®. In patients referred for BMD 
measurement a DXA scan at least at two specific sites is performed. Osteoporotic and 
osteopenic patients are identified by using WHO T-Score thresholds. MATosteo is 
applied to calculate applicability and adherence to guideline recommendation. Audit 
findings are used to identify care issues for follow-up with the GP. Specific treatment 
decisions for the individual patient are made according to clinical guidance and a 
treatment plan is created.  
 
The implementation of a pharmaceutical care tool to guide community pharmacy interventions in osteoporosis 
!30 
Both osteoporotic/osteopenic patients as well as patients with normal bone mass are 
given specific advice concerning regular low impact weight bearing exercise, high 
intensity strength training, smoking cessation, reduction of alcohol consumption to less 
than 10 units/week and calcium rich diet with an aimed intake of more than 1000 
mg/day in order to prevent (further) bone loss. During a follow-up process the patient’s 
understanding of prevention advice and treatment administration instructions is 
checked, the patient is informed about possible treatment changes agreed on with the 
GP after applying the MAT and possible clinical risk factors like e.g. falls can be 
identified (Luf 2009). 
1.3. Clinical guidelines 
Clinical guidelines represent the view of the institute establishing them and are based 
on the available evidence. Healthcare professionals are expected to fully follow the 
guidelines although decisions have to be made according to the individual 
circumstances in individual patients (NICE 2008).  
In the UK, two clinical guidelines provide recommendations for the management of 
osteoporosis in practice:  
• Scottish Intercollegiate Guidelines Network (SIGN) Guideline 71: Management 
of Osteoporosis (2003) and  
• National Institute for Health and Clinical Excellence (NICE) Technology 
Appraisal Guidance 160 (Alendronate, etidronate, risedronate, raloxifene and 
strontium ranelate for the primary prevention of osteoporotic fragility fractures in 
postmenopausal women) and 161 (Alendronate, etidronate, risedronate, 
raloxifene, strontium ranelate and teriparatide for the secondary prevention of 
osteoporotic fragility fractures in postmenopausal women) 
Both deal with the management of osteoporosis and the timely identification of 
osteoporotic patients and the prevention of osteoporotic fractures in particular (NICE 
2008; SIGN 2003). Treatment recommendations are based on meta- analyses, 
systematic reviews of randomised controlled trials (RCTs), case control and cohort 
studies, case reports and expert opinions. The level of evidence is categorised into 
eight different levels, depending on the quality of the source the evidence is based of 
(e.g. evidence drawn from reviews with high risk of bias is less reliable than evidence 
from reviews with low risk of bias).  Grade of recommendation ranks from A to D, 
referring to the strength of evidence on which the recommendation is based (SIGN 
2003) 
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1.4. Clinical audit and medication assessment tool (MAT) 
NICE defines a clinical audit as a ‘quality improvement process that seeks to improve 
patient care and outcomes’. During the process of a clinical audit, a systematic review 
of care is conducted.  An assessment whether explicit standards are met or not is 
conducted.  These standards are based on the best available evidence. In case the 
standard is not met, the reason for this non- adherence has to be identified and change 
has to be implemented. An agreement on change should result in the establishment of 
an action plan. The audit should be re-conducted in the future In order to sustain 
improvement (NICE 2002) 
A medication assessment tool enables the researcher to conduct an assessment of 
quality of medicines use. In other words, it represents a systematic approach to 
measure quality of prescribing. The MAT is comprised of a certain number of criteria; 
each criterion is based on an evidence based guideline recommendation. Clinical 
guidelines are nowadays of increasing importance in the delivery of healthcare. The 
identification of low or intermediate adherence to guideline recommendation can be 
used as a systematic process to address pharmaceutical care issues in case 
discussions with prescribers(McAnaw et al. 2003). 
In 2007-08, Ms Aisha Al- Harthi, MSc in Clinical Pharmacy student in the University of 
Strathclyde, developed the first draft of a MAT for osteoporosis (MATosteo) comprising 
of 20 criteria. In 2008, Eva Past further developed the MAT resulting in 23 criteria (Past 
2008). Johanna Schlais modified the MAT in 2008. It was then comprised of 26 criteria 
(Schlais 2008). In 2009, Anton Luf adapted the MAT to current guideline 
recommendations, reducing the number of criteria to 21. The current MATosteo, 
referred to as ‘final tool’ was further developed by the research group (see appendix 3) 
and consists of 19 criteria. 
1.5. GPASS® and READ codes 
GPASS®, the ‘General Practice Administration System for Scotland’ is a software 
programme to manage, store and retrieve patient records. It is widely used in Scotland, 
approximately 80% of Scottish GPs are currently using GPASS®. This IT-system 
allows to register patients electronically as well as to refer patients to hospitals 
electronically. GPASS® is liked to laboratories, so laboratory results are received 
electronically by the GP. Furthermore electronic transfer of prescriptions to pharmacies 
is emerging. GPASS® puts a barcode on each prescription which is scanned by the 
pharmacist and stored electronically in the pharmacy (NHSScotland 2009). 
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READ codes represent clinical terms. Clinical terms are categorised in topics such as 
‘signs and symptoms’, ‘treatment and therapies’, ‘investigations’, ‘occupations’, 
‘diagnosis’, ‘drugs’ and ‘appliances’. Each clinical term is encoded by a unique READ 
code. READ codes are intended for use by healthcare professionals for clinical 
application and allow recorded material to be stored and analysed for purposes of audit 
and statistics (NHSUK 2009). Patient data such as diagnoses, drugs etc is stored in the 
form of READ codes in the GPASS® software system (NHSScotland 2009). 
1.6. Microsoft Access 
Microsoft Access® is a database to store and retrieve data. The user can create e.g. 
tables (enables to store the information in rows and columns) and queries (enables to 
store information in questions). Data can be stored, manipulated and analysed in an 
easy way(Harkin et al. 1999). 
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2- AIMS AND OBJECTIVES 
2.1. Aims 
The aims of this project wereto 
• demonstrate the use of a medication assessment tool for osteoporosis 
(MATOsteo) in the evaluation of the level of adherence to osteoporosis 
guidelines.  
• demonstrate inter-rater reliability of the tool  
• assess the value of a fracture risk evaluation service provided by community 
pharmacists 
2.2. Objectives 
• To undertake a literature review of the epidemiology of osteoporosis and 
measures taken by public health experts in order to address the disease.  
• Revise a MATOsteo (originally designed by previous researchers) and redesign 
database protocols. Test the protocols on a GPASS® database and evaluate 
inter-rater reliability. 
• Test the sensitivity of the MATOsteo in a comparison of patient samples drawn 
from two clinical settings and further revise the tool as necessary.  
• Test on a larger scale audit the revised MATOsteo. and compare results with 
those of another student. 
• Validate a potential service by which community pharmacists might contribute to 
osteoporosis detection and management. Propose potential starting points for 
community pharmacists to get involved in osteoporosis detection and 
management. 
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3- STUDY DESIGN 
The study is a retrospective survey including the application of a tool designed for 
medication assessment in the field of osteoporosis. 
3.1.  Subjects and Settings: 
3.1.1.  Subjects 
3.1.1.1. Patients 
Data of two different samples of patients was extracted from GPASS®. The first 
sample of patients comprised patients from two general practitioner practices in 
Clydebank and Paisley previously drawn from GPASS® during an earlier project to 
design the MATOsteo. Data of a second sample of patients was extracted from 
GPASS®, patients were recruited from a third practice, a GP practice in 
Springburn.Inclusion criteria for patients for whom specific guideline criteria are 
applicable were 
• Patients alive who are registered with the GP practice on date 
• Patients who are diagnosed with osteoporosis or osteopenia 
3.1.1.2. Interviewees 
Interviews were conducted with interviewees drawn from community pharmacy, 
general practice medicine, fracture risk clinics and public health specialists. 
3.1.2. Settings 
Settings were GP practices that offered permission for the audit. The patients should 
be situated in general medical practice within Community Health Partnerships in 
Renfrewshire and/or Greater Glasgow. 
Interviews were conducted with interviewees who have been nominated to participate 
and accepted the invitation, including health care professionals in Glasgow and Malta. 
3.1.3. Study site 
The project was conducted at the University of Strathclyde, Glasgow, UK. 
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3.1.4. Investigator 
The investigator was a diploma student at the University of Vienna (Austria) and a 
visiting scholar at the University of Strathclyde, UK.  
3.1.5. Supervision 
Prof Stephen A Hudson, Professor of Pharmaceutical Care and Dr Julienne Johnson, 
lecturer in Pharmacy Practice, within the Pharmaceutical Care Health Service Unit at 
the University of Strathclyde, Glasgow, and Prof Oskar Hoffmann from the Department 
of Pharmacology and Toxicology, University of Vienna, supervised this project. The 
research group referred to in this project included the supervisors, the investigator and 
another student. 
3.1.6. Collaborators 
Collaborators were Mr Ian Towle, Senior Teaching Fellow within the Pharmaceutical 
Care Health Service Unit at the University of Strathclyde who enabled the data 
extraction from site C. Mrs Susan McKellar, research assistant, was involved in the 
data analysis. 
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4- METHODS 
4.1. Literature research 
At first, a literature research was conducted in order to identify current evidence- based 
recommendations for the treatment and management of osteoporosis. The investigator 
mainly focussed on the guidelines published by the Scottish Intercollegiate Guidelines 
Network (SIGN) since they represent the most relevant information source for 
Scotland. Furthermore the National Institute for Clinical Excellence (NICE) has 
provided a technological appraisal including guidance both for primary and secondary 
prevention of osteoporosis. Both of them have also been taken into account. They are 
valid for the whole of the United Kingdom. 
In addition, the database MEDLINE was consulted via the search engine PubMed in 
order to gain further background information regarding the need of pharmaceutical care 
in this context. For this purpose, different search keywords were used alone or in 
various combinations. The results given by PubMed were narrowed down by 
specification of the keywords as well as by use of the search function on the journal 
papers homepages. 
4.2. Medication assessment tool- MATosteo 
A medication assessment tool (MAT) for the management of osteoporosis was 
designed by previous researchers.  Originally developed by Aisha Al- Harthi in 2008, 
MATosteo was reviewed by several researchers. Eva Past and Johanna Schlais 
changed the MAT from originally 20 criteria to 28 respectively 26 criteria (Past 2008; 
Schlais 2008). In 2009, Anton Luf reviewed the MATosteo, creating a tool comprised of 
21 criteria. During this project, the research group further revised the MATosteo. The 
number of criteria was reduced to 19 criteria. 
The MAT is a criterion based tool, each criterion representing a certain guideline 
recommendation. Each criterion consists of two parts termed qualifier and standard 
(see example below). The qualifying statement identifies patients who are eligible for 
application of the standard. The standard expresses the action that should be 
implemented in those patients who meet the requirements defined within the qualifier. 
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Example for a MAT- criterion: 
A patient with a diagnosis of disease X…            qualifier 
…should be prescribed the drug Y.                           standard 
 
To each criterion six answer categories were possible (Yes, unjustified non-adherence, 
justified non-adherence, insufficient data on the standard, insufficient data on the 
qualifier and not applicable). After applying the MAT criteria to the data set, two main 
values were calculated: adherence to the requirements set up in the standard and 
applicability to the qualifying statement. Adherence and applicability were calculated by 
using the following formulas:  
Adherence =
Yes!
Yes,No(U),IDS!
'100  
Equation 1 
 
 
Applicability =
Yes,No(U),IDS!
n '100 
Equation 2 
 
(95% confidence intervals; ‘n’ representing the total number of criteria) 
The level of adherence was ranked arbitrarily as follows: 
!70%  High level of adherence  
50-69.9% Intermediate level of adherence 
<50%  Low level of adherence 
 
The following table shows six possible answers to the MAT criteria. 
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Table 4 Six answer-categories to MAT criteria 
Answer Explanation 
Not applicable – NA 
 
The patient does not meet the qualifying statement. 
He/she is not diagnosed with disease X. 
Yes 
 
A certain treatment recommended by the guidelines is 
implemented in eligible patients. The patient with 
disease X receives drug Y. 
No, unjustified – No(U) The action was not implemented. The patient with 
disease X does not receive drug Y and there is no 
explicitly documented reason for the non-prescription. 
No, justified – No(J) 
 
The action was not implemented but the prescriber 
reported an explicit reason (i.e. a justification) for not 
complying with the standard. The patient with disease X 
does not receive drug Y for a justified reason. 
Insufficient data on the qualifier - 
IDS 
 
There is not enough information available whether the 
patient meets the requirements set up in the qualifier. 
The investigator cannot identify if the patient was 
actually diagnosed with disease X. Therefore it cannot 
be ascertained if the standard was implemented 
correctly. 
Insufficient data on the standard – 
IDQ 
There is not enough information available if the action 
was implemented. The investigator cannot identify if 
drug Y was prescribed. 
 
4.3. Data Collection 
In Scotland patients’ data is stored in GPASS®. This software program enables the 
quick accessibility of recorded data.The data is listed in chronological order and can be 
ranked easily according to the information needed like e.g. age, sex, medication, 
READ codes etc. The extracted data was sorted and downloaded into an Access 
database by using Microsoft queries, which have been especially created for GPASS®. 
The inclusion criteria for patients for whom specific guideline criteria were applicable 
were: 
• Patients alive who are registered with the GP practice on date 
• Patients who are diagnosed with osteoporosis or osteopenia 
 
Three GP practices within Greater Glasgow offered permission for the audit. 319 
patients were applicable to a clinical audit of adherence to specific guidelines. Data 
including sex, age, medication, DEXA scans, sustained fractures, alcohol consumption, 
BMI and clinical conditions like chronic kidney disease (CKD), rheumatoid arthritis, 
Morbus Crohn, thrombosis etc and parameters like e.g. GRF were extracted from 
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GPASS® and stored in Microsoft Excel® spreadsheets before being imported to a 
Microsoft Access® database.  
The data collection has caused certain difficulties since many clinical parameters like 
e.g. GFR and T-Scores were not accessible. 
4.4. Data analysis 
The data analysis was performed by using the Microsoft Access® form ‘Query Builder’. 
This form has been designed previously during the course of a different project by 
Tobias Dreischulte. It represents a tool, which enables the investigator to analyze, 
store and retrieve patient data (see section 4.5.). The instructions, how to apply 
Microsoft Access® to the sample of patient data, have been previously designed by 
Johanna Schlais in 2008 in form of so called ’Database protocols’. These database 
protocols enable independent researchers to apply the MAT to various sets of data. 
The use of database protocols guarantees results showing reproducibility not varying 
from researcher to researcher. The database protocols were redesigned and adapted 
to the needs of the ‘Query Builder’, which was applied in this context for the first time. 
In addition further changes were done upon the data base protocol in order to clarify 
and shorten it and a manual how to use the ‘Query Builder’ was created in order to 
ensure reproducibility of results achieved by successive researchers. The newly 
designed database protocols were tested on a GPASS® database. 
Two independent researchers applied the revised MAT to the same set of data in order 
to evaluate inter-rater reliability. Sensitivity of the MAT was tested on three patient 
samples. All examinations were performed in Microsoft Access® and the results stored 
and further calculated in Microsoft Excel®. 
4.5. Query Builder 
As mentioned before, the Query Builder is a Microsoft Access® form which enables the 
researcher to retrieve information whether a single patient or a sample of patients are 
adherent to a certain statement set up in guideline recommendation. Certain specific 
data can be accessed rapidly, but before applying the Query Builder to the dataset, 
appropriate tables containing all the data intended to be assessed have to be created. 
As first step, the appropriate READ codes representing diagnosis, clinical conditions, 
drugs and clinical investigations which were relevant in the context of this project were 
identified and a table in Microsoft Excel®created. The READ codes were drawn from 
the Internet. Due to the existence of subsets of READ codes, so called ‘MAT Data 
items’ were created in order to eliminate the task of scanning the data for all kind of 
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subtypes of READ codes. For each subset of READ Codes, a MAT data item 
summarizing different READ Codes with the same meaning was created. 
 
Table 5 Example for MAT data items 
READ Code Description MAT Data item 
N3305 Drug-induced osteoporosis Osteoporosis 
N330C Osteoporosis localized spine Osteoporosis 
N3318 Osteoporosis + Pathological fracture of 
lumbar vertebrae 
Osteoporosis 
N3319 Osteoporosis + Pathological fracture of 
thoracic vertebrae 
Osteoporosis 
N331A Osteoporosis + Pathological fracture of 
cervical vertebrae 
Osteoporosis 
 
A table containing the patients’ patient keys, READ codes encoding all kinds of patient 
information and the date on which the record was made on GPASS® was created. The 
Query Builder is a very efficient, but sensitive tool and depends largely on consistency 
in terms of nomenclature. For this reason it is necessary to term the created table 
‘Patients: NHS Read codes_QOF and MAT data items_tbl’. The table was created in 
Microsoft Excel®. 
 
Table 6 Examples for: Patients: NHS Read codes_QOF and MAT data items_tbl 
PatientKey ReadCode MAT Data item DateRecorded 
1103.C8746.Patient ZQ021 CHD 24/01/2005 
1105.C8746.Patient 42W.. DM 17/07/2002 
 
The uncommon spelling ‘ReadCode’ without capital letters and a space between the 
two terms results from the sensitivity of the Query Builder concerning changes in 
naming. 
Furthermore the table ‘Patients: Drug History_tbl’ was created in Microsoft Excel® 
containing patientkey, drug name, drug category, preparation, dose and frequency. 
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Table 7 Examples for: ‘Patients: Drug History_tbl’ 
 
PatientKey  
drug_name 
 
drug_category 
 
preparation  
dose 
 
frequency 
 
1035.C8746.Patient 
 
Omeprazole 
 
PPI 
 
CAPS 10MG 
 
1 Cap 
 
In the morning 
 
1033.C8746.Patient 
 
Furosemide 
 
Loop diuretics 
 
TABS 40MG 
 
2 Tabs 
 
In the morning 
 
In the same manner the table ‘Patients: Investigations_tbl’ was created. For each 
subset of values a MAT data item was created. Besides patientkey and data item this 
table is composed of the value and the unit measure of the individual investigation as 
well as of the date at which the investigation had taken place. e.g.: 
Table 8 Examples for table ‘Patients: Investigations_tbl’ 
 
Again the uncommon spelling results from the necessity of adhering to the spelling set 
up in the Query Builder.  
The created tables were imported to Microsoft Access®. 
4.4. Database Protocols 
The database protocols have been designed in order to enable the application of the 
MATosteo to patient data drawn from GPASS®, a software program enabling storage 
and management of patient data. For each MAT criterion a separate database protocol 
exists. The individual database protocols were merged into one entire protocol 
containing the instructions how to apply the 19 criteria of the MAT to an individual 
sample of patients. In a previous project conducted by Johanna Schlais, READ codes 
were used to identify eligible patients who were meeting the qualifier and/or standard. 
Patient data is stored in form of READ codes in the GPASS® system. A patient with a 
diagnosis of osteoporosis would not be recorded as ‘osteoporotic’ or ‘osteoporosis’, but 
PatientKey data_item Value Unit ofMeasure DateRecorded 
1033.C8746.Patient Overweight 34.21 kg/m2 14.06.2005 
1051.C8746.Patient BMI 16.29 kg/m2 07.12.2007 
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with the READ code ‘N330’ encoding osteoporosis. Similarly, READ codes are used to 
encode all kind of other diseases and conditions, drugs that were prescribed in a 
patient as well as investigations conducted. A disadvantage of processing patient via 
the use of READ codes is the existence of subsets of READ codes. As shown in the 
example below, there are 18 different subtypes of READ codes encoding for a DEXA 
scan performed on spine or hip. The research group agreed on merging subsets of 
READ codes and on creating so call ‘MAT data items’ simplifying the database 
protocols.  
In former database protocols, patients who were adherent to the requirements of 
qualifier and/or standard were identified by accessing ‘queries’ within Microsoft 
Access®. Queries had to be built up by using READ codes in order to identify patients 
receiving certain drugs, diagnosed with certain diseases or conditions etc. Using the 
‘Query Builder’ simplified this since it was not necessary anymore to run large number 
of queries as required by previous database protocols. 
 
 
Table 9Database protocol of a MAT criterion designed by J. Schlais 
Criterion 4 
Measurement of the BMD by DEXA scan 
Is performed at least at the two specific sites – namely anteroposterior spine and hip 
Identify patients, who comply with qualifier as follows (Denominator): 
Identify patients with a diagnosis of osteoporosis/osteopenia 
Step 1 Inclusion of osteoporosis  
 READ code [N330.., NyuBC] GPASS sampling 
 
DEXA scan is performed at least the two specific sites (Numerator) 
Step 2 Inclusion of those with measurement of the BMD by DEXA scan – anteroposterior spine and hip 
 Apply a Query using READ code [58F, 66U6, 58EG, 
58EH, 58EC, 58ED, 58EE, 58EF, 58EG, 58EH, 58EI, 
58EJ, 58EL, 58EM, 58EN, 58EK, 58EN, 58EM]  
Access Query, Manually 
 
This criterion deals with the evidence- based recommendation that measurement of 
BMD should be performed at two specific sites, namely spine and hip in order to 
achieve reliable results. It represents a retrospective assessment whether osteoporotic 
or osteopenic patients have been diagnosed according to guideline recommendation. A 
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query was applied for this criterion by using several READ codes expressing various 
methods of BMD- measurement. Individual patients had to be examined manually by 
comparing the dates on which the examinations had been performed in order to find 
out whether the DEXA scan had been performed at both sites.  
 
 
Table 10 Database protocol of the same criterion in the new draft 
Criterion 2 !
Measurement of the BMD by DEXA scan!
Is performed at least at the two specific sites – namely anteroposterior spine and hip!
Step What? How? 
 
Step 1 
 
Identify patients 
with a measured 
BMD by DEXA 
scan measured 
on two specific 
sites 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
• ‘Hip scan’ for criterion 1 
• ‘Lumbar scan’ for criterion 2 
Press ‘view’ 
Create a new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1[1], c2[1], d1, d2 
In ‘SQL view’ change ‘and’ to ‘or’ ! [(((tbl_temp.c1)="1")) 
OR (((tbl_temp.c2)="1"));] 
 
 
Step 2 
 
Identify Yes, 
No(U) 
 
Export results to Microsoft Excel® 
! Patients with a DEXA scan performed on 
two specific sites at the same day!= Yes 
! Patients with a DEXA scan performed on 
only one site or with DEXA scans performed 
on two specific sites but not at the same 
day= No(U) 
! No(J)=0 (there is no justification for non-
adherence) 
 
 
The step of GPASS® sampling was excluded since patient suffering from osteoporosis 
and osteopenia had been identified previously on GPASS® via use of READ codes 
and had been stored in appropriate tables within the Query Builder. Similarly, 
information concerning individual BMD-measurements in individual patients had been 
stored in tables. This information can now be accessed at this stage by selecting the 
terms ‘Hip scan’ and ‘Lumbar scan’ for the criteria- fields of the so called READ code- 
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field of the ‘Query Builder’. By pressing the icon ‘view’, hip- and spine-scans on eligible 
patients are displayed. Unfortunately it is necessary to run a query in order to specify 
the results. By changing the ‘AND’ in the SQL- View to ‘OR’, all performed scans are 
displayed. Otherwise only patients who indeed have had scans performed on both 
sides would be displayed. That way it is also possible to indicate non-adherent patients 
who had a scan performed only on one site. This step might just be excluded in case 
the investigator does not request the information mentioned before.  
 
4.5. Validation of a potential community pharmacy-service 
A validation of a potential community pharmacy-based service for detection and 
management of osteoporosis was conducted via performance of interviews with 
healthcare specialists form community pharmacy, general practice medicine, fracture 
risk clinics and public health specialists in order to assess whether an application of 
MATosteo together with a fracture risk assessment score can provide a feasible and 
reliable audit delivered by community pharmacists alongside with GPs. For this 
purpose, a certain interview schedule was designed to gain relevant information from 
healthcare specialists. 
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5- RESULTS 
5.1. Revision of MATosteo 
The draft of the MATosteo designed by Anton Luf was further revised mainly in terms 
of wording and numbering. Criterion 1 was reworded from ‘A patient diagnosed with 
osteoporosis has been assessed by DEXA scan’ to ‘A patient diagnosed with 
osteoporosis has a recorded DEXA scan to confirm osteoporosis’ in order to point out 
the diagnostic background of the DEXA scan.  
In former criterion 6, which was renumbered to criterion 10 teriparatide as well as 
contraindications to teriparatide were added to the list of different agents eligible for 
osteoporosis treatment.  
Former criteria 14, 15 and 16, each of them assessing the prescribing of a single 
bisphosphonate, namely alendronate, risedronate and etidronate, were combined to 
criterion 14 of the final draft. This criterion enables the investigator to scan a patient’s 
prescription records for those three bisphosphonates as well as to determine whether a 
patient was prescribed the preferred choice by checking manually the dates on which 
the individual bisphosphonate has been prescribed. 
Former criterion 19 dealing with the prescribing of raloxifene and strontium ranelate in 
postmenopausal women who are intolerant to bisphosphonates and requiring 
secondary prevention of fractures, was renumbered to 17. Strontium ranelate was 
removed from this criterion since its use is assessed on sufficiently in criterion 16.The 
condition ‘with a diagnosis of osteoporosis’ formally required by the qualifier was 
removed. The condition ‘with at least one osteoporotic fracture’ was reworded to ‘is 
receiving it for secondary prevention’ and moved from the qualifier to the standard, as 
well as the requirement ‘has an identifiable reason for not being prescribed a 
bisphosphonate’.  
In criterion 18, which deals with the prescribing of teriparatide, the requirement 
‘postmenopausal woman diagnosed with osteoporosis’ was removed since the age, 
which is required in order to receive teriparatide, includes being postmenopausal (55 
and older).The term ‘who has an contraindication to strontium ranelate’ was removed 
since possible contraindications to strontium ranel
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breastfeeding, conditions practically impossible in patients receiving teriparatide due to 
the age required for the prescription of teriparatide, namely 55 and over. 
Similar changes were done to criterion 19 dealing with the prescribing of calcitonin.  
The following table indicates the revision of MATosteo in detail by comparing the final 
draft, which was agreed on by the research group with the previous draft produced by 
Anton Luf. 
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Table 11 Comparison MATosteo final draft with draft Anton Luf
Criterion Draft Anton Luf Final draft Comments 
1 A patient with a diagnosis of osteoporosis  
has been assessed by DEXA scan  
 
[Justification for not referring to a DEXA Scan 
Patient > 60 years and > 2 vertebral fractures imply a 
diagnosis of osteoporosis or  
a postmenopausal woman " 75 years and two or more 
independent clinical risk factors for fracture or indicators of low 
BMD]  
 
Independent clinical risk 
factors  
Indicators for low BMD 
" low body mass index 
defined as less than 22 
kg/m² 
" parental history of hip 
fracture, 
" ankylosing spondylitis " alcohol intake of 4 or 
more units/d 
" Crohn’s disease " rheumatoid arthritis  
" conditions that result in 
prolonged immobility 
 
" untreated premature 
menopause 
 
  
 
 
 
 
 
 
A patient with a diagnosis of osteoporosis  
has a recorded DEXA Scan to confirm 
osteoporosis 
 
[Justification for not being assessed by DEXA scan to 
confirm osteoporosis 
Patient > 60 years and > 2 vertebral fractures imply a 
diagnosis of osteoporosis or  
a postmenopausal woman " 75 years and two or more 
independent clinical risk factors for fracture or indicators of 
low BMD]  
 
Independent clinical risk 
factors  
Indicators for low BMD 
" low body mass index 
defined as less than 
22 kg/m² 
" parental history of hip 
fracture, 
" ankylosing spondylitis " alcohol intake of 4 or 
more units/d 
" Crohn’s disease " rheumatoid arthritis  
" conditions that result 
in prolonged 
immobility 
 
" untreated premature 
menopause 
 
   
Thewording of the criterion was 
slightly changed in order to point out 
the diagnostic background of the 
DEXA scan. 
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2 Measurement of the BMD by DEXA scan  
is performed at least at the two specific sites – 
namely, anteroposterior spine and hip. 
The same  
3 A patient with a recorded diagnosis of 
osteoporosis 
is prescribed supplementary calcium (±vitamin D).  
 
[Justification for non-prescribing calcium and vitamin D: There 
is a record that the patient has an adequate dietary intake of 
calcium and no vitamin D deficiency.] 
 
The same  
4 A patient with a recorded diagnosis of 
osteoPENIA  
is prescribed supplementary calcium (± vitamin D) 
for the prevention of osteoporosis.  
 
[Justification for non-prescribing calcium and vitamin D: There 
is a record that the patient has an adequate dietary intake of 
calcium and no vitamin D deficiency.] 
 
The same  
5 A patient with confirmed vitamin D deficiency 
or aged > 65  
is prescribed vitamin D.  
The same  
6 A patient with osteoporosis and NOT 
prescribed  any of the following: 
A patient prescribed supplementary calcium  The criterion was revised concerning 
contents and numbering. Teriparatide 
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bisphosphonates, raloxifene, strontium 
ranelate or calcitonin  
has a recorded contra-indication to each agent 
(see below) 
[Contraindications to bisphosphonates are: 
# oesophageal strictures or achalasia 
# inability to remain upright for > 30 min after 
ingestion  
# hypocalcaemia 
# osteomalacia (etidronate)  
# moderate renal impairment (CrCl <  35 mL/min)  
# pregnancy and breast feeding]  
[Contraindications to raloxifene are: 
# past/present venous thromboembolic events 
# hepatic impairment 
# cholestasis  
# severe renal impairment (CrCl < 10 mL/min)  
# endometrial cancer 
# uterine bleeding 
# pregnancy and breast feeding] 
[Contraindications to strontium ranelate are: 
# pregnancy and breast feeding 
# hypersensitivity] 
[Contraindications to calcitonin are: 
# hypocalcaemia 
# hypersensitivity] 
 
is prescribed a daily dose of 500 – 1500 mg 
calcium.  
 
and contraindications to teriparatide 
were added to the list. See criterion 
10 final draft. Former criterion 6 in 
the draft Luf is now criterion 10. 
7 A patient prescribed supplementary calcium  
is prescribed a daily dose of 500 – 1500 mg 
calcium.  
 
A patient prescribed vitamin D  
is prescribed a daily dose of 10 – 20 µg (400 - 
800 IU) vitamin D.  
 
Criteria 7 and 8 remained identical 
concerning contents but were 
changed regarding numbering from 
former 7 in draft Luf to 6 in the final 
draft respectively 8 to 7. 
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8 A patient prescribed vitamin D  
is prescribed a daily dose of 10 – 20 µg (400 - 
800 IU) vitamin D.  
 
Apatientwith a recorded diagnosis of 
osteoporosis 
is prescribed an oral bisphosphonate as first-
line therapy. 
 
Recorded reasons for non-conformance (justification): 
 
As mentioned before, criterion 8 draft 
Luf represents criterion 7 final draft. 
Criterion 8 of the final draft was 
changed concerning numbering, it is 
consistent with criterion 10 draft Luf. 
9 A patient with osteoporosis and NOT 
prescribed  any of the following: 
bisphosphonates, raloxifene, strontium 
ranelate or calcitonin  
is prescribed "1000mg calcium plus 800 IU 
vitamin D per day 
 
 
A patient with a recorded diagnosis of 
osteoPENIA  
is prescribed an oral bisphosphonate as first-
line therapy.  
 
Recorded reasons for non-conformance (justification): 
 
See criterion 11. Contents and 
wording remained identical, 
numbering was changed from former 
9 to 11. 
10 Apatientwith a recorded diagnosis of 
osteoporosis 
is prescribed an oral bisphosphonate as first-line 
therapy. 
 
Recorded reasons for non-conformance (justification): 
 
A patient with osteoporosis and NOT 
prescribed  any of the following: 
bisphosphonates, raloxifene, strontium 
ranelate,  calcitonin or teriparatide 
has a recorded contra-indication to each agent 
(see below) 
[Contraindications to bisphosphonates are: 
# oesophageal strictures or achalasia 
# inability to remain upright for > 30 min after 
ingestion  
# hypocalcaemia 
Criteron 10 draft Luf represents 
criterion 8 final draft. Contents and 
wording remained identical. 
Criterion 10 in the final draft 
represents criterion 6 draft Luf. 
Teriparatide and contraindications to 
teriparatide were added to the list. 
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# osteomalacia (etidronate)  
# moderate renal impairment (CrCl <  35 mL/min)  
# pregnancy and breast feeding]  
[Contraindications to raloxifene are: 
# past/present venous thromboembolic events 
# hepatic impairment 
# cholestasis  
# severe renal impairment (CrCl < 10 mL/min)  
# endometrial cancer 
# uterine bleeding 
# pregnancy and breast feeding] 
[Contraindications to strontium ranelate are: 
# pregnancy and breast feeding 
# hypersensitivity] 
[Contraindications to calcitonin are: 
# hypocalcaemia 
# hypersensitivity] 
[Contraindications to teriparatide are: 
# pre-existing hypercalcaemia 
# skeletal malignancies or bone metastases 
# metabolic bone diseases 
# including Paget’s disease and 
hyperparathyroidism 
# unexplained raised alkaline phosphatase 
# previous radiation therapy to the skeleton] 
 
11 A patient with a recorded diagnosis of 
osteoPENIA  
is prescribed an oral bisphosphonate as first-line 
therapy.  
 
Recorded reasons for non-conformance (justification): 
A patient with osteoporosis and NOT 
prescribed  any of the following: 
bisphosphonates, raloxifene, strontium 
ranelate or calcitonin  
is prescribed "1000mg calcium plus 800 IU 
vitamin D per day 
 
Numbering was changed from former 
11 to 9. Criterion 11 of the final draft 
represents criterion 9 draft Luf. 
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12 A patient who is prescribed a bisphosphonate 
has no reason on record  to avoid 
bisphosphonates.  
 
[Reasons to avoid bisphosphonates are: 
" contraindication to bisphosphonates  
o oesophageal strictures or achalasia 
o inability to remain upright for > 30 min 
after ingestion 
o hypocalcaemia 
o osteomalacia (etidronate)  
o moderate renal impairment (CrCl <  35 
mL/min)  
o pregnancy and breast feeding 
 
" inability to comply with the instructions for use of 
bisphosphonates  
o ingestion on an empty stomach 
o washing the medication down with 250 ml 
water 
o avoidance of food for 30 min 
o avoidance of lying flat within 30 min of 
ingestion 
 
" unsatisfactory response to bisphosphonates  
o another fracture occurs  
o decrease in BMD despite adherence to 
treatment 
 
" intolerance to bisphosphonates 
o oesophageal ulceration 
o erosion or stricture 
o severe lower GI symptoms] 
o  
 
The same  
13 A patient receiving treatment for 
osteoporosis/osteopenia 
The same  
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is prescribed a standard dose regimen.    
 
" Prevention (in 
osteopenia) 
" Treatment (of 
osteoporosis) 
Postmenopausal Osteoporosis 
" Alendronic acid 
 5 mg daily PO  10 mg daily or 70 mg  once 
weekly PO 
" Disodium etidronate 
 400 mg for 14 days PO; 
1,25 g calcium carbonate for 
76 days PO 
400 mg for 14 days PO, 
1,25 g calcium carbonate 
for 76 days PO 
" Ibandronic acid (not in guidelines)  
  150 mg once a month PO  
or 3 mg every 3 months IV 
" Risedronate sodium  
 5 mg daily PO  5 mg daily PO  
or 35 mg weekly PO  
" Calcitonin  
  200 units daily intranasally 
 
" Raloxifene  
 60 mg daily PO  60 mg daily PO 
" Strontium ranelate 
  2 g daily PO 
" Teriparatide 
  20 micrograms daily, for a 
maximum duration of 
treatment of 18 months 
 
Osteoporosis in men 
" Alendronic acid!
  10 mg daily PO 
Glucocorticoid-induced Osteoporosis 
" Alendronic acid  
 5 mg daily PO   5 mg daily PO  
" Disodium etidronate 
 400 mg for 14 days PO, 
1,25 g calcium carbonate for 
76 days PO 
 400 mg for 14 days PO, 
1,25 g calcium carbonate 
for 76 days PO 
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" Risedronate sodium  
 5 mg daily PO   
" Teriparatide 
  20 micrograms daily, for a 
maximum duration of 
treatment of 18 months 
   
14 A postmenopausal woman when started on 
bisphosphonate therapy  
was initiated on alendronate. 
 
A patient with osteoporosis on 
bisphosphonate therapy  
is on the preferred choice* 
* 1- Alendronate, 2-risedronate, 3-intermittent 
cyclical etidronate 
 
Criteria 14, 15 and 16 of draft Luf 
were merged to criterion 14 in the 
final draft. Whereas it has initially 
been investigated separately on 
alendronate, risedronate and 
etidronate, criterion 14 now focuses 
equally on each of them. The 
criterion audits at the same whether 
a patient is receiving alendronate, 
risedronate OR etidronate. If this was 
the case, the investigator had to 
check manually the dates of the 
prescrption in order to confirm 
adherence to the order set up in 
guidelines recommendation 
(alendronate in the first place, 
risedronate as a second choice and 
etidronate as a third). 
15 A postmenopausal woman diagnosed with 
osteoporosis/osteopenia and not treated with 
alendronate 
is prescribed risedronate.  
A patient who is on long-term glucocorticoid 
therapy 
(> 7.5 mg prednisolone or equivalents for > 3 
months) 
is prescribed a bisphosphonate.  
 
See criterion 14 final draft. 
Criterion 15 of the final draft 
represents criterion 17 draft Luf. 
Contents and wording remained 
identical. 
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16 A postmenopausal woman with > 2 vertebral 
fractures and NOT treated with alendronate or 
risedronate 
is prescribed intermittent cyclical etidronate1.  
 
A postmenopausal woman prescribed 
strontium ranelate has an identifiable reason 
for not being prescribed a bisphosphonate 
 
Reasons for non-use of bisphosphonates are 
" contraindication to bisphosphonates (see 12) 
" inability to comply with the recommendations for 
use of bisphosphonates (see 12) 
" intolerance to bisphosphonates (see12)] 
 
Criterion 16 draft Luf: See criterion 
14 final draft. 
Criterion 16 of the final draft 
represents criterion 18 draft Luf. The 
condition ‘with a diagnosis of 
osteoporosis’ formally required by the 
qualifier, was removed. The condition 
‘being prescribed strontium ranelate’ 
was moved from the standard to the 
qualifier, the condition ‘having an 
identifiable reason for not being 
prescribed a bisphosphonate’ was 
moved from the qualifier to the 
standard.  
17 A patient who is on long-term glucocorticoid 
therapy 
(> 7.5 mg prednisolone or equivalents for > 3 
months) 
is prescribed a bisphosphonate.  
 
A postmenopausal woman prescribed 
raloxifene  
is receiving it for secondary prevention and has 
an identifiable reason for not being prescribed a 
bisphosphonate  
 
[Reasons for non-use of bisphosphonates are 
" contraindication to bisphosphonates (see 12) 
" inability to comply with the recommendations for 
use of bisphosphonates (see 12) 
" intolerance to bisphosphonates (see 12)] 
Criterion 17 draft Luf was changed in 
aspects of numbering. Former 
criterion 17 draft Luf is now criterion 
15 in the final draft. 
Criterion 17 final draft was derived 
from criterion 19 draft Luf. The 
condition ‘with a diagnosis of 
osteoporosis’ formally required by the 
qualifier was removed. The condition 
‘with at least one osteoporotic 
fracture’ was reworded to ‘is 
receiving it for secondary prevention’ !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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and moved from the qualifier to the 
standard, as well as the requirement 
‘has an identifiable reason for not 
being prescribed a bisphosphonate’. 
Strontium ranelate was removed 
from this criterion since its use is 
assessed on sufficiently in criterion 
16. 
18 A postmenopausal woman with a diagnosis of 
osteoporosis, who has an identifiable reason 
for not being prescribed a bisphosphonate 
is prescribed strontium ranelate. 
 
[Reasons for non-use of bisphosphonates are 
Contraindications to bisphosphonates 
" contraindication to bisphosphonates (see 12) 
" inability to comply with the recommendations for use 
of bisphosphonates (see 12) 
" intolerance to bisphosphonates (see12)] 
 
 
A patient prescribed teriparatide is prescribed it for 
secondary prevention and meets at least one of the 
following 2 criteria 
" has a reason to avoid bisphosphonates 
(See 12) 
" has an intolerance to strontium ranelate 
o persistent nausea 
o persistent diarrhoea 
And has DEXA scan assessment that puts them in one the 
following groups 
 
" aged ! 65 years with a T-Score " -4 SD 
" aged ! 65 years with a T-Score " -3.5 SD 
and 
has more than two fractures 
" aged 55-64 years with a T-Score " -4 and 
has 
more than two fractures 
 
See criterion 16 final draft. 
Criterion 18 of the final draft is 
derived from criterion 20 draft Luf. 
The requirement ‘postmenopausal 
woman diagnosed with osteoporosis’ 
was removed since the age, which is 
required in order to receive 
teriparatide, includes being 
postmenopausal (55 and older). The 
term ‘with at least one osteoporotic 
fracture’ was reworded to ‘is 
receiving it for secondary prevention’. 
The action, that a patient is receiving 
teriparatide was moved from the 
standard to the qualifying statement 
since it is easier to assess its use in 
the first place instead of assessing 
reasons to avoid bisposphonates, 
intolerance to strontium ranelate etc  
before. The term ‘who has an 
contraindication to strontium ranelate’ 
was removed since contraindications 
to strontium ranelate would be 
pregnancy and breastfeeding, a 
condition that is practically 
impossible in patients receiving 
teriparatide since they have to be of 
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a certain age, namely 55 and over. 
 
19 A postmenopausal woman diagnosed with 
osteoporosis with at least one osteoporotic 
fractures who has an identifiable reason for 
not being prescribed a bisphosphonate  
is prescribed strontium ranelate or raloxifene. 
 
[Reasons for non-use of bisphosphonates are 
Contraindications to bisphosphonates 
" contraindication to bisphosphonates (see 12) 
" inability to comply with the recommendations for use 
of bisphosphonates (see 12) 
" intolerance to bisphosphonates (see 12)] 
 
A patient prescribed calcitonin is prescribed 
it for secondary prevention after 
bisphosphonate, raloxifene or strontium 
ranelate have been tried or have reasons for 
excluding from consideration 
 
[Reasons for non-use of bisphosphonates are 
" contraindication to bisphosphonates (see 12) 
" inability to comply with the recommendations for 
use of bisphosphonates (see 12) 
" intolerance to bisphosphonates (see 12)] 
 
 
Criterion 19 draft Luf correlates with 
criterion 17 of the final draft. See 
criterion 17 final draft. 
Contents of criterion 19 of the final  
draft were derived from former 
criterion 21 Luf. The action, that a 
patient is prescribed calcitonin, was 
moved from the standard to the 
qualifying statement since it is easier 
to assess whether a patient is 
receiving calcitonin then to assess 
the existence of possible 
contraindications etc in eligible 
patients. The requirement of being 
postmenopausal and being 
diagnosed with osteoporosis were 
removed since having sustained 
osteoporotic fractures is qualification 
that needs to be fulfilled for being 
prescribed calcitonin. The condition 
‘postmenopausal woman’ was 
removed since calcitonin is also 
indicated for the secondary 
prevention of osteoporosis in men. 
The term ‘not treated with a 
bisphosphonate, raloxifene or 
strontium ranelate’ was reworded to 
‘is prescribed … after 
bisphosphonate, raloxifene or 
strontium ranelate have been tried or 
have reasons for excluding from 
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consideration’ in order to clarify the 
motive for not prescribing any of 
these drugs. 
20 A postmenopausal woman diagnosed with 
osteoporosis and at least one osteoporotic 
fractures  
who has either 
 
" a reason to avoid bisphosphonates 
(See 12) 
" a contraindication to strontium 
ranelate 
o pregnancy 
o breast-feeding 
" an intolerance to strontium ranelate 
o persistent nausea 
o persistent diarrhoea 
and who is either 
" aged ! 65 years with a T-Score " -4 SD 
" aged ! 65 years with a T-Score " -3.5 
SD and 
has more than two fractures 
" aged 55-64 years with a T-Score " -4 
and has 
more than two fractures 
is prescribed teriparatide. 
 
 See criterion 18 final draft 
21 A postmenopausal woman diagnosed with 
osteoporosis with at least one vertebral 
fracture and NOT treated with a 
bisphosphonate, raloxifene or strontium 
ranelate  
is prescribed calcitonin. 
 See criterion 19 final draft. 
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5.2. Overall adherence and applicability of the total study sample 
Measurable endpoints of the study were the identification whether medication use in 
osteoporosis is according to the guidelines used in this study or not. The guidelines 
used were SIGN 71 (2003) and NICE 160 and 161 (2008). The application of 
MATosteo to patient data of three different GPs enabled the assessment and 
identification of applicability and adherence to guideline recommended treatment and 
treatment strategies in eligible patients. Furthermore this audit allowed the evaluation 
and comparison of quality of prescribing in patients located in different GPs. The 
following tables show demographic patient information of the three GPs. 
Table 12 Demographics GP A 
Patient subgroup Number of patients 
Total number of patients 464 
Osteoporotic patients 138 
Osteopenic patients 16 
Men 13 
Women 141 
Male osteoporotic patients 12 
Female osteoporotic patients 126 
Male osteopenic patients 1 
Female osteopenic patients 15 
Postmenopausal 139 
 
Table 13 Demographics GP B 
Patient subgroup Number of patients 
Total number of patients 62 
Osteoporotic patients 62 
Osteopenic patients 0 
Men 7 
Women 55 
Male osteoporotic patients 7 
Female osteoporotic patients 55 
Male osteopenic patients 0 
Female osteopenic patients 0 
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Postmenopausal 54 
 
Table 14 Demographics GP C 
Patient group Number of patients 
Total number of patients 103 
Osteoporotic patients 59 
Osteopenic patients 44 
Men 7 
Women 96 
Male osteoporotic patients 5 
Female osteoporotic patients 54 
Male osteopenic patients 2 
Female osteopenic patients 42 
Postmenopausal 94 
 
The following tables show overall adherence and applicability of the total study sample 
to each criterion. Adherence and applicability are reported for each patient sample 
(each GP) separately as well as for all three GPs together. For each criterion, the 
number of applicable patients was calculated by summing up ‘Yes’-, ‘No, unjustified’- 
and ‘Insufficient data on the standard’- answers. Percentage of applicability was 
calculated for each criterion. Adherence to each criterion was calculated by dividing the 
number of ‘Yes- answers’ by the number of applicable patients, multiplied with 100. 
Furthermore the 95% confidence interval was calculated.  
5.2.1. Applicabilty 
Applicability was observed to be very low in criteria 1 and 4. These criteria deal with 
osteopenic patients. Numbers of osteopenic patients were very low in the study 
sample, which might result from the fact that there is not enough importance attached 
with this disease, its diagnosis and implications. 
For criteria including a high number of subheadings a significantly low applicability was 
shown, which results from the difficulty to meet every single requirement set up in 
concerned criteria. Criterion 12 for example, includes a high number of subheadings: 
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A patient who is prescribed a bisphosphonate 
has no reason on record to avoid bisphosphonates.  
In order to fulfil the requirements set up in the standard, a patient has to meet at least 
one statement of the four groups (subheadings) indicated below: 
" contraindication to bisphosphonates: 
o oesophageal strictures or achalasia 
o inability to remain upright for > 30 min after ingestion 
o hypocalcaemia 
o osteomalacia (etidronate)  
o moderate renal impairment (CrCl <  35 mL/min)  
o pregnancy and breast feeding 
 
" inability to comply with the instructions for use of bisphosphonates  
o ingestion on an empty stomach 
o washing the medication down with 250 ml water 
o avoidance of food for 30 min 
o avoidance of lying flat within 30 min of ingestion 
 
" unsatisfactory response to bisphosphonates 
o another fracture occurs  
o decrease in BMD despite adherence to treatment 
 
" intolerance to bisphosphonates 
o oesophageal ulceration 
o erosion or stricture 
o severe lower GI symptoms] 
 
In criterion 15, applicability was reported to be 0 in most cases, a result from the fact 
that there was only one patient with long-term prescription of oral glucocorticoids found 
in the patient sample. Attention might have to be drawn to inhalative glucocorticoids, 
but assessment of patients prescribed the latter were not included in this project since 
inhalative administration of steroids is not explicitly recommended by guidelines to be 
accompanied by preventive osteoporosis treatment. 
In criterion 16, applicability was found to be very low, resulting from the fact that only 
very few patients (3 out of 319) were prescribed strontium ranelate although it is 
recommended as treatment alternative in patients who are not eligible for 
bisphosphonate therapy. 
Applicability in criterion 17 was 0 since there were no patients found to receive 
raloxifene in the patient sample. Subsequently the term ‘no result’ had to be reported 
for adherence.  
In criterion 18, ‘no result’ had to be reported for adherence since there were no 
applicable patients who were prescribed teriparatide. 
‘No result’ due to the non-existence of applicable patients was also reported for 
criterion 19 since there were no patients receiving calcitonin. 
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5.2.2. Overall adherence-practice A 
In practice A, overall adherence to guideline recommendation was observed to be 
65.8%. 
For 6 out of 19 criteria high level of adherence (70% and over) was reported. In 7 
criteria level of adherence was found to be intermediate (50-69.9%) and in 2 criteria it 
was low (below 50%). In 4 criteria, ‘no result’ was reported, since there were no 
applicable patients. 
Criteria indicating high level of adherence were criteria 7 and 8 (in patients receiving 
calcium respectively vitamin D, the appropriate dose is prescribed) with 98,8% 
respectively 98.7% of adherence. Furthermore adherence was high in criterion 12 with 
83.0% (patients receiving antiresorptive or osteoanabolic treatment do not have a 
contraindication to this treatment). Similarly criterion 13 (patients prescribed treatment 
for osteoporosis are prescribed a standard regimen) was highly adhered to with 86.2%. 
Criterion 14 showed 87.8% of adherence (patients receiving a bisphosphonate receive 
the preferred choice). The criterion with the highest level of adherence was criterion 16 
with 100% of adherence. This criterion deals with the requirement that patients who are 
prescribed strontium ranelate have to present a contraindication for bisphosphonates. 
Low level of adherence was reported for criterion 2 with 34.4% requiring DXA scans on 
two specific sites. Furthermore criterion 9 was shown to be poorly adhered to, requiring 
prescription of calcium and vitamin D in untreated patients with only 20.4% of 
adherence. 
For criteria 1, 4, 5, 6, 10 and 11 intermediate adherence was reported, ranking from 
55.1 to 60.8%. These criteria require diagnosis of osteoporosis to be set up by DEXA 
scan, supplementary calcium to be prescribed in osteoporotic and osteopenic patients, 
vitamin D to be prescribed in patients with vitamin D deficieny or over the age of 65, 
prescription of appropriate treatment in patients diagnosed with osteoporosis as well as 
prescribing of bisphosphonates as first line therapy for osteoporosis and osteopenia. 
For criteria 15, 17, 18 and 19 ‘no result’ was reported, since there were no patients 
found to receive long-term oral glucocorticoid therapy, raloxifene, teriparatide or 
calcitonin. 
The implementation of a pharmaceutical care tool to guide community pharmacy interventions in osteoporosis !
!63 
Table 15 Overall adherence practice A
Practice A (154 patients) 
n= 2926 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
1  Patient with a diagnosis of 
osteoporosis has a recorded DEXA 
scan 
22/154 
14.3% 
 
 
77 6 55 0 0 132/154 
85.7% 
77/132 
58.3% 
(49.9-66.7) 
2 Patient with measured BMD by 
DEXA scan has measures takenat 
spine and hip 
61/154 
39.6% 
32 0 55 6 0 93/154 
60.4% 
32/93 
34.4% 
(24.7-44.1) 
3 Patient with osteoporosis is 
prescribed supplementary calcium 
16/154 
10.4% 
76 0 62 0 0 138/154 
89.6% 
76/138 
55.1% 
(46.8-63.4) 
4 Osteopenic patient is prescribed 
supplementary calcium 
138/216 
89.6% 
9 0 7 0 0 16/154 
10.4% 
9/16 
56.3% 
(32-80.6) 
5 Patient with confirmed vitamin D 
deficiency or age ! 65years is 
prescribed vitamin D 
30/154 
19.5% 
73 0 51 0 0 124/154 
80.5% 
73/124 
58.9% 
(50.2-67.6) 
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Practice A (154 patients) 
n= 2926 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
6 
 
Patient with osteoporosis is treated 
with antiresorptive/osteoanabolic 
agent (Biphopshonates,  raloxifene, 
strontium ranelate, calcitonin or 
teriparatide) 
16/154 
10.4% 
84 0 54 0 0 138/154 
89.6% 
84/138 
60.8% 
(52.7-68.9) 
7 Patient prescribed calcium is 
prescribed 500-1500 mg 
69/154 
44.8% 
84 0 1 0 0 85/154 
55.2% 
84/85 
98.8% 
(96.5-101.1) 
8 Patient prescribed vitamin D is 
prescribed 400-800 IU 
76/154 
49.4% 
77 0 1 0 0 78/154 
50.6% 
77/78 
98.7% 
(96.2-101.2) 
9  
 
Patient with osteoporosis 
untreated 
byantiresorptive/anabolic agent  
(BPs, raloxifene, strontium ranelate 
or calcitonin) is prescribed >=1000mg 
calcium plus 800 IE vitamin D 
100/154 
64.9% 
11 0 42 1 0 54/154 
35.1% 
11/54 
20.4% 
(9.7-31.1) 
10 
 
Patient with osteoporosis is 
prescribed an oral BP as first-line 
therapy 
16/154 
10.4% 
81 0 57 0 0 138/154 
89.6% 
81/138 
58.7% 
(50.5-66.9) 
11  
 
Osteopenic patient is prescribed an 
oral BP as first-line therapy 
(Canadian guidelines only) 
138/154 
89.6% 
9 0 7 0 0 16/154 
10.4% 
9/16 
56.3% 
(32-80.6) 
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Practice A (154 patients) 
n= 2926 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
12 
 
Patient treated with 
antiresorptive/osteoanabolic agent 
has no contra-indication on record 
(Biphopshonates,  raloxifene, 
strontium ranelate, calcitonin or 
teriparatide 
60/154 
39% 
78 0 16 0 0 94/154 
61% 
78/94 
83.0% 
(75.4-90.6) 
13 Patient  receiving treatment for 
osteopenia/osteoporosis is 
prescribed a standard dose regimen 
 
60/154 
39% 
81 0 10 3 0 94/154 
61% 
81/94 
86.2% 
(79.2-93.2) 
14 
 
A patient with osteoporosis on 
bisphosphonate therapy  
is on the preferred choice* 
* 1- Alendronate, 2-risedronate, 3-
intermittent cyclical etidronate 
72/154 
46.8% 
72 0 10 0 0 82/154 
53.2% 
72/82 
87.8% 
(80.8-94.8) 
15 A patient who is on long-term 
glucocorticoid therapy 
(> 7.5 mg prednisolone or 
equivalents for > 3 months) 
is prescribed a bisphosphonate 
 
 
 
. 
 
154/154 
100% 
0 0 0 0 0 0/154 
0% 
nr 
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Practice A (154 patients) 
n= 2926 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
16 A postmenopausal woman 
prescribed strontium ranelate has 
an identifiable reason for not being 
prescribed a bisphosphonate 
152/154 
98.7% 
2 0 0 0 0 2/154 
1.3% 
2/2 
100.0% 
 
17 A postmenopausal woman 
prescribed raloxifene  
is receiving it for secondary 
prevention 
154/154 
100% 
0 0 0 0 0 0/154 
0% 
nr 
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Practice A (154 patients) 
n= 2926 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
18 A patient prescribed teriparatide is 
prescribed it for secondary prevention 
and meets at least one of the 
following 2 criteria 
" has a reason to avoid 
bisphosphonates (See 12) 
" has an intolerance to 
strontium ranelate 
o persistent nausea 
o persistent diarrhoea 
And has DEXA scan assessment that puts 
them in one the following groups 
 
" aged ! 65 years with a T-
Score " -4 SD 
" aged ! 65 years with a T-
Score " -3.5 SD and 
has more than two 
fractures 
" aged 55-64 years with a T-
Score " -4 and has 
more than two fractures 
 
 
 
 
 
 
 
 
154/154 
100% 
0 0 0 0 0 0/154 
0% 
nr 
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Practice A (154 patients) 
n= 2926 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
19 A patient prescribed calcitonin is 
prescribed it for secondary prevention 
after bisphosphonate, raloxifene or 
strontium ranelate have been tried or 
have reasons for excluding from 
consideration 
 
[Reasons for non-use of bisphosphonates 
are 
" contraindication to 
bisphosphonates (see 12) 
" inability to comply with the 
recommendations for use of 
bisphosphonates (see 12) 
" intolerance to bisphosphonates 
(see 12)] 
 
154/154 
100% 
0 0 0 0 0 0/154 
0% 
nr 
Overall  
(%) 
1642 846 6 428 10 0 1284 846/1284 
65.8% 
(62.3-69.3) !
 
N/A: not applicable; No(J): justified non-adherence to the guideline; No(U): unjustified non-adherence to the guideline; IDS: insufficient data on the standard; IDQ: 
insufficient data on the qualifier; CI: confidence interval; S1: Search 1;nr: no result !!
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5.2.3. Overall adherence-practice B 
In practice B, overall adherence to the clinical guidelines used in this study was observed to be 
52.1%. 
Level of adherence was high (70% and over) in 4 out of 19 criteria, intermediate (50-69.9%) in 
3 criteria and low (below 50%) in 4 criteria. For 6 criteria ‘no result’ was reported for adherence 
since there were no patients applicable to the qualifying statements. 
Criteria presenting significantly high level of adherence were criteria 7 and 8 with 100% 
respectively 94.1% of adherence. These criteria represent the requirement, that patients who 
are prescribed calcium respectively vitamin D should be prescribed the appropriate dose. 
Furthermore criterion 13 was observed to be highly adhered to with 74.5%, requiring 
prescription of standard dose regimens in osteoporosis treatment. Criterion 14 as well showed 
high level of adherence with 83.9%. This criterion checks whether patients who are prescribed 
a bisphosphonate are on the preferred choice. 
Criteria with significantly low level of adherence were criteria 1 and 2 with 1.6% respectively 
0%. These criteria represent the requirement that assessment of BMD should be performed 
via DXA scan on two specific sites. There was only one patient in practice B found to have a 
diagnosis of osteoporosis set up via DXA scan which results from the fact that there were no 
DXA- facilities available in practice Bwhich is located in a deprived area within Greater 
Glasgow. Within patients’ records the term ‘bone density measurement’ was found in most 
cases, a term that is most likely to refer to BMD assessment via radiography or some other 
technique. 
For criterion 3, which requires the prescribing of calcium in all patients diagnosed with 
osteoporosis, a low adherence of only 38.7% was reported. Furthermore criterion 12 was 
observed to be poorly adhered to with 41.9%. This criterion requires that patients who are 
prescribed antiresorptive or osteoanabolic treatment must not have a contraindication to these 
treatment options. 
For criteria 5,6 and 10 intermediate level of adherence was observed within a range from 50 to 
59.6%. These criteria deal with the prescribing of supplementary vitamin D in patients above 
the age of 64, prescribing of treatment in osteoporotic and osteopenic patients respectively the 
prescribing of bisphosphonates as first line treatment in osteoporosis-patients. 
Since there were no osteopenic patients within this patient sample, no patients were applicable 
to criteria 4 and 11 and ‘no result’ was reported for adherence. There were no patients on long-
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term oral glucocorticoid therapy, strontium ralenate, raloxifene, teriparatide or calcitonin. 
Hence, there are no results for adherence in criteria 15, 16, 17, 18 and 19. 
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Table 16 Overall adherence practice B
Practice B (62 patients) 
n= 1178 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
1  Patient with a diagnosis of 
osteoporosis has a recorded DEXA 
scan 
0/62 
0% 
 
 
1 
 
 
0 
 
 
54 
 
7 
 
0 62/62 
100% 
 
1/62 
1.6% 
(-1.5-4.7) 
2 Patient with measured BMD by 
DEXA scan has measures takenat 
spine and hip 
51/62 
82.3% 
0 
 
0 1 
 
10 
 
39 11/62 
17.7% 
0/11 
0% 
 
3 Patient with osteoporosis is 
prescribed supplementary calcium 
0/62 
0% 
24 0 38 0 0 62/62 
100% 
24/62 
38.7% 
(26.5-50.9) 
4 Osteopenic patient is prescribed 
supplementary calcium 
62/62 
100% 
0 0 0 0 0 0/62 
0% 
nr 
5 Patient with confirmed vitamin D 
deficiency or age ! 65years is 
prescribed vitamin D 
15/62 
24.2% 
28 0 19 0 0 47/62 
75.8% 
28/47 
59.6% 
(45.5-73.7) 
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Practice B (62 patients) 
n= 1178 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
6 
 
Patient with osteoporosis is treated 
with antiresorptive/osteoanabolic 
agent (Biphopshonates,  raloxifene, 
strontium ranelate, calcitonin or 
teriparatide) 
 
0/62 
0% 
31 0 31 0 0 62/62 
100% 
31/62 
50.0% 
(37.6-62.4) 
7 Patient prescribed calcium is 
prescribed 500-1500 mg 
28/62 
45.2% 
34 0 0 0 0 34/62 
54.8% 
34/34 
100.0% 
8 Patient prescribed vitamin D is 
prescribed 400-800 IU 
28/62 
45.2% 
32 0 2 0 0 34/62 
54.8% 
32/34 
94.1% 
(86.2-100.2) 
9  
 
Patient with osteoporosis 
untreated 
byantiresorptive/anabolic agent  
(BPs, raloxifene, strontium ranelate 
or calcitonin) is prescribed >=1000mg 
calcium plus 800 IE vitamin D 
31/62 
50% 
12 0 19 0 0 31/62 
50% 
 
12/31 
38.7% 
(21.6-55.8) 
10 
 
Patient with osteoporosis is 
prescribed an oral BP as first-line 
therapy 
0/62 
0% 
31 0 31 0 0 62/62 
100% 
31/62 
50.0% 
(37.6-62.4) 
11  
 
Osteopenic patient is prescribed an 
oral BP as first-line therapy 
(Canadian guidelines only) 
 
 
62/62 
0% 
0 0 0 0 0 0/62 
0% 
nr 
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Practice B (62 patients) 
n= 1178 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
12 
 
Patient treated with 
antiresorptive/osteoanabolic agent 
has no contra-indication on record 
(Biphopshonates,  raloxifene, 
strontium ranelate, calcitonin or 
teriparatide 
31/62 
50% 
13 0 5 13 0 31/62 
50% 
13/31 
41.9% 
(24.5-59.3) 
13 Patient  receiving treatment for 
osteopenia/osteoporosis is 
prescribed a standard dose regimen 
 
11/62 
17.7% 
38 0 5 8 0 51/62 
82.3% 
38/51 
74.5% 
(62.5-86.5) 
14 
 
A patient with osteoporosis on 
bisphosphonate therapy  
is on the preferred choice* 
* 1- Alendronate, 2-risedronate, 3-
intermittent cyclical etidronate 
 
31/62 
50% 
26 0 5 0 0 31/62 
50% 
26/31 
83.9% 
(71-96.8) 
 
15 A patient who is on long-term 
glucocorticoid therapy 
(> 7.5 mg prednisolone or 
equivalents for > 3 months) 
is prescribed a bisphosphonate.  
 
 
 
 
62/62 
100% 
0 0 0 0 0 0/62 
0% 
nr 
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Practice B (62 patients) 
n= 1178 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
16 A postmenopausal woman 
prescribed strontium ranelate has 
an identifiable reason for not being 
prescribed a bisphosphonate 
 
62/62 
100% 
0 0 0 0 0 0/62 
0% 
Nr 
 
 
 
17 A postmenopausal woman 
prescribed raloxifene  
is receiving it for secondary 
prevention 
62/62 
100% 
0 0 0 0 0 0/62 
0% 
Nr 
 
 
18 A patient prescribed teriparatide is 
prescribed it for secondary prevention 
and meets at least one of the 
following 2 criteria 
" has a reason to avoid 
bisphosphonates (See 12) 
" has an intolerance to 
strontium ranelate 
o persistent nausea 
o persistent diarrhoea 
And has DEXA scan assessment that puts 
them in one the following groups 
 
" aged ! 65 years with a T-
Score " -4 SD 
" aged ! 65 years with a T-
Score " -3.5 SD and 
has more than two 
fractures 
" aged 55-64 years with a T-
Score " -4 and has 
more than two fractures 
 
62/62 
100% 
0 0 0 0 0 0/62 
0% 
nr 
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Practice B (62 patients) 
n= 1178 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
19 A patient prescribed calcitonin is 
prescribed it for secondary prevention 
after bisphosphonate, raloxifene or 
strontium ranelate have been tried or 
have reasons for excluding from 
consideration 
 
[Reasons for non-use of 
bisphosphonates are 
" contraindication to 
bisphosphonates (see 12) 
" inability to comply with the 
recommendations for use of 
bisphosphonates (see 12) 
" intolerance to bisphosphonates 
(see 12)] 
 
62/62 
100% 
0 0 0 0 0 0/62 
0% 
nr 
Overall  
(%) 
660 270 0 210 38 39 518 270/518 
52.1% 
(47.8-56.4) !
N/A: not applicable; No(J): justified non-adherence to the guideline; No(U): unjustified non-adherence to the guideline; IDS: insufficient data on the standard; IDQ: 
insufficient data on the qualifier; CI: confidence interval; S1: Search 1;  nr: no result !
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5.2.4. Overall adherence-practice C 
In practice C, overall adherence to guideline recommendation was observed to be 61.4%. 
For 5 out of 19 criteria adherence was found to be of high level, 6 criteria showed intermediate 
and 5 criteria low level of adherence. In three criteria, no results could be reported since there 
were no patients applicable. 
Significantly high adherence was observed in criteria 7 and 8 with 100% both. These criteria 
require the prescribing of calcium and vitamin D in appropriate dosage. Furthermore for criteria 
15 and 16 it was reported that adherence to guidelines recommendation was 100%. However, 
in both criteria only one patient was applicable to the qualifier (patients prescribed long-term 
oral glucocorticoid therapy respectively strontium ranelate). In both cases guideline 
recommendation (prescribing of bisphosphonate prevention in steroid patients respectively 
prescribing of strontium ranelate exclusively in patients with a contraindication to 
bisphosphonates) was implemented. 
Significantly low level of adherence was observed in criterion 2 with 10.8%. This criterion 
requires the performance of DXA scan on two specific sites. Furthermore criterion 11 was 
reported to be poorly adhered to with 23.3.%. Criterion 11 requires bisphosphonate therapy to 
be first line treament in patients with osteopenia. Similarly low adherence (30.2%) was shown 
for criterion 4, which requires prescribing of supplementary calcium in osteopenic patients. 
Criterion 9 and 12 were found to be poorly adhered to with 40.9 respectively 47.9%. These 
criteria check if osteoporotic and osteopenic patients who are not receiving pharmacological 
osteoporosis treatment are prescribed calcium and vitamin D respectively if patients who 
actually do receive treatment do not have a contraindication to the latter. 
For criteria 1, 3, 5, 6, 10 and 13 intermediate level of adherence was reported. 
There were no patients applicable in criteria 17, 18 and 19, hence there could be no result 
reported.
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Table 17 Overall adherence practice C 
Practice C (103 patients) 
n= 1957 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
1  Patient with a diagnosis of 
osteoporosis has a recorded DEXA 
scan 
44/103 
42.7% 
37 1 17 5 0 59/103 
57.3% 
37/59 
62.7% 
(50.4-75.0) 
 
2 Patient with measured BMD by 
DEXA scan has measures takenat 
spine and hip 
66/103 
64.1% 
4 0 33 0 5 37/103 
35.9% 
4/37 
10.8% 
(0.8-20.8) 
3 Patient with osteoporosis is 
prescribed supplementary calcium 
43/103 
41.7% 
38 0 22 0 0 60/103 
58.3% 
38/60 
63.3% 
(51.1-75.5) 
4 Osteopenic patient is prescribed 
supplementary calcium 
60/103 
58.3% 
13 0 30 0 0 43/103 
41.7% 
13/43 
30.2% 
(16.5-43.9) 
5 Patient with confirmed vitamin D 
deficiency or age ! 65years is 
prescribed vitamin D 
34/103 
33% 
41 0 28 0 0 69/103 
67% 
41/69 
59.4% 
(47.8-70.8) 
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Practice C (103 patients) 
n= 1957 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
6 
 
A patient with osteoporosis is 
treated with an 
antiresorptive/osteoanabolic agent  
48/103 
46,6% 
38 5 12 5 0 55/103 
53,4% 
38/55 
69,1% 
(56,9-81,3) 
7 A patient prescribed 
supplementary calcium   
is prescribed a daily dose of 500-
1500 mg calcium  
52/103 
50.5% 
51 0 0 0 0 51/103 
49.5% 
51/51 
100.0% 
 
8 A patient prescribed vitamin D  
is prescribed a daily dose of 10 – 20 
µg (400 - 800 IU) vitamin D 
53/103 
51.5% 
50 
 
0 0 0 0 50/103 
48.5% 
50/50 
100.0% 
 
9  
 
Patient with osteoporosis 
untreated by 
antiresorptive/osteoanabolic agent 
is prescribed >=1000 mg calcium 
plus 800 IE vitamin D 
81/103 
78.6% 
9 0 13 0 0 22/103 
21.4% 
9/22 
40.9% 
(20.4-61,4) 
10 
 
A patient with osteoporosis is 
prescribed an oral bisphosphonate 
as first-line therapy 
49/103 
47.6% 
37 6 12 5 0 54/103 
52.4% 
37/54 
68.5% 
(56.1-80.9) 
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Practice C (103 patients) 
n= 1957 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
11  
 
A patient with osteopenia is 
prescribed an oral bisphosponate 
as first-line therapy 
60/103 
58.3% 
10 0 33 0 0 43/103 
41.7% 
10/43 
23.3% 
(10.7-35.9) 
 
12 
 
A patient who is prescribed a 
antiresorptive/osteoanabolic agent 
has no contraindication on record 
 
55/103 
53.4% 
 
23 0 2 23 0 48/103 
46.6% 
23/48 
47.9% 
(33.8-62.0) 
13 Patient  receiving treatment for 
osteopenia/osteoporosis is 
prescribed a standard dose regimen 
 
55/103 
53.4% 
31 0 15 2 0 48/103 
46.7% 
31/48 
64.6% 
(51.1-78.1) 
14 
 
A patient with osteoporosis on 
bisphosphonate therapy  
is on the preferred choice* 
• 1- Alendronate, 2-
risedronate, 3-intermittent 
cyclical etidronate 
•  
66/103 
64.1% 
32 0 5 0 0 37/103 
35.9% 
32/37 
86.5% 
(75.5-97.5) 
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Practice C (103 patients) 
n= 1957 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
15 A patient who is on long-term 
glucocorticoid therapy 
(> 7.5 mg prednisolone or 
equivalents for > 3 months) 
is prescribed a bisphosphonate.  
 
102/103 
99% 
1 0 0 0 0 1/103 
1% 
1/1 
100.0% 
16 A postmenopausal woman 
prescribed strontium ranelate has 
an identifiable reason for not being 
prescribed a bisphosphonate 
 
102/103 
99% 
1 0 0 0 0 1/103 
1% 
1/1 
100.0% 
 
17 A postmenopausal woman 
prescribed raloxifene  
is receiving it for secondary 
prevention 
103/103 
100% 
 
0 0 0 0 0 0/103 
0% 
 
 
 
 
 
 
 
 
 
nr 
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Practice C (103 patients) 
n= 1957 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
18 A patient prescribed teriparatide is 
prescribed it for secondary prevention 
and meets at least one of the 
following 2 criteria 
# has a reason to avoid 
bisphosphonates (See 12) 
# has an intolerance to 
strontium ranelate 
# persistent nausea 
# persistent diarrhoea 
And has DEXA scan assessment that puts 
them in one the following groups 
 
# aged ! 65 years with a T-
Score " -4 SD 
# aged ! 65 years with a T-
Score " -3.5 SD and 
has more than two 
fractures 
# aged 55-64 years with a T-
Score " -4 and has 
more than two fractures 
 
 
 
 
 
 
 
 
103/103 
100% 
0 0 0 0 0 0/103 
0% 
nr 
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Springburn (103 patients) 
n= 1957 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
19 A patient prescribed calcitonin is 
prescribed it for secondary prevention 
after bisphosphonate, raloxifene or 
strontium ranelate have been tried or 
have reasons for excluding from 
consideration 
 
[Reasons for non-use of 
bisphosphonates are 
# contraindication to 
bisphosphonates (see 12) 
# inability to comply with the 
recommendations for use of 
bisphosphonates (see 12) 
# intolerance to 
bisphosphonates (see 12)] 
 
103/103 
100% 
0 0 0 0 0 0/103 
0% 
nr 
Overall  
(%) 
1279/1957 
65.4% 
416 12 222 40 5 678/1957 
34.6% 
416/678 
61.4% 
(57.7-65.1) !
N/A: not applicable; No(J): justified non-adherence to the guideline; No(U): unjustified non-adherence to the guideline; IDS: insufficient data on the standard; IDQ: 
insufficient data on the qualifier; CI: confidence interval; S1: Search 1; nr: no result
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5.2.5. Overall-adherence- total patient sample 
In the total patient sample, overall adherence to the clinical guidelines used in this project was 
observed to be 61.7%, which represents intermediate level of adherence (50-69.9%). 
In 6 out of 19 criteria guideline recommendations were found to be highly adhered to, in 5 
criteria adherence was intermediate. 5 criteria were reported to be only poorly adhered to. For 
3 criteria it was not possible to report a result. 
Criteria with significantly high level of adherence were criteria 7, 8, 15 and 16. Criteria 7 and 8 
check if patients who are prescribed supplementary calcium and vitamin D are receiving the 
appropriate dose. In criterion 15 (bisphosphonate prevention for patients on long-term oral 
steroids) only patient was applicable, hence adherence was going to be either 0% or 100% 
with a probability of 50% for both cases. Similarly in criterion 16, only three patients were 
applicable (prescribed strontium ranelate). Since all of them met the standard (presented a 
contraindication to bisphosphonates), adherence was 100%. 
Criteria presenting significantly low level of adherence were criteria 1, 2, 4, 9 and 11. Criteria 1 
and 2 requiring BMD assessment via DEXA at spine and hip were shown to be adhered to in 
45.5 respectively 25% of applicable patients. Criterion 4 requires prescribing of supplementary 
calcium in osteopenic patients and was adhered in only 37% of applicable patients. 
For 5 criteria (3, 5, 6, 10 and 12) level of adherence was observed to be intermediate within a 
range from 53.1 to 65.9%. 
In criteria 17, 18 and 19 there could be no results found since there were no patients receiving 
raloxifene, teriparatide or calcitonin. 
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Table 18 Overall adherence total patient sample 
Total (319 patients) 
n= 6061 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
1  Patient with a diagnosis of 
osteoporosis has a recorded DEXA 
scan 
66/319 
20.7% 
115 7 126 12 0 253/319 
79.3% 
115/253 
45.5% 
(40.5- 50.5%) 
2 Patient with measured BMD by 
DEXA scan has measures takenat 
spine and hip 
178/319 
55.8% 
36 0 89 16 44 141/319 
44.2% 
36/141 
25.5% 
(18.3-32.7) 
3 Patient with osteoporosis is 
prescribed supplementary calcium 
59/319 
18.5% 
138 0 122 0 0 260/319 
81.5% 
138/260 
53.1% 
(47-59.2) 
4 Osteopenic patient is prescribed 
supplementary calcium 
1 22 0 37 0 0 59/319 
18.5% 
22/59 
37.3% 
(25-59.6) 
5 Patient with confirmed vitamin D 
deficiency or age ! 65years is 
prescribed vitamin D 
79/319 
24.8% 
142 0 98 0 0 240/319 
75.2% 
142/240 
59.2% 
(53-65.4) 
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Total (319 patients) 
n= 6061 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
6 
 
Patient with osteoporosis is treated 
with antiresorptive/osteoanabolic 
agent (Biphopshonates,  raloxifene, 
strontium ranelate, calcitonin or 
teriparatide) 
64/319 
20.1% 
153 5 97 5 0 255/319 
79.9% 
153/255 
60% 
(54.0-66.0) 
 
7 Patient prescribed calcium is 
prescribed 500-1500 mg 
149/319 
46.7% 
169 0 1 0 0 170/319 
53.3% 
169/170 
99.4% 
(98.2-100.6) 
8 Patient prescribed vitamin D is 
prescribed 400-800 IU 
157/319 
49.2% 
159 0 3 0 0 162/319 
50.8% 
 
159/162 
98.1% 
(96-100.2) 
9  
 
Patient with osteoporosis 
untreated 
byantiresorptive/anabolic agent  
(BPs, raloxifene, strontium ranelate 
or calcitonin) is prescribed >=1000mg 
calcium plus 800 IE vitamin D 
212/319 
66.5% 
32 0 74 1 0 107/319 
33.5% 
32/107 
29.9% 
(21.2-38.6) 
10 
 
Patient with osteoporosis is 
prescribed an oral BP as first-line 
therapy 
65/319 
20.4% 
149 6 100 5 0 254/319 
79.6% 
149/254 
58.6% 
(52.5-64.7) 
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Total (319 patients) 
n= 6061 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
11  
 
Osteopenic patient is prescribed an 
oral BP as first-line therapy 
(Canadian guidelines only) 
260/319 
81.5% 
19 0 40 0 0 59/319 
18.5% 
19/59 
32.2% 
(20.3-44.1) 
12 
 
Patient treated with 
antiresorptive/osteoanabolic agent 
has no contra-indication on record 
(Biphopshonates,  raloxifene, 
strontium ranelate, calcitonin or 
teriparatide 
146/319 
45.8% 
114 0 23 36 0 173/319 
54.23% 
114/173 
65.9% 
(58.8-73.0) 
 
13 Patient  receiving treatment for 
osteopenia/osteoporosis is 
prescribed a standard dose regimen 
 
126/319 
39.5% 
150 0 30 13 0 193/319 
60.5% 
150/193 
77.7% 
(71-84.4) 
14 
 
A patient with osteoporosis on 
bisphosphonate therapy  
is on the preferred choice* 
* 1- Alendronate, 2-risedronate, 3-
intermittent cyclical etidronate 
169/319 
53% 
130 0 20 0 0 150/319 
47% 
130/150 
86.7% 
(81.3-92.1) 
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Total (319 patients) 
n= 6061 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
15 A patient who is on long-term 
glucocorticoid therapy 
(> 7.5 mg prednisolone or 
equivalents for > 3 months) 
is prescribed a bisphosphonate. 
 
 
318/319 
99.7% 
1 0 0 0 0 1/319 
0.3% 
1/1 
100.0% 
16 A postmenopausal woman 
prescribed strontium ranelate has 
an identifiable reason for not being 
prescribed a bisphosphonate 
 
316/319999.
1% 
3 0 0 0 0 3/319 
0.9% 
3/3 
100.0% 
 
17 A postmenopausal woman 
prescribed raloxifene  
is receiving it for secondary 
prevention 
 
 
 
 
 
 
 
319/319 
1% 
0 0 0 0 0 0/319 
0% 
 
 
 
 
 
 
 
nr 
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Total (319 patients) 
n= 6061 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
18 A patient prescribed teriparatide is 
prescribed it for secondary prevention 
and meets at least one of the 
following 2 criteria 
" has a reason to avoid 
bisphosphonates (See 12) 
" has an intolerance to 
strontium ranelate 
o persistent nausea 
o persistent diarrhoea 
And has DEXA scan assessment that 
puts them in one the following groups 
 
" aged ! 65 years with a T-
Score " -4 SD 
" aged ! 65 years with a T-
Score " -3.5 SD and 
has more than two 
fractures 
" aged 55-64 years with a T-
Score " -4 and has 
more than two fractures 
 
 
 
 
 
 
 
 
319/319 
100% 
0 0 0 0 0 0/319 
0% 
nr 
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Total (319 patients) 
n= 6061 criteria 
N/A 
% 
Yes 
% 
No(J) 
% 
No(U) 
% 
IDS 
% 
IDQ 
% 
Applicable 
Applicability 
Adherence 
(CI 95%) 
19 A patient prescribed calcitonin is 
prescribed it for secondary prevention 
after bisphosphonate, raloxifene or 
strontium ranelate have been tried or 
have reasons for excluding from 
consideration 
 
[Reasons for non-use of 
bisphosphonates are 
" contraindication to 
bisphosphonates (see 12) 
" inability to comply with the 
recommendations for use of 
bisphosphonates (see 12) 
" intolerance to 
bisphosphonates (see 12)] 
 
319/319 
100% 
0 0 0 0 0 0/319 
0% 
nr 
Overall  
(%) 
3581/6061 
59.1% 
1532 18 860 88 44 2480/6061  
40.9% 
1532/2480 
61.7% 
(59.8-63.6) !
N/A: not applicable; No(J): justified non-adherence to the guideline; No(U): unjustified non-adherence to the guideline; IDS: insufficient data on the standard; IDQ: 
insufficient data on the qualifier; CI: confidence interval; S1: Search 1; nr: no result
The implementation of a pharmaceutical care tool to guide community pharmacy interventions in osteoporosis !
!90 
The following tables show ranking of level of adherence to each criterion in practice A, B and C 
as well as of the whole study sample.  
In practice A, 6 criteria were reported to be highly adhered to with a mean of 92.4%. 
Intermediate level of adherence was observed in 7 criteria with a mean of 57.7%. In 2 criteria 
adherence was found to be low with a mean of 27.4%. In 4 criteria no results could be reported 
since there were no patients applicable to these criteria. 
Table 19 Ranking in level of adherence practice A 
Ranking Level of 
adherence 
Criterion number and description Adherence Applicability 
1 C16: Patient prescribed strontium ranelate 
has a reason to avoid bisphosphonates 
100% 1.3% 
2 C 7: Patient prescribed supplementary 
calcium is prescribed the appropriate dose 
98.8% 55.2% 
3 C 8: Patient prescribed supplementary 
vitamin D is prescribed the appropriate dose 
98.7% 50.6% 
4 C 14: Patient on a bisphosphonate is 
prescribed the preffered choice 
87.8% 53.2% 
5 C 13: Patient prescribed osteoporosis 
treatment is prescribed standard dose 
regimen 
86.2% 61% 
6 
 
 
 
 
High 
 
C 12: Patient prescribed 
antiresorptive/osteoanabolic treatment has 
no contraindication to the agent 
83.0% 61% 
7 C 6: Patient diagnosed with osteoporosis is 
prescribed treatement 
60.8% 89.6% 
8 C 5: Patient with vitamin D deficieny or aged 
over 65 is prescribed vitamin D 
58.9% 80.5% 
9 C 10: Osteporotic patient is prescribed a 
bisphosphonate as first line therapy 
58.7% 89.6% 
10 C 1: Patient with a diagnosis of osteoporosis 
was diagnosed via DEXA scan 
58.3% 85.7% 
11 C 4: Osteopenic patient is prescribed 
supplementary calcium 
56.3% 10.4% 
12 C 11: Osteopenic patient prescribed 
bisphosphonate as first line therapy 
56.3% 10.4% 
13 
 
 
 
 
 
Intermediate 
C 3: Osteoporotic patient prescribed 
supplementary calcium 
55.1% 89.6% 
14  C 2: DEXA scan performed at two specific 
sites (spine and hip) 
34.4% 60.4% 
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15 Low C 9: Patients not prescribed 
antiresorptive/osteoanablic treatment are 
prescribed calcium and vitamin D 
20.4% 0% 
- C 15: Patient on long-term oral steroids 
receiving a bisphosphonate 
- 0% 
- C 17: Patient prescribed raloxifene is 
prescribed it for secondary prevention 
- 0% 
- C 18: Patient prescribed teriparatide meets 
requirements for being prescribed 
teriparatide 
- 0% 
- 
 
No result 
 
C 19: Patient prescribed calcitonin meets 
requirements for being prescribed calcitonin 
- 0% 
 
In practice B, high adherence was reported for 4 criteria with a mean of 88.1%. Intermediate 
adherence was observed in 3 criteria with a mean of 53.3%. 5 criteria were found to be poorly 
adhered to with a mean of 24.2%. In 7 criteria no results could be found since there were no 
applicable patients. 
Table 20 Ranking in level of adherence practice B 
Ranking Level of 
adherence 
Criterion number and description Adherence Applicability 
1 C 7: Patient prescribed supplementary 
calcium 
100% 54.8% 
2 C 8: Patient prescribed supplementary 
vitamin D is prescribed the appropriate dose  
94.1% 54.8% 
3 C 14: Patient on a bisphosphonate is 
prescribed the preffered choice 
83.9% 50% 
4 
 
 
 
 
High 
 C 13: Patient prescribed osteoporosis 
treatment is prescribed standard dose 
regimen 
74.5% 82.3% 
5 C 5: Patient with vitamin D deficieny or aged 
over 65 is prescribed vitamin D 
59.6% 75.8% 
6 C 6: Patient diagnosed with osteoporosis is 
prescribed treatement 
50% 100% 
7 
 
Intermediate 
C 10: Osteporotic patient is prescribed a 
bisphosphonate as first line therapy 
50% 100% 
8 C 12: Patient prescribed 
antiresorptive/osteoanabolic treatment has 
no contraindication to the agent 
41.9% 50% 
9 
 
 
C 3: Osteoporotic patient prescribed 38,7% 100% 
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supplementary calcium 
10 C 9: Patients not prescribed 
antiresorptive/osteoanablic treatment are 
prescribed calcium and vitamin D 
38.7% 50% 
11 C 1: Patient with a diagnosis of osteoporosis 
was diagnosed via DEXA scan 
1.6% 100% 
12 
 
Low 
 
C 2: DEXA scan performed at two specific 
sites (spine and hip) 
0% 17.7% 
- C 4: Osteopenic patient is prescribed 
supplementary calcium 
- 0% 
- C 11: Osteopenic patient prescribed 
bisphosphonate as first line therapy 
- 0% 
- C 15: Patient on long-term oral steroids 
receiving a bisphosphonate 
- 0% 
- C 16: Patient prescribed strontium ranelate 
has a reason to avoid bisphosphonates 
- 0% 
- C 17: Patient prescribed raloxifene is 
prescribed it for secondary prevention 
- 0% 
- C 18: Patient prescribed teriparatide meets 
requirements for being prescribed 
teriparatide 
- 0% 
- 
 
No result 
C 19: Patient prescribed calcitonin meets 
requirements for being prescribed calcitonin 
- 0% 
 
In practice C, 5 criteria were highly adhered to with a mean of 97.3%. In 6 criteria intermediate 
adherence was observed with a mean of 64.6%. 5 criteria were found to be of low level of 
adherence with a mean of 30.6%. In 3 criteria no results could be found due to non-existence 
of applicable patients.  
Table 21 Ranking in level of adherence practice C 
Ranking Level of 
adherence 
Criterion number and description Adherence Applicability 
1 C 7: Patient prescribed supplementary 
calcium is prescribed the appropriate dose 
100% 49.5% 
2 C 8: Patient prescribed supplementary 
vitamin D is prescribed the appropriate dose 
100% 48.5% 
3 C 15: Patient on long-term oral steroids 
receiving a bisphosphonate 
100% 58.3% 
4 
 
 
 
High 
 
C16: Patient prescribed strontium ranelate 
has a reason to avoid bisphosphonates 
100% 1% 
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5 C 14: Patient on a bisphosphonate is 
prescribed the preffered choice 
86.5% 35.9% 
6 C 6: Patient diagnosed with osteoporosis is 
prescribed treatement 
69.1% 53.4% 
7 C 10: Osteporotic patient is prescribed a 
bisphosphonate as first line therapy 
68.5% 52.4% 
8 C 13: Patient prescribed osteoporosis 
treatment is prescribed standard dose 
regimen 
64.6% 46.7% 
9 C 3: Osteoporotic patient prescribed 
supplementary calcium 
63.3% 58.3% 
10 C 1: Patient with a diagnosis of osteoporosis 
was diagnosed via DEXA scan 
62.7% 57.3% 
11 
 
 
 
 
 
Intermediate 
C 5: Patient with vitamin D deficieny or aged 
over 65 is prescribed vitamin D 
59.4% 67% 
12 C 12: Patient prescribed 
antiresorptive/osteoanabolic treatment has 
no contraindication to the agent 
47.9% 46.6% 
13 C 9: Patients not prescribed 
antiresorptive/osteoanablic treatment are 
prescribed calcium and vitamin D 
40.9% 46.7% 
14 C 4: Osteopenic patient is prescribed 
supplementary calcium 
30.2% 35.9% 
15 C 11: Osteopenic patient is prescribed a 
bisphosphonate as first line therapy 
23.3% 1% 
16 
Low 
C 2: DEXA scan performed at two specific 
sites (spine and hip) 
10.8% 1% 
- C 17: Patient prescribed raloxifene is 
prescribed it for secondary prevention 
- 0% 
- C 18: Patient prescribed teriparatide meets 
requirements for being prescribed 
teriparatide 
- 0% 
- 
 
 
No result 
C 19: Patient prescribed calcitonin meets 
requirements for being prescribed calcitonin 
- 0% 
 
For the whole study sample, 6 criteria were found to be highly adhered to with a mean of 
93.7%. In 5 criteria intermediate level of adherence was observed with a mean of. 59.4% Low 
level of adherence could was found in 5 criteria with a mean of 34.1%. For criteria, no results 
could be found since there were no patients applicable to these criteria. 
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Table 22 Ranking in level of adherence total patient sample 
Ranking Level of 
adherence 
Criterion number and description Adherence Applicability 
1 C 15: Patient on long-term oral steroids 
receiving a bisphosphonate 
100% 0.3% 
2 C16: Patient prescribed strontium ranelate 
has a reason to avoid bisphosphonates 
100% 0.9% 
3 C 7: Patient prescribed supplementary 
calcium is prescribed the appropriate dose 
99.4% 53.3% 
4 C 8: Patient prescribed supplementary 
vitamin D is prescribed the appropriate dose 
98.1% 50.8% 
5 C 14: Patient on a bisphosphonate is 
prescribed the preffered choice 
86.7% 47% 
6 
 
 
 
 
High 
 
C 13: Patient prescribed osteoporosis 
treatment is prescribed standard dose 
regimen 
77.7% 60.5% 
7 C 12: Patient prescribed 
antiresorptive/osteoanabolic treatment has 
no contraindication to the agent 
65.9% 79.9% 
8 C 6: Patient diagnosed with osteoporosis is 
prescribed treatement 
60% 53.3% 
9 C 5: Patient with vitamin D deficieny or aged 
over 65 is prescribed vitamin D 
59.2% 50.8% 
10 C 10: Osteporotic patient is prescribed a 
bisphosphonate as first line therapy 
58.6% 33.5% 
11 
 
 
Intermediate 
C 3: Osteoporotic patient prescribed 
supplementary calcium 
53.1% 81.5% 
12 C 1: Patient with a diagnosis of osteoporosis 
was diagnosed via DEXA scan 
45.5% 79.3% 
13 C 4: Osteopenic patient is prescribed 
supplementary calcium 
 
37.3% 18.5% 
14 C 11: Osteopenic patient is prescribed a 
bisphosphonate as first line therapy 
32.2% 18.5% 
15 C 9: Patients not prescribed 
antiresorptive/osteoanablic treatment are 
prescribed calcium and vitamin D 
29.9% 33.5% 
16 
 
 
 
Low 
C 2: DEXA scan performed at two specific 
sites (spine and hip) 
25.5% 44.2% 
-  C 17: Patient prescribed raloxifene is 
prescribed it for secondary prevention 
- 0% 
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- C 18: Patient prescribed teriparatide meets 
requirements for being prescribed 
teriparatide 
- 0% 
- 
 
No result 
C 19: Patient prescribed calcitonin meets 
requirements for being prescribed calcitonin 
- 0% 
 
 
The following bar charts were designed to highlight the differences in level of adherence 
between the three GPs. Adherence was observed to be particularly low in GP B, especially in 
criteria 1 (1.6%) and 2 (0%) dealing with DEXA scans. Criteria dealing with osteopenic patients 
(4 and 11) could not be applied to this patient sample since it was solemnly comprised of 
osteoporotic patients while there were no patients diagnosed with osteopenia. ForGP C 
particularly low adherence was reported for criterion 2, requiring diagnosis by DEXA scan 
performed at two specific sites. In all other criteria level of adherence was more or less similar, 
except for an especially high adherence in GP A for criterion 12 requiring no contraindications 
on record for patients receiving antiresorptive/ osteoanabolic agents.  
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2  
Bar chart 1 Adherence to criteria 1-4 !
 
Bar chart 2 Adherence to criteria 5-8 
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Bar chart 3 Adherence to criteria 9-12 !
 
Bar chart 4 Adherence to criteria 13-16 
 
For criteria 17, 18 and 19 there could be no result reported since there were no patients 
applicable to these criteria. 
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The following flowcharts show adherence to the clinical guidelines used in this project (SIGN 
71 and NICE 160 and 161) concerning preferred order in treatment options in both primary and 
secondary prevention of osteoporosis in postmenopausal women, men and patients with 
glucocorticoid- induced osteoporosis drawn from GP A and B. 
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PRIMARY PREVENTION 
C: 108/138 (78.3%) 
Postmenopausal  
C: 97/108 (89.8%) 
SECONDARY  PREVENTION 
C: 30/138 (21.7%) 
 
Men  
C: 7/108  (6.5%) 
Postmenopausal 
C: 25/30 (83.3%) 
Men 
C: 5/30 (16.7%) 
Glucocorticoid-
induced 
Glucocorticoid-
induced 
OSTEOPOROSIS 
C: 138 
Alendronate 
C: 14/25 (56%) 
Teriparatide 
C: 0/25 (0%) 
 
Alendronate 
C: 51/97 (52.6%) 
Risedronate 
C: 0 
 
Strontium ranelate 
C: 1/97 (1.03%) 
 
Alendronate 
C: 4/7 (57.1%) 
Alendronate 
Risedronate 
Etidronate 
Risedronate 
C: 0/25 P: (0%) 
Strontium ranelate 
or raloxifene C: 1/25 
(4%) 
Calcitonin 
C: 0/25 (0%) 
Alendronate 
Risedronate 
C: 0/5 (0%) 
Teripatide 
C: 0/5 (0%) 
Calcitonin 
C: 0/5 (0%) 
Alendronate 
Risedronate 
Etidronate 
Etidronate 
C: 0 
 
Etidronate 
C: 1/25 (4%)! Etidronate C: 0/5 (0%) 
TOTAL 
52/97 (53.6%) 
 
TOTAL 
4/7(57.1%) 
accordingt to the 
guidelines 
6/7 (85.7%) 
[2/7 Risedronate 
(not justified 
according to the 
guidelines)] 
TOTAL 
16/25 (64%) 
 
TOTAL 
2/5 (40%) 
 
Table 23 Flowchart practice A !
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PRIMARY PREVENTION 
P: 59/62 (95.2%) 
Postmenopausal 2 
P: 53/59 (89.8%) 
SECONDARY  PREVENTION 
P: 3/62 (4.8%) 
Men  
P: 5/59 (8.5%) 
Postmenopausal 
P: 1/3 (33.3%) 
Men 
P: 2/3 (66.6%) 
Glucocorticoid-
induced 
Glucocorticoid-
induced 
OSTEOPOROSIS 
 P: 62 
Alendronate 
P: 0/1 (0%) 
Teriparatide 
P: 0/1 (0%) 
 
Alendronate P: 22/53 
(41.5%) 
Risedronate 
P: 4/53 (7.5%) 
Strontium ranelate 
P: 0/53 (0%) 
Alendronate 
P: 3/5  (60%) 
Alendronate 
Risedronate 
Etidronate 
Risedronate 
P: 0/1 (0%) 
Strontium ranelate 
or raloxifene 
P: 0/1 (0%) 
Calcitonin 
P: 0/1 (0%) 
Alendronate 
Risedronate 
P: 0/2  (0%) 
Teripatide 
5 P: 0/2 (0%) 
Calcitonin 
P: 0/2 (0%) 
Alendronate 
Risedronate 
Etidronate 
Etidronate 
P: 1/53 (1.9%) 
Etidronate 
P: 0/1 (0%) 
Etidronate 
P: 0/2 (0%) 
TOTAL 
27/53 (50.9%) 
 
TOTAL 
P: 3/5  (60%) 
TOTAL 
P: 0/1 (0%) 
TOTAL 
P: 1/2 (50%) 
 Table 24 Flowchart practice B 
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5.3. Inter-rater reliability testing 
Inter-rater reliability testing of the MATosteo was conducted by two independent 
researchers and showed mean agreements of 99% for both applicability and 
adherence. Calculations were performed for the patient samples drawn from GP A and 
B, using the draft of MATosteo preceding the final tool, which was comprised of 21 
criteria instead of 19.  Minimum agreement in applicability was 90%, maximum 100% 
shown in 15 out of 21 criteria. Minimum adherence was 95% with 100% shown in 
18/21 criteria.  Total agreement in ’Yes’- results was achieved in 18 out of 21 criteria 
with a mean agreement of 99.6%. The two researchers fully agreed in terms of justified 
non-adherences in 21 out of 21 criteria. Concerning unjustified non-adherence, total 
agreement was achieved in 19 criteria with a mean agreement of 99.9%. See appendix 
5. 
5.4. Results of the validation of a potential community pharmacy- based 
service for the management of osteoporosis- Interviews 
Health care specialists stated that the population did not have enough knowledge 
about osteoporosis, especially not about the implications of the disease, although there 
seemed to be a certain awareness of osteoporosis since many people have relatives or 
friends who are sufferers. Information provided about the disease by community 
pharmacists and in general was reported to be insufficient. An increase in provision of 
information through e.g. leaflets was confirmed to encourage more patients to refer 
themselves for diagnosis. It was reported that public health campaigns, nationally as 
well as locally have not yet taken place in Glasgow respectively Scotland but would 
contribute to create knowledge and awareness among patients. Interviewees 
suggested pharmacists to contribute in a public health campaign via speaking to 
patients, providing leaflets and posters.  
 
Furthermore it was affirmed that an assessment of patients’ knowledge would improve 
treatment outcomes. Use of questionnaires or checklists including risk factors like prior 
fracture, age, gender, family history, drug use like steroids, early menopause etc 
alongside with the indication of the appropriate action that should be taken, was 
confirmed to be capable of increasing identification rates in osteoporosis. The FRAX® 
tool was reported to be a useful tool which could be applied by community pharmacists 
to calculate fracture probability in patients in order to give appropriate advice or refer 
for diagnosis. Nevertheless it is not widely used in Glasgow due to the existence of the 
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DADS (direct access DEXA service) criteria that are basically equivalent to the FRAX® 
criteria. However, the FRAX® tool was reported to be of use in the making of treatment 
decisions in osteopenic patients whether to initiate treatment or not. Time was reported 
to be the limitating factor for calculation of fracture probability by using the FRAX® via 
community pharmacists.  
Health care specialists stated that pharmacists did not sufficiently focus on the 
connection between diet, exercise, smoking etc and osteoporosis in the provision of 
health education and recommendation. It was reported that neither general medical 
practitioners nor community pharmacists provided sufficient support in medicines 
compliance to osteoporosis treatment. Interviewees affirmed that it would be useful to 
create a standard procedure for patients receiving osteoporosis treatment in order to 
increase the number of compliant patients. Health care specialists referred to the 
existence of a service intended for delivery by community pharmacists to follow up 
patients prescribed osteoporosis treatment. It was stated that only very few 
pharmacists actually were doing it. Implementation of measures to encourage 
pharmacists to provide long-term support was appreciated. 
Interviewees reported that community pharmacists were usually not able to identify the 
duration of a patient’s oral steroid therapy and were therefore incapable of indicating 
that the patient was suggested for bisphosphonate therapy. Hence, a service delivered 
by community pharmacies capable of identifying issues such as steroid patients not 
receiving preventive treatment for osteoporosis, was appreciated. 
Measurement of adherence to clinical guidelines in osteoporosis patients was found to 
be unnecessary by several interviewees. From their point of view treatment was 
initiated exclusively by specialists ‘who usually operate according to guideline 
recommendation’. Interviewees estimated adherence to guideline recommended 
prescribing to be approximately 80%. 
5.5. Results literature review: Measures to address osteoporosis- current 
strategies and projects 
5.5.1. Falls prevention- A Glasgow model of care 
In Glasgow a Pharmacist-led model of care is targeting the problem of falls prevention. 
This model of care represents a systematic multidisciplinary approach to the problem of 
patients falling and sustaining fractures and was suggested by health care 
professionals to be incorporated into the NHS Primary and Secondary Care systems. 
Glasgow has a funded Strategy for Osteoporosis and Falls Prevention (see section 
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5.5.2.). The model is based on more than 60 randomised trials of interventions to 
prevent falls (Lowrie 2008). It consists on identification and referral of patients living in 
the community who are over the age of 65 and have fallen in the past year via 
community pharmacists. The patient’s contact details are transferred to the Home Falls 
Prevention Programme (HFPP) who arranges an appointment with a worker trained in 
multidimensional risk assessment who will undertake a screening visit at the patient’s 
home in order to identify risk factors for falling, especially environmental risk factors 
(Lowrie 2008).  
 
The community pharmacist can refer patients to the HFPP or the patients can refer 
themselves. Onward referral from the HFPP to the pharmacy is also taking place in 
case a patient is receiving more than three repeat medicines and agrees to a 
medication review (Lowrie 2008). The medication review is a key intervention within the 
model besides the identification of high-risk patients. Such medication reviews used to 
be delivered by falls-specialist pharmacists, but now they are increasingly delivered by 
the community pharmacist nominated by the patient, which creates a perfect follow- up 
scenario since the community pharmacist is in regular contact with the patient and can 
identify ongoing problems and intervene. The medication review is a structured 
discussion between the pharmacist and the patient respectively his or her carer and 
tackles issues such as a patient’s condition, medicines and expectations. A main 
component of the review is the identification of drugs increasing the risk of falling. 
Centrally acting drugs or drugs affecting blood pressure contribute to the risk of falling 
via mechanism like sedation, orthostatic hypotension, confusion, blurred vision etc 
especially when four or more drugs are taken at the same time(Lowrie 2008). 
 
The review may include a withdrawal of potentially fall inducing drugs or a dose 
reduction. If the pharmacist delivering the review is a supplementary prescriber, 
changes to treatment are can be done immediately. Otherwise suggestions are made 
to the GP or consultant. Onward referral to other health or social care partners may 
take place following the review. The medication review should lead to an agreement to 
change in treatment between pharmacist and patient. The pharmacist will follow up any 
recommended changes in order to ensure the patient understood, accepted and 
adheres to them (Lowrie 2008).  
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5.5.2. NHS Greater Glasgow: Strategy for Osteoporosis and Falls 
Prevention 
This strategy is a sub set of the Glasgow City Older People’s strategic framework and 
has been developed by the multidisciplinary Osteoporosis and Falls Steering group, 
which was comprised of representatives of geriatric medicine, osteoporosis services, 
allied health professionals, public health, planning and local authority social work. It 
was implemented in 2006. The aim of the strategy was to ’reduce the number of falls 
which result in serious injury and ensure effective treatment and rehabilitation for those 
who have fallen’ by  
• Prevention (including the prevention and treatment of osteoporosis 
• Improving the diagnosis, care and treatment of those who have fallen 
• Rehabilitation and long term support (NHS 2006) 
Sub groups of health care professionals participated in the development of the 
strategy. Those were the Care Homes Subgroup, the Home Falls Subgroup, the 
Hospital Subgroup, the Osteoporosis subgroup and the Physical Activity subgroup.  
The focus of the strategy was put onto several target groups,  
• the population as a whole 
•  individuals at risk of falling 
•  individuals at risk of injury from falling 
•  individuals at risk of fracture and 
• individuals affected psychologically by falls (NHS 2006) 
I: Approach to prevent falls in the general population 
1.: Public Health Approach 
The approach to reduce the incidence and impact of falls in the general population was 
based on actions to ‘encourage appropriate weight-bearing and strength enhancing 
physical activity, promote health eating (including adequate intake of calcium) and 
reduce smoking’. The National Osteoporosis Society recommends in its Primary Care 
Strategy for Osteoporosis and Falls of 2002 the following life stage approach: 
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Table 26 Lifestyle recommendations according to age 
Life stage Area for action 
From conception to 
school age 
Maternal well being 
Healthy diet 
Adequate safe sunshine exposure 
Adequate weight bearing physical activity 
School age Healthy diet 
Adequate safe sunshine exposure 
Adequate weight bearing physical activity 
Avoidance of smoking 
Caution about excessive dieting and athletic amenorrhoea 
Young adults Women with amenorrhoea/early menopause 
Healthy diet 
Adequate safe sunshine exposure 
Adequate weight bearing physical activity 
Avoidance of smoking 
Caution about excessive dieting and athletic amenorrhoea 
Alcohol within recommended safe limits 
Adults at midlife Women at menopause 
Healthy diet 
Adequate safe sunshine exposure 
Adequate weight bearing physical activity 
Avoidance of smoking 
Caution about excessive dieting and athletic amenorrhoea 
Alcohol within recommended safe limits 
65+ Selective case finding for people at high risk of osteoporosis 
Falls prevention measures 
Healthy diet 
Adequate safe sunshine exposure 
Adequate weight bearing physical activity 
Avoidance of smoking 
Alcohol within recommended safe limits 
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2.: Local health promotion strategies 
National school meal guidelines ‘Hungry for Success’ were implemented in Primary 
Schools to provide assured availability of adequately calcium containing food. The 
NHS Greater Glasgow reformulated its Food and Health Policy to establish new 
standards for nutrition in hospitals, which focussed on the adequate calcium and 
vitamin D intake in continuing care beds for older people (NHS 2006).  
II: Preventing falls in individuals at home 
There are several places where a patient who has fallen can be referred to: 
• the Interdisciplinary Response and Intervention Service (IRIS) 
• the Discharge and Rehabilitation Team (DART) 
• the Community Older People’s Teams (COPTs) 
• the Day Hospital 
• the Home Falls Prevention Programme 
• Falls clinics 
During a pilot falls project to which patients were referred to via GPs, health, social 
workers, carers and self-referal, a screening tool for risk factors and a plan for 
appropriate interventions were developed. A trained OT support worker under the 
supervision of a clinical lead undertakes the screening of all patients who are referred 
to the service. The screening tool includes short assessment tools like mini mental 
state, timed up and go (TUAG), Hospital Anxiety and Depression Scale. The 
assessment enables the service to refer patients appropriately for further assessment 
and/or intervention to 
• DXA scan 
• Physiotherapy/ exercise programme 
• Day Hospital review 
• Pharmacy-medication review 
• Optometry 
• Podiatry 
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• Occupational Therapy 
The service includes a Falls Administration Centre, which enables the gathering of 
basic information about the patient and the direct referral to the appropriate service 
(NHS 2006). 
Outpatient Falls Clinics 
In Greater Glasgow there are five outpatient falls clinics. Patients with syncope 
(transient loss of consciousness), complex pharmacology and 2 or more falls with 
preceding symptoms are referred to an outpatient falls clinic. The clinics undertake a 
medical review with ‘Falls Screening Documentation’, which is provided by the Home 
Falls Prevention service. Following this consultants etc from the hospital meet to 
discuss and agree on an appropriate action plan (NHS 2006). 
Standardised exercise programme 
Referral to exercise programmes is based on the individual patient’s conditions. All 
hospitals run exercise programmes. Programmes will be increased to ten weeks and 
delivered on a twice-weekly basis. These will be physiotherapy led for the first six 
weeks and then coach- led. On discharge, patients will be referred into level 1. 
Community programmes take place in community based centres throughout NHS 
Greater Glasgow. Falls prevention programmes are run alongside with the exercise 
programme. Many patients, particularly the elderly ones, require transportation to the 
centres or hospital where their exercise programme is taking place. This is provided by 
ambulance transportation for patients attending the hospital based programme or the 
level 1 programme (NHS 2006). 
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Table 27 Patient specific exercise programmes 
Programme Target group 
Hospital based Suitable for frail, functionally dependent 
individuals who require high level of supervision 
Level 1(Community based) Suitable for patients who are slightly more 
independent 
Level 2 (Community based) Higher level balance activities for functionally 
independent patients 
Level 3 (Hospital based 
osteoporosis class) 
Primarily for the postmenopausal osteoporosis 
group. Also suitable for low risk fallers. 
Level 4  Primarily for the postmenopausal osteoporosis 
group. Also suitable for independent older 
individuals for prevention purposes. 
Exercise booklet/video 
(basic seated warm up and 
exercises in sitting and standing) 
Suitable for all patients. (This will be used in 
care homes settings as a home based physical 
intervention). Plus separate osteoporosis video. 
 
Community pharmacies 
The majority of Glasgow’s community pharmacists have received training to identify 
patients who are at risk of osteoporosis and/or falling, to deliver medication reviews 
and to provide support in medication compliance with osteoporosis treatment. The 
contract for community pharmacies offers a potential possibility for patient contacts and 
continuity and consistency in long-term support of patients receiving osteoporosis 
and/or who are at risk of falling. As mentioned before, the community pharmacy 
contribution consists on  
• identifying patients/customers at risk of falling 
•  offering relevant and appropriate information 
•  referring to the Home Falls Prevention Programme, 
• delivering medication reviews for patients referred by the HFPP 
Pharmacists also deliver medication reviews in falls clinics in collaboration with 
secondary care based pharmacists. This provides the additional benefit of linking the 
community pharmacy with the clinical setting and enables a pre- as well as a post-clinic 
appointment with the community pharmacist (NHS 2006). 
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Direct Access to DXA services 
All patients who have fallen are assessed for risk factors of osteoporosis according to 
the criteria used for the Direct Access DXA service (DADS) (NHS 2006). 
Preventing falls in patients who live in care homes 
Many inhabitants of care homes frail, ill and/or have mobility problems. Every inhabitant 
who has recently fallen is provided with a ‘Falls Action Plan’. This plan includes 
documentation of a patient’s individual environmental/personal and communication 
needs, any behaviours leading to falls as well as aids and equipment to prevent falls. 
Each care home reviews all falls on a three- monthly cycle or more frequently if 
required. Action plans for inhabitants who fall frequently, might be reviewed. Guidance 
for equipment to reduce risk of falls was established. This guidance includes seating, 
bed rails, non-slip mats, lap straps and low-level beds or mattresses. Hip protectors 
might protect residents who fall and might be implemented. Older people living in care 
homes receive calcium and vitamin D supplementations. Residents who present the 
following problems associated with falls risk are referred to the appropriate service in 
order to reduce the risk of falling: 
• problems in gait, balance, mobility and muscle weakness  
• osteoporosis risk 
• perceived functional ability and fear relating to falling 
• visual impairment 
• cognitive impairment (will be referred for neurological examination) 
• urinary incontinence 
• medications increasing the risk of falling (NHS 2006) 
Staff of care homes is trained to deliver exercise programmes for the residents. The 
programme is based on the exercise book and video. Residents who are functionally 
more able should attend the level 1 class in the nearest community. Furthermore the 
staff receives training concerning the identification of environmental risk factors, 
identification of personal risks and the use of mobility aids (NHS 2006). 
Falls prevention co- coordinators should be employed in order to increase the 
awareness of falls prevention and management and to support the care home in the 
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development and the review of falls action plans as well provide help in patients eligible 
for hip protectors(NHS 2006).  
 
Preventing falls in patients in hospitals 
In the clinical setting, ‘Hospital Falls Coordinators’ ensure that all wards carry out 
effective risk assessment and appropriate interventions and provide staff and patient 
education. Furthermore equipment and hip protectors are overviewed. Patients with 
gait problems are referred to physiotherapy and receive a structured exercise plan. 
Patients who fall and do not fracture are referred for osteoporosis risk assessment via 
DADS criteria (NHS 2006). 
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6- DISCUSSION 
Osteoporosis is an asymptomatic disease that often remains undiagnosed and 
untreated, resulting in mortality, morbidity and impaired quality of life, socially, 
emotionally and financially (Lewiecki 2009a). It has been predicted that in 20 years’ 
time approximately one quarter of the European population will be above the age of 65 
(Woolf and Akesson 2003). The fact that incidence in fractures increases with age 
combined with the expanding population of elderly people results in a growing burden 
of osteoporosis. Therefore progress in diagnosis and identification of individuals at high 
fracture risk is crucial. Even though evidence based interventions for diagnosis, 
prevention and treatment of the disease exist, it has been observed that they are not 
applied in clinical practice or only to a certain, small extent (Woolf and Akesson 2003).  
 
An adequate intake of calcium and vitamin D is regarded as baseline therapy for both 
prevention as well as treatment of osteoporosis (Lewiecki 2009b). Elderly people in 
particular are considered for calcium and vitamin D supplementation (Woolf and 
Akesson 2003).  Assessment of the patient sample in this study showed that guideline 
recommendations concerning calcium and vitamin D are only poorly adhered to. Oral 
bisphosphonates are considered to be first line therapy for osteoporosis. However their 
use may be limited due to gastrointestinal side effects (Lewiecki 2009a). Assessment 
of the patient data in this project showed that treatment alternatives such as alternative 
oral bisphosphonates, i.v. bisphosponates, strontium ranelate, raloxifene, calcitonin or 
teriparatide are only very rarely prescribed.  
 
Pharmacological interventions to prevent fractures are most clinically and cost effective 
when targeted at people who are at highest risk of sustaining fractures. Individuals who 
are at highest risk can be identified via previous fractures and low bone density since 
they are strong risk factors for sustaining a subsequent fracture. Combining these with 
other risk factors allows the identification of those patients who are at highest risk. 
Management of high-risk patients should be according to their risks and needs (Woolf 
and Akesson 2003). Drug intolerance, complexity of dosing regimens and poor 
understanding of the benefits and risks of the treatment are the major limitations in 
osteoporosis treatment. Therefore there is a substantial need for effective strategies to 
maximize compliance, long-term tolerance and persistence with therapy (Lewiecki 
2009a). To sum up, there is a substantial need for development of strategies to 
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address osteoporosis, to screen and identify more individuals who are at high risk, to 
give systematic patient specific advice, to provide individual patient-specific treatment, 
to follow up treatment and ensure long-term efficacy, tolerance and safety of treatment.  
 
Assessment of patient data of osteoporosis and osteopenia patients in this project 
showed that 40% of patients are receiving no treatment at all although they are eligible 
for treatment and although alternative treatment options exist. In many patients there 
could be no documented reason such as e.g. a contraindication to a certain agent 
found to justify this non-prescribing of both first line and second line therapy. 
Prescribing of supplementary calcium and vitamin D was observed to be low, 
especially in osteopenic patients. 30% of patients eligible for osteoporosis treatment 
but not receiving antiresorptive or osteoanablioc treatment were not prescribed 
supplementary calcium and vitamin D. 
6.1.  Problems and challenges within the conduction of the study 
Major limitation to the feasibility of the implementation of MATosteo was the 
accessibility of patient data. Crucial information such as results from certain 
investigations was not accessible for the researcher on GPASS®. There was no 
access to actual T- Scores (BMD measurement values), so there could be no 
judgement made whether a diagnosis of osteoporosis or osteopenia was reliable and 
set up according to WHO-criteria or not. Furthermore lab results such as Creatinine 
Clearance (CrCl) were not accessible. In many cases documentation was restricted to 
an entry of ‘chronic kidney disease’ or ‘chronic kidney disease stage 3’ or ‘chronic 
kidney disease stage 4’. Therefore the investigator was not able to determine whether 
a patient presents an explicit contraindication to bisphosphonates respectively 
raloxifene or not.  
 
Bisposphonates are contraindicated in patients presenting a CrCl below 35 ml/min, 
which represents a stage within CKD stage 3. Raloxifene is contraindicated in patients 
with a CrCl below 10 ml/min (CKD stage 4). In some cases   serum creatinine was 
reported which does not allow an explicit categorisation of renal impairment. Another 
problem was the inconsistency in documentation regarding wording. For example there 
could be entries of ‘chronic renal failure’, ‘renal impairment’, ‘chronic kidney disease’, 
‘CKD’ and ‘Serum Creatinine raised’. All these terms represent the same condition and 
aggravate the data extraction from GPASS®. In many cases documentation was 
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incomplete. Documentation of ‘HRT’ did not allow the investigator to determine whether 
a woman was receiving hormone replacement therapy for alleviation of 
postmenopausal symptoms or for osteoporosis treatment. Furthermore gaps in 
documentation were discovered in weight and height. Body mass index (BMI) was 
hardly ever documented. 
A correct data collection is crucial for the accurate conduction of the study. Due to the 
reasons mentioned before the data collection has to be conducted by trained stuff 
presenting certain background information in pharmacology and the software system 
GPASS®. 
6.2. Adherence of the GP clinics to guideline recommendation 
The purpose of this study was to evaluate the extent to which prescribers handle 
medicine use according to guideline recommendation. Overall adherence of 61.7% to 
clinical guidelines for the management of osteoporosis represents intermediate level of 
adherence. This information might be a first stage to take steps to increase guideline 
adherence in osteoporosis management. Local health specialists estimated adherence 
to guideline recommended prescribing to be approximately 80%, which has been 
shown to be not the case with a mean of only 60%.  
6.2.1. Calcium and vitamin D 
The study revealed that level of adherence to guideline recommendation in prescribing 
of supplementary calcium and vitamin D is insufficient. Within the total study sample 
only 53.1% of patients with osteoporosis and 37.3% of patients with osteopenia were 
prescribed calcium. 59.2% of patients aged 65 and over were prescribed vitamin D. 
29.9% of patients with osteoporosis who were not receiving antiresorptive/ 
osteoanabolic treatment, were prescribed supplementary calcium and vitamin D 
meaning that approximately 70% of patients with osteoporosis remain completely 
untreated. 
For GP A significantly high adherence was observed in criteria 7 and 8 stating that 
prescribed dosing regimens in calcium and vitamin D prescriptions are correct. In 84 
out of 85 respectively 77 out of 78 patients the correct dosage was prescribed. 
However, applicability in these criteria was shown to be only 55.2% respectively 50.6%. 
This means that only 85 out of eligible 154 (55.2%) patients were prescribed calcium 
and 78 out of 154 (50.6%) were prescribed vitamin D. Although calcium and vitamin D 
supplementation is regarded as baseline therapy in the prevention and treatment of 
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osteoporosis and osteopenia (Lewiecki 2009a), the number of patients receiving 
supplements is significantly low with approximately a half of eligible patients. 
Similarly forGP B adherence to criteria 7 and 8 was 100% and 94.1% with 34 out of 34 
and 32 out of 32 patients. Again, applicability to these criteria was only 54.8% since 
only 34 out of 62 (54.8%) were prescribed supplementary calcium and vitamin D. 
For GP C criteria 7 and 8 were adhered to by 100% with 51 out of 51 and 50 out of 50 
patients. However the patient sample drawn from GP C was comprised of 103 patients, 
all of them eligible for calcium and vitamin D supplementation, meaning that 
approximately 50% of patients were missed for supplementation. 
Although in most calcium and vitamin D prescriptions the appropriate dosage is 
prescribed, approximately half of eligible osteoporotic and osteopenic patients are not 
receiving supplementary calcium and vitamin D at all. For GP B criterion 3 requiring 
supplementary calcium in osteoporotic patients was only met by 24 out of 62 applicable 
(osteoporotic) patients (38.7%), a fact that indicates significant insufficiency in 
prescribing of supplementary calcium. For GP C only 30.2% of osteopenic patients 
were found to receive calcium.  
 For criterion 9 requiring prescribing of supplementary calcium and vitamin D in 
osteoporotic patients who are not receiving any treatment (antiresorptive or 
osteoanabolic), adherence was found to be only 29.9% (20.4% (11/54) for GP A, 
38.7% (12/31) for GP B and 40.9% (9/22) for GP C).  
Besides low rate in prescriptions, incompliance to regular intake of and vitamin D might 
also contribute to the non- adherence to supplementation of calcium and vitamin D. 
Since long-term prescriptions have to be picked up at the GP every month it might be 
possible that patients are merely incompliant to supplements and do not pick up their 
prescription on a monthly basis which would result in a non-existing of an active 
prescription record. This might be misinterpreted by the investigator as a non-existence 
of a prescription. The investigator suggests to conduct further research within the field 
of compliance in order to identify the underlying reason for the significantly low 
adherence to supplementation, especially in patients who do not present an active 
prescription record for any kind of osteoporosis treatment. 
Similarly as for calcium and vitamin D supplementation, in antiresorptive and 
osteoanabolic treatment it has been found that appropriate dosages were prescribed. 
For GP A 81 (86.2%) of 94 applicable patients were prescribed the appropriate dose 
regimen. Similarly 74.5% adherence (38 out of 51 applicable patients) was reported for 
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GP B. However, rates of actual prescribing of treatment were found to be rather 
insufficient. 
6.2.2. Antiresorptive/ osteo-anabolic treatment 
Although local health specialists estimated adherence in prescribing to be around 80%, 
the study showed that only 60% of osteoporosis-patients of the total study sample were 
actually prescribed antiresorptive/ osteoanabolic treatment. This percentage represents 
intermediate level of adherence to guideline recommendation.  
There were 58.6% of patients with osteoporosis and only 32.3% of patients with 
osteopenia were observed to receive a bisphosphonate as first line therapy, suggesting 
that osteopenic patients remain significantly undertreated. 
Some 65.9% of patients receiving treatment had no contraindications to these agents 
on records, a percentage that is apparently too low. Criterion 12 requires that patients 
receiving antiresorptive or osteoanabolic treatment do not have a contraindication to 
those agents. 94 out of 154 (61%) patients were applicable to this requirement 
(prescribed either antiresorptive or osteoanbolic treatment), 78 out of those 94 patients 
were adherent to the standard and did not have a contraindication on record.  
Criterion 14 requires that osteoporotic patients on bisphosphonate therapy should be 
on the preferred choice (alendronate or alternatively risedronate or as third choice 
etidronate). 72 patients out of 82 patients prescribed a bisphosphonate were adherent 
to the standard. Adherence to this criterion is 87.8%. Similarly adherence was 83.9% 
for GP B (26 out of 31 patients) and 86.5% for GP C (32 out of 37 applicable patients). 
Adherence of 100% in patients drawn from GP C was reported for criterion 16, 
requiring a prescription of strontium ranelate exclusively for patients who have a 
contraindication to bisphosphonates.  
 
There were only 2 patients prescribed strontium ranlelate, both of them presenting an 
identifiable reason to avoid bisposphonate therapy. Similarly for GP C one patient 
presenting a reason to avoid bisphosphonates was prescribed strontium ranelate, so 
adherence was 100%. Furthermore 100% was reported for criterion 15 for GP C. This 
criterion requires bisphosphonate prevention for patients receiving long-term steroid 
therapy. There was one patient receiving long-term steroids, he was prescribed a 
bisphosphonate.  
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Given the fact that various alternatives in antiresorptive and osteoanabolic treatment 
exist, contraindications in individual patients to certain medications can be taken into 
account and appropriate, alternative treatment options for each patient can be found. 
No patients were found to receive iv bisphosphonates, only 9 out of 319 patients were 
prescribed risedronate respectively etidronate. Only 3 out of 319 patients were found to 
receive strontium ranelate. There have been no patients on raloxifene, teriparatide or 
calcitonin. These facts suggest that rates in prescribing of alternative treatment options 
should be increased. 
6.2.3. DEXA scan 
Significantly low adherence in all three GPs was reported for criteria 1 and 2 requiring 
diagnosis of osteoporosis to be set up via DEXA scan (criterion 1) at two specific sites 
(criterion 2). For the requirement set up in criterion 1 stating that a patient with 
osteoporosis should have a recorded DEXA scan adherence was observed to be 
45.5%. In criterion 2 suggesting that a DEXA scan should be performed at two specific 
sites, namely spine and hip at the same date, adherence was even less with 25.5%. 
These findings suggest that diagnosing in osteoporosis is not necessarily reliable since 
the recommended action (performance of DEXA scan at spine and hip) is only taken in 
very few patients. 
Whereas adherence in criterion 1 was 58.3% in GP A (77/132) and 62.7% in GP C 
(37/59), it was only 1.6% in GP B (1 patient out of 62 osteoporotic patients diagnosed 
via DEXA scan). This might be due to the fact that GP B is located in a rather deprived 
area within Greater Glasgow did not have access to DEXA scan facilities for a long 
time. However the requirement for performance of DEXA scans on two specific sites, 
namely spine and hip (criterion 2), was poorly adhered to in all three GPs. In GP A 32 
out of 93 applicable patients (34.4%) adhered to guideline recommendation, 0% in GP 
B and 4 out of 37 applicable patients (10.8%) in GP C.  
6.2.4. Non-significant results 
Several criteria presenting high levels of adherence were found to be not necessarily of 
statistical significance due to very low numbers of applicable patients. 
For example: ‘A patient receiving strontium ranelate has a contraindication to 
bisphosphonates’. For this criterion, level of adherence was reported to be 100%. 
However applicability was only 0.9 with only 3 out of 319 patients who were actually 
prescribed strontium ranlelate. 
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Similarly for criterion 15 (‘A patient receiving long-term oral glucocorticoid therapy is 
prescribed a bisphosphonate) level of adherence was 100%. As in the criterion 
mentioned before, applicability was extremely low with only 0.3% since there was only 
1 out of 319 patients receiving long-term oral steroid therapy and therefore meeting the 
qualifying statement.  
This shows that the results from the statistical analysis have to be handled with care 
and interpreted carefully. Significantly high levels of adherence are not necessarily 
statistically meaningful, applicability has to be taken into account as well. 
6.3. Contribution of the pharmacist 
The community setting represents an ideal location to assess the risk of various 
diseases in random customers.  
Pharmacists can participate in the management and prevention of osteoporosis via e.g. 
providing relevant lifestyle advice, helping to find the optimal medication for the 
individual patient, supporting long-term compliance with osteoporosis treatment or/and 
reviewing a patient’s medication since they are experts within the field of 
pharmacotherapy and drugs. The community pharmacist is situated in the ideal 
position to provide the aspects mentioned before since he or she is in constant and 
regular contact with patients. Awareness of the risk and consequences of osteoporosis 
as well as adequate training in order to gain the skills required to deliver 
pharmaceutical care for the management of osteoporosis are crucial preconditions for 
pharmacists.  
In the clinical setting, the clinical pharmacist has to have full access to a patient’s 
diagnosis, laboratory results and other information in order to be able to provide a 
medication review and to share his or her knowledge of drug therapy in the most 
beneficial way for the patient (SIGN 2003). Hence interdisciplinary teamwork among 
doctors and pharmacists is crucial. Furthermore this interdisciplinary team consists of 
nurses, nutritionists and technicians. This aspect of pharmaceutical care is mainly 
taking place in the hospital since the clinical pharmacist has most access to a patient’s 
information. This is (at least so far) unlikely to be the case for community pharmacists 
whose access to a patient’s recorded diagnosis and other information is very restricted 
or even non-existing. Given the availability of certain data, medication reviews can also 
be delivered by a community pharmacist.  
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6.4. Strenghts and limitations of this project 
A clear strength of this study is that guideline recommendation for the management 
and prevention of osteoporosis was derived from the latest version of relevant 
guidance. 
MATosteo has been developed in a multi-stage process, which allowed the research 
group to review and revise the tool in order to obtain the most relevant draft presenting 
highest practicability, applicability and feasibility for its use in practice. 
The tool was applied to patients located within three different GPs and applied by two 
independent researchers in order to assess inter-rater reliability of the tool. It was 
shown that MATosteo represents a reliable tool, which provides reproducible and 
reliable results when applied by different researchers. Furthermore application of the 
tool was found to be not too time-consuming.  
A limitation of the project is that the local Glasgow guidelines were not included. It 
might be useful to conduct a survey to measure adherence to these local guidelines. 
The tool does not cover management of chronic and acute pain of osteoporotic 
fractures, which is a crucial aspect of osteoporosis therapy. 
MATosteo cannot be applied by untrained staff, a pharmacological background was 
identified to be crucial precondition since appropriate knowledge is necessary for the 
data collection as well as for interpretation of medical history of individual patients (e.g. 
knowledge of medical conditions representing a contraindication for bisphosphonate 
therapy).  
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6.5. Proposals for future research 
The investigator suggests to conduct a survey on the correlation between patient 
education (modifiable risk factors, instructions for use of bisphosphonates, necessity of 
calcium and vitamin D supplementation) and compliance respectively outcomes of 
treatment since the problem of compliance might be a major factor contributing to low 
adherence to guideline recommendation. 
This study revealed that lately licensed treatment options (iv bisphosphonates, 
teriparatide, calcitonin) are not integrated into osteoporosis treatment. Identification of 
possible reasons as well as creation of measures to allow integration of these 
treatment options might be issues for future research.  
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7- CONCLUSION 
MATosteo has been shown to be a useful tool in the evaluation of level of adherence to 
clinical guidelines. The application of the MAT by two independent researchers to the 
same set of patient data indicated reliability of the MAT in the administration to 
electronical medical records. MATosteo represents a sensitive tool, which can be used 
for comparison of prescribing in different clinical settings as well as for a large-scale 
audit of medication use. 
The assessment of the patient data of the three GP practices revealed an overall non-
adherence to guideline recommendation of 38.3%. These findings represent a first 
stage in identifying and addressing pharmaceutical care issues in the management of 
osteoporosis. Identification of low guideline adherence in patients could be discussed 
with the responsible GP in order to optimize beneficial treatment effects for patients. 
Adherence to guideline recommendation was particularly low in the prescribing of 
supplementary calcium and vitamin D and the diagnosing via specific DEXA scan. Low 
level of adherence to calcium and vitamin D supplementation might partly result from 
non-compliance. Further research should be conducted in this field of compliance. 
Osteopenia was found to remain significantly undertreated. Methods to arise 
awareness of this issue and to draw the attention to osteopenic patients who are 
suggested to receive certain treatment in order to prevent the development of 
osteoporosis should be established. Furthermore it has been detected that prescribing 
of alternative treatment options like iv bisphosphonates or strontium ranelate is 
practically non-existing. These findings might be used as a starting point for 
pharmacoeconomical research.  
A community pharmacy based service to identify patients at high risk for osteoporosis 
and fractures was found to be useful and feasible. Community pharmacists are 
considered to be skilled and capable of contributing in the detection and management 
of osteoporosis. Furthermore community pharmacists are located in an ideal position 
for delivery of such a service as they are in constant contact with patients. As possible 
start points a fracture risk assessment in individual patients via the Internet tool 
FRAX®, provision of relevant advise and referral according to the calculated risk as 
well as assessment of quality of prescribed medication were identified. Furthermore 
pharmacists could participate in falls prevention in case appropriate training is 
provided. The limitating factor for the implementation of a pharmaceutical care tool for 
community pharmacy interventions in osteoporosis was identified to be bringing up 
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extra time for the delivery of such a service. This was reported to be solvable by 
reimbursing community pharmacists for the delivery of the service, as it is the case for 
e.g. provision of smoking cessation advises. 
 
 
 
 
 
 
 
 
The implementation of a pharmaceutical care tool to guide community pharmacy interventions in osteoporosis !
!122 
REFERENCES 
 
Aktories, K., Förstermann, U., Hofman, F., and Forth, W. (2005). Allgemeine und 
spezielle Pharmakologie und Toxikologie. 
Barrett-Connor, E., Siris, E.S., Wehren, L.E., Miller, P.D., Abbott, T.A., Berger, M.L., 
Santora, A.C., and Sherwood, L.M. (2005). Osteoporosis and fracture risk in 
women of different ethnic groups. J Bone Miner Res 20, 185-194. 
Berenguer, B., La Casa, C., de la Matta, M.J., and Martin-Calero, M.J. (2004). 
Pharmaceutical care: past, present and future. Curr Pharm Des 10, 3931-3946. 
Bitsch, T. (1997). Klinikleitfaden Rheumatologie, Vol 2.Auflage. 
Blahos, J. (2007). Treatment and prevention of osteoporosis. Wien Med Wochenschr 
157, 589-592. 
BNF (2009). British National Formulary 57. In BNF 57. 
Chakkalakal, D.A. (2005). Alcohol-induced bone loss and deficient bone repair. Alcohol 
Clin Exp Res 29, 2077-2090. 
Chatziavramidis, A., Mantsopoulos, K., Gennadiou, D., and Sidiras, T. (2008). 
Intranasal complications in women with osteoporosis under treatment with nasal 
calcitonin spray: case reports and review of the literature. Auris Nasus Larynx 35, 
417-422. 
Cipolle, R.J., Strand, L.M., and Morley, P.C. (2004). Pharmaceutical care practice: The 
clinician's guide. 
Compston, J.E. (2001). Sex steroids and bone. Physiol Rev 81, 419-447. 
Copeland, C., and Worsley, A. (2009). Osteoporosis features of disease and diagnosis. 
Clinical Pharmacist 1, 4. 
Cummings, S.R., and Melton, L.J. (2002). Epidemiology and outcomes of osteoporotic 
fractures. Lancet 359, 1761-1767. 
Faulkner, K.G. (2005). The tale of the T-score: review and perspective. Osteoporos Int 
16, 347-352. 
Harkin, S., Gerhart, T., and Hansen, K. (1999). Using Microsoft Access 2000, 1. edn 
(MacMillan Computer Publishing, Que corporation). 
Hartikainen, S., Lönnroos, E., and Louhivouri, K. (2007). Medication as a Risk Factor 
for Falls: Critical Systematic Review. Journal of Gerontology: MEDICAL 
SCIENCES 62A. 
Hepler, C.D., and Strand, L.M. (1990). Opportunities and responsibilities in 
pharmaceutical care. Am J Hosp Pharm 47, 533-543. 
Hettenkofer, H.J. (1998). Rheumatologie, Vol 3.Auflage. 
Hirschhorn, J.N., and Gennari, L. (2008). Bona fide genetic associations with bone 
mineral density. N Engl J Med 358, 2403-2405. 
Hoidrup, S., Prescott, E., Sorensen, T.I., Gottschau, A., Lauritzen, J.B., Schroll, M., and 
Gronbaek, M. (2000). Tobacco smoking and risk of hip fracture in men and 
women. Int J Epidemiol 29, 253-259. 
Jehle, P.M., and Pfeilschifter, J. (2009). [Osteoporosis - Which therapy is confirmed?]. 
Internist (Berl). 
The implementation of a pharmaceutical care tool to guide community pharmacy interventions in osteoporosis !
!123 
Kanis, J.A. (2002). Diagnosis of osteoporosis and assessment of fracture risk. Lancet 
359, 1929-1936. 
Kanis, J.A., Johnell, O., Oden, A., Johansson, H., and McCloskey, E. (2008a). FRAX 
and the assessment of fracture probability in men and women from the UK. 
Osteoporos Int 19, 385-397. 
Kanis, J.A., McCloskey, E.V., Johansson, H., Strom, O., Borgstrom, F., and Oden, A. 
(2008b). Case finding for the management of osteoporosis with FRAX--
assessment and intervention thresholds for the UK. Osteoporos Int 19, 1395-
1408. 
Karsdal, M.A., Henriksen, K., Arnold, M., and Christiansen, C. (2008). Calcitonin: a 
drug of the past or for the future? Physiologic inhibition of bone resorption while 
sustaining osteoclast numbers improves bone quality. BioDrugs 22, 137-144. 
Kazakia, G.J., and Majumdar, S. (2006). New imaging technologies in the diagnosis of 
osteoporosis. Rev Endocr Metab Disord 7, 67-74. 
Kenneth, D.W., and Klesges, R.C. (2001). A Meta-Analysis of the Effects of Cigarette 
Smoking on Bone Mineral Density. Calcif Tissue Int 68. 
Korpelainen, R., Keinanen-Kiukaanniemi, S., Heikkinen, J., Vaananen, K., and 
Korpelainen, J. (2006). Effect of impact exercise on bone mineral density in 
elderly women with low BMD: a population-based randomized controlled 30-
month intervention. Osteoporos Int 17, 109-118. 
Law, A.V., and Shapiro, K. (2005). Impact of a community pharmacist-directed clinic in 
improving screening and awareness of osteoporosis. J Eval Clin Pract 11, 247-
255. 
Law, M.R., and Hackshaw, A.K. (1997). A meta-analysis of cigarette smoking, bone 
mineral density and risk of hip fracture: recognition of a major effect. BMJ 315, 
841-846. 
Lewiecki, E.M. (2009a). Current and emerging pharmacologic therapies for the 
management of postmenopausal osteoporosis. J Womens Health (Larchmt) 18, 
1615-1626. 
Lewiecki, E.M. (2009b). Managing osteoporosis: challenges and strategies. Cleve Clin 
J Med 76, 457-466. 
Li, C., Paris, O., Siegel, S., Roschger, P., Paschalis, E., Klaushofer, K., and Fratzl, P. 
(2009a). Strontium is Incorporated Into Mineral Crystals Only in Newly Formed 
Bone During Strontium Ranelate Treatment. J Bone Miner Res. 
Li, M., Xing, X.P., Zhang, Z.L., Liu, J.L., Liu, D.G., Xia, W.B., and Meng, X.W. (2009b). 
Infusion of ibandronate once every 3 months effectively decreases bone 
resorption markers and increases bone mineral density in Chinese 
postmenopausal osteoporotic women: a 1-year study. J Bone Miner Metab. 
Lowrie, R. (2008). Pharmacy and the falling elderly: from evidence base to model of 
care, R. Lowrie, ed. 
Luf, A. (2009). 
Mauck, K.F., and Clarke, B.L. (2006). Diagnosis, screening, prevention, and treatment 
of osteoporosis. Mayo Clin Proc 81, 662-672. 
McAnaw, J., Hudson, S., and MCGlynn, S.T. (2003). Development of an evidence-
based medication assessment tool to demonstrate the quality of drug therapy use 
in patients with heart failure. . International Journal of Pharmacy Practice R17. 
The implementation of a pharmaceutical care tool to guide community pharmacy interventions in osteoporosis !
!124 
Migliaccio, S., Brama, M., and Malavolta, N. (2009). Management of glucocorticoids-
induced osteoporosis: role of teriparatide. Ther Clin Risk Manag 5, 305-310. 
Miller, P.D. (2008). Anti-resorptives in the management of osteoporosis. Best Pract 
Res Clin Endocrinol Metab 22, 849-868. 
Morgan, S.L., and Kitchin, B. (2008). Osteoporosis: handy tools for detection, helpful 
tips for treatment. J Fam Pract 57, 311-320. 
Naylor, K.E., Clowes, J.A., Finigan, J., Paggiosi, M.A., Peel, N.F., and Eastell, R. 
(2009). The effect of cessation of raloxifene treatment on bone turnover in 
postmenopausal women. Bone. 
NHS (2006). Strategy for Osteoporosis and Falls Prevention, N.H.S.G. Glasgow, ed. 
NHSScotland (2009). GPASS- Clinical Software. 
NHSUK (2009). NHS- Connecting for Health, N. UK, ed. 
NICE (2002). Principles of best practice in clinical audit. 
NICE (2004). NICE 21: Assessment and prevention of falls in elderly people, 
N.I.f.H.a.C. Excellence, ed. 
NICE (2008). Alendronate, etidronate, risedronate, raloxifene and strontium ranelate 
for the primary prevention of osteoporotic fragility fractures in postmenopausal 
women. In NICE technology appraisal guidance 160, N.I.f.H.a.C. Excellence, ed. 
(NICE). 
NOS (2009), N.O. Society, ed. 
Past, E. (2008). The implementation of evidence based practice in osteoporosis 
treatement and prevention: Development of a medication assessment tool 
(Vienna, University of Vienna). 
Peters, M.L., Leonard, M., and Licata, A.A. (2001). Role of alendronate and risedronate 
in preventing and treating osteoporosis. Cleve Clin J Med 68, 945-951. 
Reginster, J. (2007). Managing the osteoporotic patient today. Bone 40, 12-18. 
Reid, I.R. (2008). Anti-resorptive therapies for osteoporosis. Semin Cell Dev Biol 19, 
473-478. 
Rey, J.R., Cervino, E.V., Rentero, M.L., Crespo, E.C., Alvaro, A.O., and Casillas, M. 
(2009). Raloxifene: mechanism of action, effects on bone tissue, and applicability 
in clinical traumatology practice. Open Orthop J 3, 14-21. 
Roux, C., and Thomas, T. (2008). Optimal use of FRAX. Joint Bone Spine. 
Schettler, G., and Greten, H. (1998). Innere Medizin, Vol 9.Auflage. 
Schlais, J. (2008). Evaluation of implementation of evidence-based practice in the 
treatment and prevention of osteoporosis (Glasgow, University of Strathclyde). 
Siegenthaler, W., Kaufmann, W., Hornbostel, H., and Waller, H.D. (1992). Lehrbuch 
der Inneren Medizin, Vol 3. Auflage. 
SIGN (2003). SIGN 71: Management of osteoporosis- A national clinical guideline, 
S.I.G. Network, ed. 
Silverman, S. (2009). Selecting patients for osteoporosis therapy. J Bone Miner Res 
24, 765-767. 
Snelling, A.M., Crespo, C.J., Schaeffer, M., Smith, S., and Walbourn, L. (2001). 
Modifiable and nonmodifiable factors associated with osteoporosis in 
postmenopausal women: results from the Third National Health and Nutrition 
Examination Survey, 1988-1994. J Womens Health Gend Based Med 10, 57-65. 
The implementation of a pharmaceutical care tool to guide community pharmacy interventions in osteoporosis !
!125 
Sontag, A., Wan, X., and Krege, J.H. (2009). Benefits and risks of raloxifene by 
vertebral fracture status. Curr Med Res Opin. 
Strand, L.M., Cipolle, R.J., Morley, P.C., and Perrier, D.G. (1991). Levels of 
pharmaceutical care: a needs-based approach. Am J Hosp Pharm 48, 547-550. 
Styrkarsdottir, U., Halldorsson, B.V., Gretarsdottir, S., Gudbjartsson, D.F., Walters, 
G.B., Ingvarsson, T., Jonsdottir, T., Saemundsdottir, J., Center, J.R., Nguyen, 
T.V., Bagger, Y., Gulcher, J.R., Eisman, J.A., Christiansen, C., Sigurdsson, G., 
Kong, A., Thorsteinsdottir, U., and Stefansson, K. (2008). Multiple genetic loci for 
bone mineral density and fractures. N Engl J Med 358, 2355-2365. 
Tamura, Y., Okinaga, H., and Takami, H. (2004). Glucocorticoid-induced osteoporosis. 
Biomed Pharmacother 58, 500-504. 
WHO (2003). Prevention and management of osteoporosis. In Technical report series 
921, W.H. Organization, ed. (Geneva). 
Woolf, A.D., and Akesson, K. (2003). Preventing fractures in elderly people. BMJ 327, 
89-95. 
 
 
 
 
 
 
The implementation of a pharmaceutical care tool to guide community pharmacy interventions in osteoporosis !
!126 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The implementation of a pharmaceutical care tool to guide community pharmacy interventions in osteoporosis !
!127 
 
APPENDIX 1: PROJECT PROTOCOL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The implementation of a pharmaceutical care tool to guide community pharmacy interventions in osteoporosis !
!128 
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1.  Introduction 
 
1.1. Definition 
Osteoporosis is a systematic skeletal disease characterized by low bone density and 
micro architectural deterioration of bone tissue with a consequent increase of bone 
fragility.  
 
Low bone density occurs with advancing age [1]. By the third decade of life there is a 
gradual loss of bone mass [2]. But since it remains asymptomatic in many cases, it is 
not usually diagnosed until fractures occur [1]. Since life expectancy is increasing and 
the number of elderly people is rising, osteoporosis will become a global problem within 
the next decades [3]. 
 
1.2. Prevalence/Epidemiology 
Approximately one in three women and one in twelve men over the age of 50 are likely 
to suffer an osteoporotic fracture [5].Osteoporosis is more common in women due to the 
lower bone peak mass [1] and the decrease in oestrogen production after the 
menopause [2]. Osteoporotic fragility fractures occur most commonly in the vertebrae, 
hip and wrist and cause disability, pain, reduced quality of life and are associated with 
increased mortality and morbidity [2]. 
 
Osteoporosis can be divided in two categories, primary and secondary osteoporosis. 
Primary osteoporosis is usually associated with age and/or sex (postmenopausal 
women). Secondary osteoporosis occurs when an underlying disease (e.g.  
hypogonadism), deficiencies (e.g. malnutrition) or drugs (e.g. glucocorticoids) cause 
osteoporosis. Further risk factors for osteoporosis are a low body mass index, smoking, 
excessive alcohol intake, decreased physical activity and low dietary intake of calcium 
[4]. 
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2.  Research Question, Aims and Objectives 
 
2.1. Research questions 
 
1. Can a medication assessment tool for osteoporosis (MATOsteo) reliably be 
administered to computerised medical records? 
2. Is the MATOsteo asensitive tool for comparing prescribing practices in different 
clinical settings? 
3. Does the MATOsteo together with a fracture risk assessment score offer a 
potential osteoporosis service for provision from a community pharmacy?  
 
2.2. Aims:  
• To demonstrate the use of a medical assessment tool for osteoporosis 
(MATOsteo) in the evaluation of the level of adherence to osteoporosis guidelines.  
 
• To demonstrate the inter-rater reliability of such a tool.  
 
• To assess the value of a fracture risk evaluation service provided by community 
pharmacists 
 
2.3. Objectives: 
• To undertake a literature review of the epidemiology of osteoporosis and 
measures taken by public health experts in order to address the disease.  
 
• To revise a MATOsteo (originally designed by previous researchers) and redesign 
database protocols. Test the protocols on a GPASS® database and evaluate 
inter-rater reliability. 
 
• Test the sensitivity of the MATOsteo in a comparison of patient samples drawn from 
two clinical settings and further revise the tool as necessary.  
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• Test on a larger scale audit the revised MATOsteo. Each student take one patient 
sample and compare with the other student. 
 
• Validate a potential service by which community pharmacists might contribute to 
osteoporosis detection and management.Propose potential starting points for 
community pharmacists to get involved in osteoporosis detection and 
management. 
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3.  Study Design, Subjects and Settings 
 
3.1. Study Design:  
 
Retrospective survey including the application of a tool designed for medication 
assessment in the field of osteoporosis 
 
3.2. Subjects and Settings: 
 
3.2.1. Subjects:  
 
1. Patients from two practices in Clydebank and Paisley previously used in an 
earlier project to design the MATOsteo 
2. Patients recruited from a third practice to be compared with those from a 
fourth  
3. Interviewees (4-6) drawn from community pharmacy, general practice 
medicine, fracture risk clinics and public health specialists 
The inclusion criteria for patients for whom specific guideline criteria are applicable are: 
• Patients alive who are registered with the GP practice on date 
• Patients who are diagnosed with osteoporosis or osteopenia 
 
3.2.2. Settings: 
• GP practices offering permission for the audit. The patients should be situated 
in general medical practice within Community Health Partnerships in 
Renfrewshire and/or Greater Glasgow. 
• Interviewees who have been nominated to participate and accepted the 
invitation 
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4.  Methods 
To undertake a literature review of the epidemiology of osteoporosis and measures 
taken by public health experts in order to address the disease 
For the purpose of this project information was gathered by using journal papers 
accessed via databases (e.g. PubMed®, Medlineplus® and ClinicalTrials.gov). 
The number of articles presented was narrowed down by using a combination of 
certain keywords. Useful articles were identified by reading abstracts. 
MATOsteo which will be tested regarding reliability is based on Scottish Intercollegiate 
Network (SIGN) 71 and National Institute for Clinical Excellence (NICE) guidelines. 
 
To revise a MATOsteo (originally designed by previous researchers) and redesign 
database protocols. Test the protocols on a GPASS® database and evaluate inter-
rater reliability. 
MATOsteo will be tested by analysing data drawn from Clydebank GP and Paisley GP. 
The patients’ files will be manipulated by using Microsoft Access® and Microsoft Excel® 
to extract the patients’ data and compare only project related information according to 
database protocols designed by previous researchers. [7] 
Microsoft Access® is a database to store and retrieve data. [7, 9] The user can create 
e.g. tables (enables to store the information in rows and columns) and queries (enables 
to store information in questions). [7, 9] Data can be stored, manipulated and analysed in 
an easy way. [7, 9] 
These two elements will be used to build up a relationship between the data. [7]  
After entering the data into Microsoft Access® database, this data is stored in a table. [7, 
9]But in general tables are not used to interact with the data directly. [7, 9] Therefore the 
researcher may use queries. [7, 9] 
Statistical analysis will be done by using SPSS. 
 
Test the sensitivity of the MATOsteo in a comparison of patient samples drawn from two 
clinical settings and further revise the tool as necessary.  
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Test on a larger scale audit the revised MATOsteo.  Each student take one patient 
sample and compare with the other students. 
Ian Towle will provide help in order to collect data of two or more GPs within Greater 
Glasgow and Clyde by withdrawing it from GPASS®. 
MATOsteo will be tested by analysing data drawn from Clydebank GP and Paisley GP. 
The patients’ files will be manipulated by using Microsoft Access® and Microsoft Excel® 
to extract the patients’ data and compare only project related information according to 
database protocols designed by previous researchers. 
Statistical analysis will be done by using SPSS. 
 
Validate a potential service by which community pharmacists might contribute to 
osteoporosis detection and management.Propose potential starting points for 
community pharmacists to get involved in osteoporosis detection and management 
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APPENDIX 2: MATosteo ANTON LUF 
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Medication Assessment Tool for use in osteoporosis/osteopenia (MATOsteo) – 
Draft Anton Luf 
 
 
 
Patient Code:    
 
Date and setting:  
 
 
Key for the six answer categories: 
 
NA Not applicable 
Yes Standard is adhered to in eligible patients 
No(J) No, but justified 
No(U) No, unjustified 
IDQ Insufficient data to address the qualifying statement 
IDS Insufficient data to address the standard statement 
 
 
 
 
Definitions: 
Osteoporosis … is defined as a value of bone mineral density at least 2.5 standard 
deviations below the young adult mean (T-score < - 2.5). 
 
Osteopenia … is defined as a value of bone mineral density between 1 and 2.5 standard 
deviations below the young adult mean (T-score < - 1 and > - 2.5).  
 
DEXA scan Dual-energy X-ray absorptiometry is a method to assess the bone mineral 
density. The result is expressed in relation to the young adult mean (T-score) 
in standard deviation units.  
 
BMD Bone mineral density (g/cm2) = Bone mineral content (g/cm) / width at the 
scanned line (W)  
 
 
References:  
1 Scottish Intercollegiate Guidelines Network (SIGN). Management of Osteoporosis 71 (April 
2004 Update) 
 
2 National Institute for Clinical Excellence (NICE). Alendronate, etidronate, risedronate, 
raloxifene, strontium ranelate for the primary prevention of osteoporotic fragility fractures in 
postmenopausal women Technology Appraisal TA160, October 2008 
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3 National Institute for Clinical Excellence (NICE). Alendronate, etidronate, risedronate, 
raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic 
fragility fractures in postmenopausal women Technology Appraisal TA161, October 2008 
 
4 Summary of the 2002 Canadian Guidelines for the Diagnosis and Management of 
Osteoporosis (2005 Update) 
 
5 British National Formulary (BNF) 56, September 2008 
 
!
!
NA  Yes No 
(J) 
No 
(U) 
IDQ 
 
IDs Ref 
!
Diagnosis of osteoporosis/osteopenia  
 
1 A patient with a diagnosis of osteoporosis  
has been assessed by DEXA scan  
 
[Justification for not referring to a DEXA Scan 
Patient > 60 years and > 2 vertebral fractures imply a 
diagnosis of osteoporosis or  
a postmenopausal woman " 75 years and two or more 
independent clinical risk factors for fracture or indicators of low 
BMD]  
 
Independent clinical risk 
factors  
Indicators for low BMD 
" low body mass index 
defined as less than 22 
kg/m² 
" parental history of hip 
fracture, 
" ankylosing spondylitis " alcohol intake of 4 or 
more units/d 
" Crohn’s disease " rheumatoid arthritis  
" conditions that result in 
prolonged immobility 
 
" untreated premature 
menopause 
 
   
#! # # # # # 1,2,3 
2 Measurement of the BMD by DEXA scan  
is performed at least at the two specific sites – 
namely, anteroposterior spine and hip. 
 
# # # # # # 1 
!
Calcium and vitamin D supplementation 
 
3 A patient with a recorded diagnosis of 
osteoporosis # # # # # # 1 
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is prescribed supplementary calcium (±vitamin D).  
 
[Justification for non-prescribing calcium and vitamin D:There 
is a record that the patient has an adequate dietary intake of 
calcium and no vitamin D deficiency.] 
 
4 A patient with a recorded diagnosis of 
osteoPENIA  
is prescribed supplementary calcium (± vitamin D) 
for the prevention of osteoporosis.  
 
[Justification for non-prescribing calcium and vitamin D: There 
is a record that the patient has an adequate dietary intake of 
calcium and no vitamin D deficiency.] 
 
# # # # # # 4 
5 A patient with confirmed vitamin D deficiency 
or aged > 65  
is prescribed vitamin D.  
 
# # # # # # 1 
6 A patient with osteoporosis and NOT 
prescribed  any of the following: 
bisphosphonates, raloxifene, strontium 
ranelate or calcitonin  
has a recorded contra-indication to each agent 
(see below) 
[Contraindications to bisphosphonates are: 
# oesophageal strictures or achalasia 
# inability to remain upright for > 30 min after 
ingestion  
# hypocalcaemia 
# osteomalacia (etidronate)  
# moderate renal impairment (CrCl <  35 mL/min)  
# pregnancy and breast feeding]  
[Contraindications to raloxifene are: 
# past/present venous thromboembolic events 
# hepatic impairment 
# cholestasis  
# severe renal impairment (CrCl < 10 mL/min)  
# endometrial cancer 
# uterine bleeding 
# pregnancy and breast feeding] 
[Contraindications to strontium ranelate are: 
# pregnancy and breast feeding 
# hypersensitivity] 
[Contraindications to calcitonin are: 
# hypocalcaemia 
# hypersensitivity] 
# # # # # # 1,2,5 
7 A patient prescribed supplementary calcium  
is prescribed a daily dose of 500 – 1500 mg 
calcium.  
# # # # # # 1,4 
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8 A patient prescribed vitamin D  
is prescribed a daily dose of 10 – 20 µg (400 - 
800 IU) vitamin D.  
 
# # # # # # 1 
9 A patient with osteoporosis and NOT 
prescribed  any of the following: 
bisphosphonates, raloxifene, strontium 
ranelate or calcitonin  
is prescribed "1000mg calcium plus 800 IU 
vitamin D per day 
 
 
# # # # # # 1 
10 Apatientwith a recorded diagnosis of 
osteoporosis 
is prescribed an oral bisphosphonate as first-line 
therapy. 
 
Recorded reasons for non-conformance (justification): 
__________________________________________ 
 
# # # # # # 1,4 
11 A patient with a recorded diagnosis of 
osteoPENIA  
is prescribed an oral bisphosphonate as first-line 
therapy.  
 
Recorded reasons for non-conformance (justification): 
__________________________________________ 
 
# # # # # # 4 
12 A patient who is prescribed a bisphosphonate 
has no reason on record  to avoid 
bisphosphonates.  
 
[Reasons to avoid bisphosphonates are: 
" contraindication to bisphosphonates  
o oesophageal strictures or achalasia 
o inability to remain upright for > 30 min 
after ingestion 
o hypocalcaemia 
o osteomalacia (etidronate)  
o moderate renal impairment (CrCl <  35 
# # # # # # 1,2,5 
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mL/min)  
o pregnancy and breast feeding 
 
" inability to comply with the instructions for use of 
bisphosphonates  
o ingestion on an empty stomach 
o washing the medication down with 250 ml 
water 
o avoidance of food for 30 min 
o avoidance of lying flat within 30 min of 
ingestion 
 
" unsatisfactory response to bisphosphonates  
o another fracture occurs  
o decrease in BMD despite adherence to 
treatment 
 
" intolerance to bisphosphonates 
o oesophageal ulceration 
o erosion or stricture 
o severe lower GI symptoms] 
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!!  NA  Yes No (J) No (U) IDQ 
 
IDs Ref 
13 A patient receiving treatment for 
osteoporosis/osteopenia 
is prescribed a standard dose regimen.    
 
" Prevention (in 
osteopenia) 
" Treatment (of 
osteoporosis) 
Postmenopausal Osteoporosis 
" Alendronic acid 
 5 mg daily PO  10 mg daily or 70 mg  once 
weekly PO 
" Disodium etidronate 
 400 mg for 14 days PO; 
1,25 g calcium carbonate for 
76 days PO 
400 mg for 14 days PO, 
1,25 g calcium carbonate 
for 76 days PO 
" Ibandronic acid (not in guidelines)  
  150 mg once a month PO  
or 3 mg every 3 months IV  
" Risedronate sodium  
 5 mg daily PO  5 mg daily PO  
or 35 mg weekly PO  
" Calcitonin  
 200 units daily intranasally 
 
" Raloxifene  
 60 mg daily PO  60 mg daily PO 
" Strontium ranelate 
  2 g daily PO 
" Teriparatide 
  20 micrograms daily, for a 
maximum duration of 
treatment of 18 months 
 
Osteoporosis in men 
" Alendronic acid!
  10 mg daily PO 
Glucocorticoid-induced Osteoporosis 
" Alendronic acid  
 5 mg daily PO   5 mg daily PO  
" Disodium etidronate 
 400 mg for 14 days PO, 
1,25 g calcium carbonate for 
76 days PO 
 400 mg for 14 days PO, 
1,25 g calcium carbonate 
for 76 days PO 
" Risedronate sodium  
 5 mg daily PO   
" Teriparatide 
  20 micrograms daily, for a 
maximum duration of 
treatment of 18 months 
   
# # # # # # 1,5 
14 A postmenopausal woman when started on 
bisphosphonate therapy  
was initiated on alendronate. 
 
# # # # # # 2,3 
 15 A postmenopausal womandiagnosed with 
osteoporosis/osteopenia and not treated with 
alendronate 
is prescribed risedronate.  
# # # # # # 1 
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16 A postmenopausal woman with > 2 vertebral 
fractures and NOT treated with alendronate 
or risedronate 
is prescribed intermittent cyclical etidronate".  
 
# # # # # # 1 
  NA  Yes No 
(J) 
No 
(U) 
IDQ 
 
IDs Ref 
17 A patient who is on long-term glucocorticoid 
therapy 
(> 7.5 mg prednisolone or equivalents for > 3 
months) 
is prescribed a bisphosphonate.  
 
 
# # # # # # 1 
18 A postmenopausal woman with a diagnosis 
of osteoporosis, who has an identifiable 
reason for not being prescribed a 
bisphosphonate 
is prescribed strontium ranelate. 
 
[Reasons for non-use of bisphosphonates are 
Contraindications to bisphosphonates 
" contraindication to bisphosphonates (see 12) 
" inability to comply with the recommendations for 
use of bisphosphonates (see 12) 
" intolerance to bisphosphonates (see12)] 
 
# # # # # # 2 
19 A postmenopausal woman diagnosed with 
osteoporosis with at least one osteoporotic 
fractures who has an identifiable reason for 
not being prescribed a bisphosphonate  
is prescribed strontium ranelate or raloxifene. 
 
[Reasons for non-use of bisphosphonates are 
Contraindications to bisphosphonates 
" contraindication to bisphosphonates (see 12) 
" inability to comply with the recommendations for 
use of bisphosphonates (see 12) 
" intolerance to bisphosphonates (see 12)] 
 
 
# # # # # # 3 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!" standard dose regimen see criterion 13!
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20 A postmenopausal woman diagnosed with 
osteoporosis and at least one osteoporotic 
fractures  
who has either 
 
" a reason to avoid bisphosphonates (See 
12) 
" a contraindication to strontium ranelate 
o pregnancy 
o breast-feeding 
" an intolerance to strontium ranelate 
o persistent nausea 
o persistent diarrhoea 
and who is either 
" aged ! 65 years with a T-Score " -4 SD 
" aged ! 65 years with a T-Score " -3.5 SD 
and 
has more than two fractures 
" aged 55-64 years with a T-Score " -4 and 
has 
more than two fractures 
is prescribed teriparatide. 
 
 
# # # # # # 3 
21 
 
A postmenopausal womandiagnosed with 
osteoporosis with at least one vertebral fracture 
and NOT treated with a bisphosphonate, 
raloxifene or strontium ranelate  
is prescribed calcitonin.  
 
 
# # # # # # 1 
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APPENDIX 3: MATosteo FINAL TOOL 
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Medication Assessment Tool for use in osteoporosis/osteopenia (MATOsteo) – 
Final Tool 
 
 
 
Patient Code:    
 
Date and setting:  
 
 
Key for the six answer categories: 
 
NA Not applicable 
Yes Standard is adhered to in eligible patients 
No(J) No, but justified 
No(U) No, unjustified 
IDQ Insufficient data to address the qualifying statement 
IDS Insufficient data to address the standard statement 
 
 
 
 
Definitions: 
Osteoporosis … is defined as a value of bone mineral density at least 2.5 standard 
deviations below the young adult mean (T-score < - 2.5). 
 
Osteopenia … is defined as a value of bone mineral density between 1 and 2.5 standard 
deviations below the young adult mean (T-score < - 1 and > - 2.5).  
 
DEXA scan Dual-energy X-ray absorptiometry is a method to assess the bone mineral 
density. The result is expressed in relation to the young adult mean (T-score) 
in standard deviation units.  
 
BMD Bone mineral density (g/cm2) = Bone mineral content (g/cm) / width at the 
scanned line (W)  
 
 
References:  
1 Scottish Intercollegiate Guidelines Network (SIGN). Management of Osteoporosis 71 (April 
2004 Update) 
 
2 National Institute for Clinical Excellence (NICE). Alendronate, etidronate, risedronate, 
raloxifene, strontium ranelate for the primary prevention of osteoporotic fragility fractures in 
postmenopausal women Technology Appraisal TA160, October 2008 
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3 National Institute for Clinical Excellence (NICE). Alendronate, etidronate, risedronate, 
raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic 
fragility fractures in postmenopausal women Technology Appraisal TA161, October 2008 
 
4 Summary of the 2002 Canadian Guidelines for the Diagnosis and Management of 
Osteoporosis (2005 Update) 
 
5 British National Formulary (BNF) 56, September 2008 
 
!
!
NA! Yes No 
(J) 
No 
(U) 
IDQ 
 
IDs Ref 
!
Diagnosis of osteoporosis/osteopenia  
 
1 A patient with a diagnosis of osteoporosis  
has a recorded DEXA Scan to confirm 
osteoporosis 
 
[Justification for not being assessed by DEXA scan to 
confirm osteoporosis 
Patient > 60 years and > 2 vertebral fractures imply a 
diagnosis of osteoporosis or  
a postmenopausal woman " 75 years and two or more 
independent clinical risk factors for fracture or indicators of low 
BMD]  
 
Independent clinical risk 
factors  
Indicators for low BMD 
" low body mass index 
defined as less than 22 
kg/m² 
" parental history of hip 
fracture, 
" ankylosing spondylitis " alcohol intake of 4 or 
more units/d 
" Crohn’s disease " rheumatoid arthritis  
" conditions that result in 
prolonged immobility 
 
" untreated premature 
menopause 
 
   
#! # # # # # 1,2,3 
2 Measurement of the BMD by DEXA scan  
is performed at least at the two specific sites – 
namely, anteroposterior spine and hip. 
 
# # # # # # 1 
!
Calcium and vitamin D supplementation 
 
3 A patient with a recorded diagnosis of 
osteoporosis # # # # # # 1 
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is prescribed supplementary calcium (±vitamin D).  
 
[Justification for non-prescribing calcium and vitamin D:There 
is a record that the patient has an adequate dietary intake of 
calcium and no vitamin D deficiency.] 
 
4 A patient with a recorded diagnosis of 
osteoPENIA  
is prescribed supplementary calcium (± vitamin D) 
for the prevention of osteoporosis.  
 
[Justification for non-prescribing calcium and vitamin D: There 
is a record that the patient has an adequate dietary intake of 
calcium and no vitamin D deficiency.] 
 
# # # # # # 4 
5 A patient with confirmed vitamin D deficiency 
or aged > 65  
is prescribed vitamin D.  
 
# # # # # # 1 
6 A patient prescribed supplementary calcium  
is prescribed a daily dose of 500 – 1500 mg 
calcium.  
 
 
# # # # # # 1,4 
7 A patient prescribed vitamin D  
is prescribed a daily dose of 10 – 20 µg (400 - 
800 IU) vitamin D.  
 
# # # # # # 1 
8 Apatientwith a recorded diagnosis of 
osteoporosis 
is prescribed an oral bisphosphonate as first-line 
therapy. 
 
Recorded reasons for non-conformance (justification): 
__________________________________________ 
 
 
 
# # # # # # 1,4 
!  NA ! Yes No (J) No (U) IDQ IDs Ref 
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9 A patient with a recorded diagnosis of 
osteoPENIA  
is prescribed an oral bisphosphonate as first-line 
therapy.  
 
Recorded reasons for non-conformance (justification): 
__________________________________________ 
 
 
# # # # # # 4 
 
10 
 
A patient with osteoporosis and NOT 
prescribed  any of the following: 
bisphosphonates, raloxifene, strontium 
ranelate,  calcitonin or teriparatide 
has a recorded contra-indication to each agent 
(see below) 
[Contraindications to bisphosphonates are: 
# oesophageal strictures or achalasia 
# inability to remain upright for > 30 min after 
ingestion  
# hypocalcaemia 
# osteomalacia (etidronate)  
# moderate renal impairment (CrCl <  35 mL/min)  
# pregnancy and breast feeding]  
[Contraindications to raloxifene are: 
# past/present venous thromboembolic events 
# hepatic impairment 
# cholestasis  
# severe renal impairment (CrCl < 10 mL/min)  
# endometrial cancer 
# uterine bleeding 
# pregnancy and breast feeding] 
[Contraindications to strontium ranelate are: 
# pregnancy and breast feeding 
# hypersensitivity] 
[Contraindications to calcitonin are: 
# hypocalcaemia 
# hypersensitivity] 
[Contraindications to teriparatide are: 
# pre-existing hypercalcaemia 
# skeletal malignancies or bone metastases 
# metabolic bone diseases 
# including Paget’s disease and 
hyperparathyroidism 
# unexplained raised alkaline phosphatase 
# previous radiation therapy to the skeleton] 
 
 
 
 
 
# 
 
 
 
 
 
 
 
# 
 
 
 
 
# 
 
 
 
 
# 
 
 
 
 
# 
 
 
 
 
# 
 
 
 
 
1,2,5 
11 A patient with osteoporosis and NOT 
prescribed  any of the following: 
bisphosphonates, raloxifene, strontium 
ranelate or calcitonin  
# # # # # # 1 
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is prescribed "1000mg calcium plus 800 IU 
vitamin D per day 
 
 
12 A patient who is prescribed a bisphosphonate 
has no reason on record  to avoid 
bisphosphonates.  
 
[Reasons to avoid bisphosphonates are: 
" contraindication to bisphosphonates  
o oesophageal strictures or achalasia 
o inability to remain upright for > 30 min 
after ingestion 
o hypocalcaemia 
o osteomalacia (etidronate)  
o moderate renal impairment (CrCl <  35 
mL/min)  
o pregnancy and breast feeding 
 
" inability to comply with the instructions for use of 
bisphosphonates  
o ingestion on an empty stomach 
o washing the medication down with 250 ml 
water 
o avoidance of food for 30 min 
o avoidance of lying flat within 30 min of 
ingestion 
 
" unsatisfactory response to bisphosphonates  
o another fracture occurs  
o decrease in BMD despite adherence to 
treatment 
 
" intolerance to bisphosphonates 
o oesophageal ulceration 
o erosion or stricture 
o severe lower GI symptoms] 
# # # # # # 1,2,5 
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!!  NA! Yes No (J) No (U) IDQ 
 
IDs Ref 
13 A patient receiving treatment for 
osteoporosis/osteopenia 
is prescribed a standard dose regimen.    
 
" Prevention (in 
osteopenia) 
" Treatment (of 
osteoporosis) 
Postmenopausal Osteoporosis 
" Alendronic acid 
 5 mg daily PO  10 mg daily or 70 mg  once 
weekly PO 
" Disodium etidronate 
 400 mg for 14 days PO; 
1,25 g calcium carbonate for 
76 days PO 
 400 mg for 14 days PO, 
1,25 g calcium carbonate 
for 76 days PO 
" Ibandronic acid (not in guidelines)  
  150 mg once a month PO  
or 3 mg every 3 months IV  
" Risedronate sodium  
 5 mg daily PO  5 mg daily PO  
or 35 mg weekly PO  
" Calcitonin  
  200 units daily intranasally 
 
" Raloxifene  
 60 mg daily PO  60 mg daily PO 
" Strontium ranelate 
  2 g daily PO 
" Teriparatide 
  20 micrograms daily, for a 
maximum duration of 
treatment of 18 months 
 
Osteoporosis in men 
" Alendronic acid!
  10 mg daily PO 
Glucocorticoid-induced Osteoporosis 
" Alendronic acid  
 5 mg daily PO   5 mg daily PO  
" Disodium etidronate 
 400 mg for 14 days PO, 
1,25 g calcium carbonate for 
76 days PO 
 400 mg for 14 days PO, 
1,25 g calcium carbonate 
for 76 days PO 
" Risedronate sodium  
 5 mg daily PO   
" Teriparatide 
  20 micrograms daily, for a 
maximum duration of 
treatment of 18 months 
   
# # # # # # 1,5 
14 A patient with osteoporosis on 
bisphosphonate therapy  
is on the preferred choice* 
* 1- Alendronate, 2-risedronate, 3-intermittent 
cyclical etidronate 
         [Preferred order as shown in the drug history] 
# # # # # # 2,3 
!
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  NA! Yes No 
(J) 
No 
(U) 
IDQ 
 
IDs Ref 
15 A patient who is on long-term 
glucocorticoid therapy 
(> 7.5 mg prednisolone or equivalents for > 
3 months) 
is prescribed a bisphosphonate.  
 
 
# # # # # # 1 
16 A postmenopausal woman prescribed 
strontium ranelate has an identifiable reason 
for not being prescribed a bisphosphonate 
 
Reasons for non-use of bisphosphonates are 
" contraindication to bisphosphonates (see 12) 
" inability to comply with the recommendations for 
use of bisphosphonates (see 12) 
" intolerance to bisphosphonates (see12)] 
 
# # # # # # 2 
17 A postmenopausal woman prescribed 
raloxiphene  
is receiving it for secondary prevention and has 
an identifiable reason for not being prescribed 
a bisphosphonate  
 
[Reasons for non-use of bisphosphonates are 
" contraindication to bisphosphonates (see 12) 
" inability to comply with the recommendations for 
use of bisphosphonates (see 12) 
" intolerance to bisphosphonates (see 12)] 
 
 
# # # # # # 3 
18 A patient prescribed teriparatide is prescribed it 
for secondary prevention and meets at least one of 
the following 2 criteria 
" has a reason to avoid bisphosphonates 
(See 12) 
" has an intolerance to strontium ranelate 
o persistent nausea 
o persistent diarrhoea 
And has DEXA scan assessment that puts them in one the 
following groups 
 
" aged ! 65 years with a T-Score " -4 SD 
" aged ! 65 years with a T-Score " -3.5 SD 
and 
has more than two fractures 
" aged 55-64 years with a T-Score " -4 and 
has 
more than two fractures 
 
# # # # # # 3 
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19 A patient prescribed calcitonin is prescribed 
it for secondary prevention after 
bisphosphonate, raloxifene or strontium 
ranelate have been tried or have reasons for 
excluding from consideration 
 
[Reasons for non-use of bisphosphonates are 
" contraindication to bisphosphonates (see 12) 
" inability to comply with the recommendations for 
use of bisphosphonates (see 12) 
" intolerance to bisphosphonates (see 12)] 
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APPENDIX 4: DATA BASE PROTOCOLS 
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CRITERION 1 
 
Step What? How? 
 
Step 1 
 
Identify patients 
with a diagnosis of 
osteoporosis who 
have been 
assessed by DEXA 
scan 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
• ‘Osteoporosis’ for criterion 1 
• ‘DXA’ for criterion 2 
• ‘DEXA IDS’ for criterion 3 
Press ‘view’ 
Sort patients by ‘Osteoporosis’ 
Delete patients who are not osteoporotic (0) 
 
 
Step 2 
 
Store results in a 
Microsoft 
Excel®spreadsheet 
 
 
Export results to Microsoft Excel® 
Sort all resultsby applying the ‘sort descending’ 
function 
Delete first row (containing ‘c1’, ‘d1’, ‘c2’…) 
 
 
 
 
Step 3 
 
Create a new table 
in Microsoft 
Access® containing 
results from step 2  
 
 
Select ‘Tables’, ‘new’, ‘import table’ in order to 
import the table created in step 2  
Select ‘First Row Contains Headings’ during the 
process of importing 
Name table ‘OS and DEXA’ 
 
 
Step 4 
 
Prepare justification 
search for “No”-
results 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
• ‘Osteoporosis’ for criterion 1 
• ‘>=60 years’ for criterion 2 
• ‘Vertebral’ for criterion 3 
• ‘>=75 years’ for criterion 4 
• ‘Female’ for criterion 5 
• ‘ICR IND BMD LOW’ for criterion 6 
Press ‘view’ 
 
 
 
Step 5 Identify patients Create new query by using ‘design view’ 
A patient with a diagnosis of osteoporosis has  
been assessed by DEXA scan 
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with osteoporosis, 
no DEXA scan, >= 
60 years and at 
least two vertebral 
fractures 
(Justification A) 
Link ‘tbl_temp’ and table ‘OS and DEXA’ via 
patientKey. 
Apply ‘patientKey’, c1[1], c2 [0] (table ‘OS an 
DEXA’), c1 [1], c2 [1],c3 [1] (‘tbl_temp’) 
Run query 1 
Export results to Microsoft Excel® 
For patients with ‘1’ in field c3 (‘tbl_temp’): 
Check manually if they sustained more than 2 
vertebral fractures by inspecting on the table 
‘Patients: NHS Read codes_QOF and MAT data 
items_tbl’ (use the search function) 
! 0 or 1 vertebral fractures: No(U) 
! 2 or more vertebral fractures No(J) 
 
Step 6 Identify patients 
with osteoporosis, 
no DEXA scan, 
>=75 years, female 
and at least 2 ICRF 
or IND for low BMD 
(Justification B) 
Create new query by using ‘design view’ 
Link ‘tbl_temp’ and table ‘OS and DEXA’ via 
patient keys 
Apply ‘patientKey’, c2 [0] (table ‘OS an DEXA’), 
c4 [1], c5 [1], c6 [1] (‘tbl_temp’) 
Run query 2 
Export data to Microsoft Excel® 
For patients with ‘1’ in field c3 (‘tbl_temp’): 
Check manually if they show 2 or more ICRF 
IND BMD by inspecting on the table ‘Patients: 
NHS Read codes_QOF and MAT data items_tbl’ 
(use the search function) 
! 0 or 1 ICRF IND BMD: No(U) 
! 2 or more ICRF IND BMD No(J) 
Remaining patients with osteoporosis but no 
DEXA scan: No(U) 
 
 
Step 7  
 
Interpret results 
from step 2 (stored 
in Microsoft Excel®) 
 
 
! Osteoporosis 1, DXA 0 and DEXA IDS 1: 
=IDS 
! Osteoporosis 1, DXA 1 and DEXA IDS 0: 
=YES 
! Osteoporosis 1, DXA 0 and DEXA IDS 0:  
      See step 5 and 6 for justifications 
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CRITERION 2 
 
 
Step What? How? 
 
Step 1 
 
Identify patients 
with a 
measured BMD 
by DEXA scan 
measured on 
two specific 
sites 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
• ‘Hip scan’ for criterion 1 
• ‘Lumbar scan’ for criterion 2 
Press ‘view’ 
Create a new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1[1], c2[1], d1, d2 
In ‘SQL view’ change ‘and’ to ‘or’! 
[(((tbl_temp.c1)="1")) OR (((tbl_temp.c2)="1"));] 
 
 
Step 2 
 
Identify Yes, 
No(U) 
 
Export results to Microsoft Excel® 
! Patients with a DEXA scan performed 
on two specific sites at the same day!= 
Yes 
! Patients with a DEXA scan performed 
on only one site or with DEXA scans 
performed on two specific sites but not 
at the same day= No(U) 
! No(J)=0 (there is no justification for non-
adherence) 
 
 
Step 3 
 
Identify IDS, 
IDQ 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
• ‘C2IDSdxa’ for criterion 1 
• ‘DEXA IDS’ (is IDQ for this criteria!) for criterion 
2 
Press ‘view’ 
Create a new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1[1], c2[1] 
In ‘SQL view’ change ‘and’ to ‘or’! 
Measurement of the BMD by DEXA scan!
Is performed at least at the two specific sites – namely anteroposterior spine 
and hip !
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[(((tbl_temp.c1)="1")) OR (((tbl_temp.c2)="1"));] 
Export results to Microsoft Excel® 
! IDS= number of patients marked with 1 in 
column c1 
! IDQ= number of patients marked with 1 in 
column c2 
 
CRITERION 3 
 
Step What? How? 
 
Step 1 
!
Identify patients 
with a diagnosis of 
osteoporosis!
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
• ‘Osteoporosis’ for criterion 1 
Press ‘view’ 
Sort patients by ‘Osteoporosis’ 
Delete patients who are not osteoporotic (0) 
Export results to Microsoft Excel®.  
Name document ‘CLY OS’  
 
Step 2 
 
Create a table 
containing patients 
with a diagnosis of 
osteoporosis 
 
Use Microsoft Access® 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel®document ‘CLY OS’ and 
rename field c1 to ‘Osteoporosis’ (Table ‘CLY 
OS’) 
 
 
Step 3 
 
Identify patients 
with a diagnosis of 
osteoporosis who 
are prescribed 
supplementary 
calcium 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Drug’ field/ ‘group’: 
• ‘Supplement’ for 
criterion 1 
Press ‘view’ 
Create new query by using 
‘desing view’ 
Select ‘tbl_temp’ and table 
‘CLY OS’ 
Link tables via ‘patientKey’ 
Apply ‘patientKey’, 
osteoporosis [1] (Table ‘CLY 
OS’) and d1 [not like “0”] 
(‘tbl_temp’) 
Patient with a recorded diagnosis of osteoporosis!
Is prescribed supplementary calcium (vitamin D) 
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Run query 1  
! Number of ‘Yes’ 
results  
 
Step 4 
 
Identify patients 
with a diagnosis of 
osteoporosis who 
are not prescribed 
supplementary 
calcium 
 
Create new query by using ‘Find Unmatched 
Query Wizard’ 
Select table ‘CLY OS’ 
Press ‘next’ 
Select ‘Queries’ / ‘query 1’ 
Press ‘next’ 
Link tables via ‘patientKey’ 
Press ‘next’ 
Select ‘patientKey’ 
Press ‘next’ 
! Number of total ‘No’ results 
 
 
Step 5 
 
Search for 
justifications of non-
adherence 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
• ‘Adequate dietary intake of calcium’ 
for criterion 1 
• ‘Adequate dietary intake of vitamin 
D’ for criterion 2 
Create new query by using ‘desing view’ 
Select ‘tbl_temp’ and ‘CLY_OS Without 
Matching Query 2’ 
Link via ‘patientKey’ 
Apply ‘patientKey’, c1[1], c2[1] 
In ‘SQL view’ change AND to OR between c1 
and c2 
Run query 3 
! Number of justified non-adherence= 
No(J) 
! Number of unjustified non-adherence= 
Number of total No-results- No(J)= 
No(U)  
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CRITERION 4 
!
Step What? How? 
 
Step 1 
!
Identify patients 
with a diagnosis of 
osteopenia!
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
• ‘Osteopenia’ for criterion 1 
Press ‘view’ 
Sort patients by ‘Osteopenia’ 
Delete patients who are not osteopenic (0) 
Export results to Microsoft Excel®.  
Name document ‘CLY ON’ 
 
 
 
Step 2 
 
Create a table 
containing patients 
with a diagnosis of 
osteopenia 
 
Use Microsoft Access® 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel®document ‘CLY ON’ and 
rename field c1 to ‘Osteopenia’ (Table ‘CLY ON’) 
 
 
Step 3 
 
Identify patients 
with a diagnosis of 
osteopenia who are 
prescribed 
supplementary 
calcium 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Drug’ field/ ‘group’: 
• ‘Supplement’ 
Press ‘view’ 
Create new query by using 
‘desing view’ 
Select ‘tbl_temp’ and table 
‘CLY ON’ 
Link tables via ‘patientKey’ 
Apply ‘patientKey’, 
osteopenia [1] (Table ‘CLY 
ON’) and d1 [not like “0”] 
(‘tbl_temp’) 
Run query 1  
! Number of ‘Yes’ 
results 
 
 
 
   
Patient with a recorded diagnosis of osteopenia!
Is prescribed supplementary calcium (vitamin D) 
!"#$%&'!
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Step 4 Identify patients 
with a diagnosis of 
osteopenia who are 
not prescribed 
supplementary 
calcium 
Create new query by using ‘Find Unmatched 
Query Wizard’ 
Select table ‘CLY ON’ 
Press ‘next’ 
Select queries/ ‘query 1’ 
Press ‘next’ 
Link tables via ‘patientKey’ 
Press ‘next’ 
Select ‘patientKey’ 
Press ‘next’ 
! Number of total ‘No’ results 
 
 
Step 5 
 
Search for 
justifications of non-
adherence 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
• ‘Adequate dietary intake of calcium’ 
for criterion 1 
• ‘Adequate dietary intake of vitamin 
D’ for criterion 2 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ and ‘CLY_ON Without 
Matching Query 2’ 
Link via ‘patientKey’ 
Apply ‘patientKey’, c1[1], c2[1] 
In ‘SQL view’ change AND to OR between c1 
and c2 
Run query 3 
! Number of justified non-adherence= 
No(J) 
! Number of unjustified non-adherence= 
Number of total No-results- No(J)= 
No(U) 
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CRITERION 5 
 
Step What? How? 
 
Step 1 
!
Identify patients with 
confirmed vitamin D 
deficiency or aged over 
65!
who are  prescribed 
vitamin D 
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
• ‘>=65 years’ for criterion 1 
• ‘Vitamin D deficiency’ for 
criterion 2 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1[1], c2 [1] 
In ‘SQL view’ change AND to OR between c1 
and c2 
Run query 1 
Export results to Microsoft Excel®.  
Name document ‘CLY patients over 65 or 
vitamin D deficiency’ 
 
 
Step 2 
 
Create a table 
containing patients aged 
65 or older 
 
Use Microsoft Access® 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel®document ‘CLY 
patients over 65’ and rename field c1 to 
‘>=65 years’ and c2 to ‘vd deficiency’ (table 
‘CLY patients over 65 or vitamin deficiency’) 
 
 
Step 3 
 
Identify patients aged 65 
years or older or with a 
confirmed vitamin d 
deficiency who are 
prescribed vitamin d 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Drug’ field/ ‘group’: 
• ‘Supplement’ 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ and table ‘CLY patients 
over 65 or vitamin deficiency’ 
Link tables via ‘patientKey’ 
Apply ‘patientKey’ (‘CLY patients over 65 or 
vitamin deficiency’) and d1 [not like “0”] 
(‘tbl_temp’) 
Run query 2 
! Number of Yes results 
A patient with confirmed vitamin D deficiency or aged 65 or older!
is prescribed vitamin D 
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Step 4 
 
Identify patients aged 65 
years or older or with a 
confirmed vitamin D 
deficiency who are not 
prescribed vitamin d  
 
Create new query by using ‘Find Unmatched 
Query Wizard’ 
Select table ’CLY patients over 65 or vitamin 
D deficiency’ 
Press ‘next’ 
Select queries/ query 2 
Press ‘next’ 
Link tables via ‘patientKey’ 
Press ‘next’ 
Select ‘patientkey’ 
Press ‘next’ 
! Number of total No results= No(U) as 
there is no justification for not 
prescribing vitamin d in this case 
 
 
 
CRITERION 6- SEARCH 1 (excluding ibandronic acid and 
zoledronic acid because they are not included in the guidelines) 
 
Step What? How? 
 
Step 1 
!
Identify patients NOT treated with 
bisphosphonate, raloxifene, strontium 
ranelate, OR calcitonin 
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select 
! ‘Osteoporosis’ for 
criterion 1 
! ‘Bisphosphonate’ for 
criterion 2 
! ‘strontium ranelate’ for 
criterion 3 
! ‘raloxifene’ for 
criterion 4 
! ‘calcitonin’ for 
! criterion 5 
 
A patient with osteoporosis and NOT prescribed any of the following: 
bisphosphonates, raloxifene, strontium ranelate or calcitonin!
has a recorded contraindication to each agent (see below(!
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Sort patients by 
‘Osteoporosis’ 
Delete patients who are not 
osteoporotic (0) 
Sort patients by different 
treatments 
(bisphosphonates, strontium 
ranelate, raloxifene, 
calcitonin) 
Delete patients who are 
receiving treatment (Mauck 
and Clarke 2006) 
 
 
Step 2 
 
Identify patients with contraindications 
tobisphosphonates, raloxifene, strontium 
ranelate AND calcitonin 
 
which are the following:  
Bisphosphonates: 
o Oesophageal strictures and achalasia 
o Inability to remain upright for > 30 min after 
ingestion 
o Hypocalcaemia 
o Osteomalacia (etidronate) 
o Moderate renal impairment (CrCl < 35 
mL/min) 
o Pregnancy and breast feeding 
 
 
Raloxifene: 
o Past/present venous thromboembolic events 
o Hepatic impairment 
o Cholestasis 
o Severe renal impairment (CrCl < 10 mL/min) 
o Endometrial cancer  
o Uterine bleeding 
o Pregnancy and breast feeding 
Strontium Ranelate: 
o Pregnancy and breast feeding 
o Hypersensitivity 
Calcitonin: 
o Hypocalcaemia 
o Hypersensitivity 
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select  
! ‘Contraindication to 
bisphosphonates’ for 
criterion 1 
!  ‘Contraindication to 
strontium ranelate’ for 
criterion 2 
! ‘Contraindication to 
raloxifene’ for criterion 
3 
 
!  ‘Contraindication to 
calcitonin’ for criterion 
4 
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Step 3 
 
 
Identify patients with IDS results  
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select  
! ‘Contraindication to 
bisphosphonates IDS’ 
for criterion 1 
!  ‘Contraindication to 
strontium ranelate 
IDS’ for criterion 2 
! ‘Contraindication to 
raloxifene IDS’ for 
criterion 3 
! ‘Contraindication to 
calcitonin IDS’ for 
criterion 4 
 
 
 
CRITERION 6- SEARCH 2 (including ibandronic acid and zoledronic 
acid because they are authorized by BNF but not by the guidelines) 
 
 
Step What? How? 
 
Step 1 
!
Identify patients NOT treated with 
bisphosphonate, raloxifene, strontium 
ranelate, OR calcitonin 
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select 
! ‘Osteoporosis’ for 
criterion 1 
! ‘Bisphosphonate’ for 
criterion 2 
! ‘Ibandro+Zoledro’ for 
criterion 3 
! ‘strontium ranelate’ for 
criterion 4 
! ‘raloxifene’ for 
criterion 5 
A patient with osteoporosis and NOT prescribed any of the following: 
bisphosphonates, raloxifene, strontium ranelate or calcitonin!
has a recorded contraindication to each agent (see below(!
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! ‘calcitonin’ for criterion 
6 
 
Sort patients by 
‘Osteoporosis’ 
Delete patients who are not 
osteoporotic (0) 
Sort patients by different 
treatments 
(bisphosphonates, strontium 
ranelate, raloxifene, 
calcitonin) 
Delete patients who are 
receiving treatment (Mauck 
and Clarke 2006) 
 
 
Step 2 
 
Identify patients with contraindications 
tobisphosphonates, raloxifene, strontium 
ranelate AND calcitonin 
 
which are the following:  
Bisphosphonates: 
o Oesophageal strictures and achalasia 
o Inability to remain upright for > 30 min after 
ingestion 
o Hypocalcaemia 
o Osteomalacia (etidronate) 
o Moderate renal impairment (CrCl < 35 
mL/min) 
o Pregnancy and breast feeding 
 
 
Raloxifene: 
o Past/present venous thromboembolic events 
o Hepatic impairment 
o Cholestasis 
o Severe renal impairment (CrCl < 10 mL/min) 
o Endometrial cancer  
o Uterine bleeding 
o Pregnancy and breast feeding 
Strontium Ranelate: 
o Pregnancy and breast feeding 
o Hypersensitivity 
Calcitonin: 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select  
! ‘Contraindication to 
bisphosphonates’ for 
criterion 1 
!  ‘Contraindication to 
strontium ranelate’ for 
criterion 2 
! ‘Contraindication to 
raloxifene’ for criterion 
3 
! ‘Contraindication to 
calcitonin’ for criterion 
4 
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o Hypocalcaemia 
o Hypersensitivity 
 
 
Step 3 
 
 
Identify patients with IDS results  
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select  
! ‘Contraindication to 
bisphosphonates IDS’ 
for criterion 1 
!  ‘Contraindication to 
strontium ranelate 
IDS’ for criterion 2 
! ‘Contraindication to 
raloxifene IDS’ for 
criterion 3 
! ‘Contraindication to 
calcitonin IDS’ for 
criterion 4 
 
 
 
CRITERION 7 
 
Step What? How? 
 
Step 1 
!
Identify patients 
prescribed 
supplementary 
calcium !
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Drug’ field/ ‘group’: 
• ‘supplement’ for criterion 1 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1, d1[not like “0”], c2, d2, c3 
Run query 1 
 
 
Step 2 
!
Identify number of 
Yes, No(J), No(U), 
 
Export results of ‘step 1’ to Microsoft Excel® 
Inspect on the results 
! Patient prescribed a daily dose of 500-
Patient prescribed supplementary calcium !
Is prescribed a daily dose of 500-1500 mg calcium!!
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IDS!
 
1500 mg calcium= Yes 
! Patient not prescribed a daily dose of 500-
1500 mg calcium= No(U) 
! documentation concerning dose, 
preparation and frequency not clear= IDS  
 
 
CRITERION 8 
 
Step What? How? 
 
Step 1 
!
Identify patients who are prescribed 
vitamin D 
 
Use Microsoft Access® 
Create new query by using 
‘design view’ 
Select table: ‘Patients: Drug 
History_tbl’ 
Apply ‘drug name’: [like 
*Adcal D3* or like *Calceos* 
or like *Calcichew D3* or like 
*Cacit D3* or  like *Calfovit 
D3* or like *colecalciferol* or 
like *vitamin d*] 
Also show dose and 
frequency. 
Run query 1  
Export results to Microsoft 
Excel® 
 
 
Step 2 Identify patients who are prescribed a 
daily dose of 10 – 20 microgram (400 
– 800 IU) vitamin D (Standard) 
 
Possible drugs containing 10 micrograms 
(400 units) colecalciferol are the 
Check manually if patients 
are receiving the appropriate 
dose regimen (especially 
focus on Calcichew D3, it is 
necessary to take it twice a 
day!) 
 
Patient prescribed vitamin D!
Is prescribed a daily dose of 10 – 20 microgram (400 – 800 IU) vitamin D 
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following: 
Adcal D3®, Calceos®, Calcichew D3® forte 
 
Possible drugs containing 11 micrograms 
(500 units) colecalciferol are the 
following: 
Cacit D3® 
 
Possible drugs containing 5 micrograms 
(200 units) colecalciferol are the 
following: 
Calcichew D3® 
 
Possible drugs containing 20 micrograms 
(800 units) colecalciferol are the 
following: 
Calfovit® 
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CRITERION 9 SEARCH 1 (excluding ibandronic acid and zoledronic 
acid, because they are not included in the guidelines) 
 
Step What? How? 
 
Step 1 
!
Identify patients 
with osteoporosis 
and NOT 
prescribed 
bisphosphonates, 
raloxifene, 
strontium ranelate 
or calcitonin 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
! ‘Osteoporosis’ for criterion 1 
! ‘Bisphosphonate’ for criterion 2 
! ‘strontium ranelate’ for criterion 3 
! ‘raloxifene’ for criterion 4 
! ‘calcitonin’ for criterion 5 
Press ‘view’ 
Create new query by using ‘design view’ 
Select  ‘tbl_temp’ 
Apply ‘patientKey’, c1 [1], c2 [0], c3 [0], c4 [0], c5 
[0] 
Run query 1 
 
 
Step 2 
 
Preparation for 
step 3 
 
Export results to Microsoft Excel® 
Select ‘File’, ‘Export’ and follow the process. 
Name document ‘Patient OS no (BP_ ralox_ 
stront_ calc)’ 
 
 
Step 3 
!
Create a table in 
Microsoft Access® 
containing data 
exported in step 2 
 
 
Use Microsoft Access® 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel®document ‘Patient OS no 
(BP_ ralox_ stront_ calc)’and rename field c1 to 
‘osteoporosis’, c2 to ‘bp (ex ibandro)’, c3 to 
‘strontium’, c4 to ‘raloxi’ and c5 to ‘calcito’ (table 
‘Criterion 9 search excluding ibandronic acid’)  
A patient with osteoporosis and NOT prescribed any of the following: 
bisphosphonates, raloxifene, strontium ranelate or calcitonin!
Isprescribed " 1000 mg calcium plus 800 IU vitamin D per day)!
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Step 4 
!
Identify 
osteoporotic 
patients who are  
prescribed 
calcium and/ or 
vitamin D!
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Drug’ field/ ‘group’: 
• ‘supplement’ for criterion 1 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ and table ‘CLY OS’ (was 
created in Criterion 3, Step 2) 
Link tables via ‘patientKey’ 
Apply ‘patientKey’, osteoporosis [1] (Table ‘CLY 
OS’) and d1 [not like “0”] (‘tbl_temp’) 
Run query 2 (query ‘CLY OS on supplement’) 
 
 
 
Step 5  
!
Identify patients 
with a diagnosis 
of osteoporosis 
and not treated 
bisphosphonates, 
raloxifene, 
strontium ranelate 
or calcitonin who 
are prescribed 
>=1000 mg 
calcium 800 IU 
vitamin D per day!
!
 
Create new query by using ‘design view’ 
Select table ‘Criterion 9 search excluding 
ibandronic acid’ and query ‘CLY OS on 
supplement’ 
Link tables via ‘patientKey’ 
Apply ‘patientKey’ (table ‘Criterion 9 search 
excluding ibandronic acid’) and d1, c2, c3, d2 
Run query 3 (query ‘Criterion 9 Yes Results’) 
Export data to Microsoft Excel® and check 
manually if the correct dose is prescribed.  
! only calcium is prescribed or only vitamin d 
is prescribed or the wrong dose is 
prescribed= No(U) 
! the correct dose is prescribed= Yes 
! documented date is not clear concerning 
dose, preparation, frequency= IDS 
 
 
Step 6  
!
Identify patients 
with a diagnosis 
of osteoporosis 
and not treated 
bisphosphonates, 
raloxifene, 
strontium ranelate 
or calcitonin who 
are not 
prescribed 
>=1000 mg 
calcium 800 IU 
vitamin d per day!
 
Create new query by using ‘Find Unmatched 
Query Wizard’ 
Select table ‘Criterion 9 Search excluding 
ibandronic acid’ 
Press ‘next’ 
Select queries/ query ‘Criterion 9 Yes Results’ 
Press ‘next’ 
Link tables via ‘patientKey’ 
Press ‘next’ 
Select ‘patientKey’ 
Press ‘next’ 
! Number additional No results= No(U) as 
there is no justification for not prescribing 
calcium and or vitamin d in this case or 
prescribing it in another dose 
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CRITERION 9- SEARCH 2 (including ibandronic acid and zoledronic 
acid because they are authorized by BNF but not by the guidelines) !
 
Step What? How? 
 
Step 1 
!
Identify patients 
with osteoporosis 
and NOT 
prescribed 
bisphosphonates, 
raloxifene, 
strontium ranelate 
or calcitonin 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
! ‘Osteoporosis’ for criterion 1 
! ‘Bisphosphonate’ for criterion 2 
! ‘Ibandro + Zoledro’ for criterion 3 
! ‘strontium ranelate’ for criterion 4 
! ‘raloxifene’ for criterion 5 
! ‘calcitonin’ for criterion 6 
Press ‘view’ 
Create new query by using ‘design view’ 
Select  ‘tbl_temp’ 
Apply ‘patientKey’, c1 [1], c2 [0], c3 [0], c4 [0], c5 
[0] 
Run query 1 
 
 
 
Step 2 
 
Preparation for 
step 3 
 
Export results to Microsoft Excel® 
Select ‘File’, ‘Export’ and follow the process. 
Name document ‘Patient OS no (BP_ ralox_ 
stront_ calc)’ 
 
 
Step 3 
!
Create a table in 
Microsoft Access® 
containing data 
exported in step 2 
 
 
Use Microsoft Access® 
 
A patient with osteoporosis and NOT prescribed any of the following: 
bisphosphonates, raloxifene, strontium ranelate or calcitonin!
Is prescribed " 1000 mg calcium plus 800 IU vitamin D per day. 
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Step 4 
!
Identify 
osteoporotic 
patients who are  
prescribed 
calcium and/ or 
vitamin D!
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Drug’ field/ ‘group’: 
• ‘supplement’ for criterion 1 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ and table ‘CLY OS’ (was 
created in Criterion 3, Step 2) 
Link tables via ‘patientKey’ 
Apply ‘patientKey’, osteoporosis [1] (Table ‘CLY 
OS’) and d1 [not like “0”] (‘tbl_temp’) 
Run query 2 (query ‘CLY OS on supplement’) 
 
 
 
Step 5  
!
Identify patients 
with a diagnosis 
of osteoporosis 
and not treated 
bisphosphonates, 
raloxifene, 
strontium ranelate 
or calcitonin who 
are prescribed 
>=1000 mg 
calcium 800 IU 
vitamin D per day!
!
 
Create new query by using ‘design view’ 
Select table ‘Criterion 9 search including 
ibandronic acid’ and query ‘CLY OS on 
supplement’ 
Link tables via ‘patientKey’ 
Apply ‘patientKey’ (table ‘Criterion 9 search 
including ibandronic acid’) and d1, c2, c3, d2 
Run query 3 (query ‘Criterion 9 Yes Results’) 
Export data to Microsoft Excel® and check 
manually if the correct dose is prescribed.  
! only calcium is prescribed or only vitamin d 
is prescribed or the wrong dose is 
prescribed= No(U) 
! the correct dose is prescribed= Yes 
! documented date is not clear concerning 
dose, preparation, frequency= IDS 
 
 
Step 6  
!
Identify patients 
with a diagnosis 
of osteoporosis 
and not treated 
bisphosphonates, 
raloxifene, 
strontium ranelate 
or calcitonin who 
are not 
prescribed 
>=1000 mg 
calcium 800 IU 
vitamin d per day!
 
Create new query by using ‘Find Unmatched 
Query Wizard’ 
Select table ‘Criterion 9 Search including 
ibandronic acid’ 
Press ‘next’ 
Select queries/ query ‘Criterion 9 Yes Results’ 
Press ‘next’ 
Link tables via ‘patientKey’ 
Press ‘next’ 
Select ‘patientKey’ 
Press ‘next’ 
! Number additional No results= No(U) as 
there is no justification for not prescribing 
calcium and or vitamin d in this case or 
prescribing it in another dose 
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CRITERION 10-SEARCH 1 (excluding ibandronic acid and 
zoledronic acid because they are not included in the guidelines) 
 
Step What? How? 
 
Step 1 
!
Identify patients with a diagnosis 
of osteoporosis who are 
prescribed an oral 
bisphosphonate (alendronic 
acid, disodium etidronate, 
risedronate sodium) as first-line 
therapy  
 
Drugs containing oral 
bisphosphonates are the following: 
Alendronic acid (Fosamax®, 
Fosavance®), disodium etidronate 
(Didronel PMO®), risedronate 
sodium (Actonel®) 
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select !
! ‘Bisphosphonate’ for 
criterion 1!
! ‘Osteoporosis’ for 
criterion 2 
! ‘raloxifene’ for criterion 
3 
! ‘strontium ranelate’ for 
criterion 4 
! ‘calcitonin’ for criterion 
5 
! ‘teriparatide’ for 
criterion 6 
Sort patients by 
‘osteoporosis’ 
Delete patients who are not 
osteoporotic (0) 
Sort patients by each 
treatment  
Delete patients who are not 
receiving any treatment (0) 
Export results to Microsoft 
Excel® 
Inspect on results, focus on 
the date:identify patients who 
were prescribed a 
bisphosphonate at first 
 
 
 
Patient with a recorded diagnosis of osteoporosis!
Is prescribed an oral bisphosphonate as first-line therapy 
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CRITERION 10-SEARCH 2 (including ibandronic acid and 
zoledronic acid because they are authorized by BNF but not by the 
guidelines) 
 
Step What? How? 
 
Step 1 
!
Identify patients with a diagnosis 
of osteoporosis who are 
prescribed an oral 
bisphosphonate (alendronic 
acid, disodium etidronate, 
risedronate sodium) as first-line 
therapy  
 
Drugs containing oral 
bisphosphonates are the following: 
Alendronic acid (Fosamax®, 
Fosavance®), disodium etidronate 
(Didronel PMO®), risedronate 
sodium (Actonel®) 
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select !
! ‘ibandro+zoledro’ for 
criterion 1!
! ‘Osteoporosis’ for 
criterion 2 
! ‘raloxifene’ for criterion 
3 
! ‘strontium ranelate’ for 
criterion 4 
! ‘calcitonin’ for criterion 
5 
! ‘teriparatide’ for 
criterion 6 
Sort patients by 
‘osteoporosis’ 
Delete patients who are not 
osteoporotic (0) 
Sort patients by each 
treatment  
Delete patients who are not 
receiving any treatment (0) 
Export results to Microsoft 
Excel® 
Inspect on results, focus on 
the date:identify patients who 
were prescribed a 
bisphosphonate at first 
Patient with a recorded diagnosis of osteoporosis!
Is prescribed an oral bisphosphonate as first-line therapy 
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Add results from search 1 
Change number of 
applicable patients 
 
 
CRITERION 11- SEARCH 1 (excluding ibandronic acid and 
zoledronic acid because they are not included in the guidelines) 
 
Step What? How? 
 
Step 1 
!
Identify patients with a diagnosis 
of osteopenia who are 
prescribed an oral 
bisphosphonate (alendronic 
acid, disodium etidronate, 
risedronate sodium) as first-line 
therapy  
 
Drugs containing oral 
bisphosphonates are the following: 
Alendronic acid (Fosamax®, 
Fosavance®), disodium etidronate 
(Didronel PMO®), risedronate 
sodium (Actonel®) 
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select !
! ‘Bisphosphonate’ for 
criterion 1!
! ‘Osteopenia’ for 
criterion 2 
! ‘raloxifene’ for criterion 
3 
! ‘strontium ranelate’ for 
criterion 4 
! ‘calcitonin’ for criterion 
5 
! ‘teriparatide’ for 
criterion 6 
Sort patients by ‘osteopenia’ 
Delete patients who are not 
osteopenic (0) 
Sort patients by each 
treatment  
Delete patients who are not 
Patient with a recorded diagnosis of osteopenia!
Is prescribed an oral bisphosphonate as first-line therapy 
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receiving any treatment (0) 
Export results to Microsoft 
Excel® 
Inspect on results, focus on 
the date:identify patients who 
were prescribed a 
bisphosphonate at first 
 
 
 
CRITERION 11- SEARCH 2 (including ibandronic acid and 
zoledronic acid because they are authorized by BNF but not by the 
guidelines) 
 
Step What? How? 
 
Step 1 
!
Identify patients with a diagnosis 
of osteopenia who are 
prescribed an oral 
bisphosphonate (alendronic 
acid, disodium etidronate, 
risedronate sodium) as first-line 
therapy  
 
Drugs containing oral 
bisphosphonates are the following: 
Alendronic acid (Fosamax®, 
Fosavance®), disodium etidronate 
(Didronel PMO®), risedronate 
sodium (Actonel®) 
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select !
! ibandro+zoledro’ for 
criterion 1!
!  ‘Osteopenia’ for 
criterion 2 
! ‘raloxifene’ for criterion 
3 
! ‘strontium ranelate’ for 
criterion 4 
! ‘calcitonin’ for criterion 
5 
! ‘teriparatide’ for 
criterion 6 
Sort patients by ‘osteopenia’ 
Delete patients who are not 
osteopenic (0) 
Sort patients by each 
treatment  
Patient with a recorded diagnosis of osteopenia!
Is prescribed an oral bisphosphonate as first-line therapy 
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Delete patients who are not 
receiving any treatment (0) 
Export results to Microsoft 
Excel® 
Inspect on results, focus on 
the date:identify patients who 
were prescribed a 
bisphosphonate at first 
 
Add results from search 1 
Change number of 
applicable patients 
 
 
CRITERION 12- SEARCH 1 (excluding ibandronic acid and 
zoledronic acid because they are not included in the guidelines) 
 
Step What? How? 
 
Step 1 
!
Identify patients  who are prescribed 
bisphosphonates (alendronic acid, 
disodium etidronate, risedronate 
sodium)  
 
Drugs containing bisphosphonates are the 
following: 
Alendronic acid (Fosamax®, Fosavance®), 
disodium etidronate (Didronel PMO®), 
risedronate sodium (Actonel®) 
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select !
! ‘Bisphosphonates’ for 
criterion 1!
!  ‘Contraindication to 
bisphosphonates’ for 
criterion 2 
! ‘inab to compl with 
instr bp’ for criterion 3 
! ‘unsatisfact response 
to bp’ for criterion 4 
! ‘intol to bp’ for criterion 
5  
Patient who is prescribed a bisphosphonate!
has no reason on record to avoid bisphosphonate 
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Step 2 Identify patients with reasons to avoid 
bisphosphonates  
 
Reasons to avoid bisphosphonates: 
 
o contraindication to bisphosphonate (see 10) 
$ Oesophageal strictures and 
achalasia 
$ Inability to remain upright for > 30 
min after ingestion 
$ Hypocalcaemia 
$ Osteomalacia (etidronate) 
$ Moderate renal impairment (CrCl < 
35 mL/min) 
$ Pregnancy and breast feeding 
o inability to comply with the instruction for use of 
bisphosphonates: (see 17) 
$ ingestion on an empty stomach 
$ washing the medication down with 
250 ml water 
$ avoidance of food for 30 min 
$ avoidance of lying flat within 30 min 
of ingestion 
o unsatisfactory response to bisphosphonates 
(another fracture occurs, decrease in BMD 
despite adherence to treatment) 
intolerance to bisphosphonates (oesophageal 
ulceration, erosion or stricture, severe lower GI 
symptoms)!
Sort by ‘Bisphosphonates’ 
Delete patients who do not 
receive bisphosphonate(0) 
Exclude patients with reasons 
to avoid bisphosphonates 
(Mauck and Clarke 2006)! 
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CRITERION 12- SEARCH 2 (including ibandronic acid and 
zoledronic acid because they are authorized by BNF but not by the 
guidelines) 
 
Step What? How? 
 
Step 1 
!
Identify patients  who are prescribed 
bisphosphonates (alendronic acid, 
disodium etidronate, risedronate 
sodium)  
 
Drugs containing bisphosphonates are 
the following: 
Alendronic acid (Fosamax®, Fosavance®), 
disodium etidronate (Didronel PMO®), 
risedronate sodium (Actonel®) 
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select !
! ‘Ibandro+ Zoledro’ for 
criterion 1!
!  ‘Contraindication to 
bisphosphonates’ for 
criterion 2 
! ‘inab to compl with 
instr bp’ for criterion 3 
! ‘unsatisfact response 
to bp’ for criterion 4 
! ‘intol to bp’ for criterion 
5 
 
 
Step 2 Identify patients with reasons to avoid 
bisphosphonates  
 
Reasons to avoid bisphosphonates: 
 
o contraindication to bisphosphonate (see 10) 
$ Oesophageal strictures and 
achalasia 
$ Inability to remain upright for > 
30 min after ingestion 
$ Hypocalcaemia 
$ Osteomalacia (etidronate) 
$ Moderate renal impairment (CrCl 
< 35 mL/min) 
$ Pregnancy and breast feeding 
o inability to comply with the instruction for use 
of bisphosphonates: (see 17) 
$ ingestion on an empty stomach 
$ washing the medication down 
with 250 ml water 
Sort by ‘Ibandro+ Zoledro’ 
Delete patients who do not 
receiveibandronic acid or 
zoledronic acid (0) 
Exclude patients with 
reasons to avoid 
bisphosphonates (Mauck and 
Clarke 2006)! 
 
Add results from search 1 
Change number of 
applicable patients 
Patient who is prescribed a bisphosphonate!
has no reason on record to avoid bisphosphonate 
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$ avoidance of food for 30 min 
$ avoidance of lying flat within 30 
min of ingestion 
o unsatisfactory response to bisphosphonates 
(another fracture occurs, decrease in BMD 
despite adherence to treatment) 
intolerance to bisphosphonates (oesophageal 
ulceration, erosion or stricture, severe lower GI 
symptoms)!
 
 
CRITERION 13 
 
Step What? How? 
 
Step 1 
 
Prepare for 
identifying main 
patient groups 
(female+ 
osteoporosis, 
postmenopausal+ 
osteoporosis, 
postmenopausal+ 
osteopenia, male+ 
osteoporosis) 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
! ‘Postmenopausal’ for criterion 1 !
! ‘Osteoporosis’ for criterion 2 
! ‘Osteopenia’ for criterion 3 
! ‘Female’ for criterion 4 
! ‘Male’ for criterion 5!
Press ‘view’ 
 
 
 
Step 2 
 
Identify female 
patients with a 
diagnosis of 
osteoporosis and 
create a table in 
Microsof Access® 
containing these 
patients 
 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c4 [1], c2 [1] 
Run and save query 1 (‘Female Osteoporosis’) 
Select ‘File’, ‘Export’ to Microsoft Excel® by 
following the process. Name document ‘Female 
OS’ 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel®document ‘Female 
OS’and rename field c4 to ‘female’ and c2 to 
‘Osteoporosis’ (table ‘Female Osteoporosis’) 
A patient receiving treatment for osteoporosis/ osteopenia!
is prescribed a standard dose regimen!
The implementation of a pharmaceutical care tool to guide community pharmacy interventions in osteoporosis !
!182 
 
 
 
Step 3 
 
Identify 
postmenopausal  
patients with a 
diagnosis of 
osteoporosis and 
create a table in 
Microsoft Access® 
containing these 
patients 
 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1 [1], c2 [1] 
Run and save query 2 (‘postmenopausal 
osteoporosis’) 
Select ‘File’, ‘Export’ to Microsoft Excel® by 
following the process. Name document 
‘Postmenopausal OS’ 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel®document 
‘Postmenopausal OS’and rename field c1 to 
‘postmenopausal’ and c2 to ‘Osteoporosis’  
(table ‘Postmenopausal Osteoporosis’)  
 
Step 4 
 
Identify 
postmenopausal  
patients with a 
diagnosis of 
osteopenia and 
create a table in 
Microsoft Access® 
containing these 
patients 
 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1 [1], c3 [1] 
Run and save query 3 (‘Postmenopausal 
Osteopenia’) 
Select ‘File’, ‘Export’ to Microsoft Excel® by 
following the process.  
Name document ‘Postmenopausal ON’ 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel®document 
‘Postmenopausal ON’ and rename field c1 to 
‘postmenopausal’ and c3 to ‘osteopenia’ (table 
‘Postmenopausal Osteopenia’)  
 
Step 5 
 
Identify male 
patients with a 
diagnosis of 
osteoporosis and 
create a table in 
Microsof Access® 
containing these 
patients 
 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c5 [1], c2 [1] 
Run and save query 4 (‘male osteoporosis’) 
Select ‘File’, ‘Export’ to Microsoft Excel® by 
following the process.  
Name document ‘Male OS’ 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel® document ‘Male OS’ and 
rename field c5 to ‘Male’ and c2 to ‘Osteoporosis’ 
(table ‘Male Osteoporosis’) 
  
 
Step 6 
!
Identify patients 
prescribed daily 2g 
PO strontium 
ranelate   
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘drug’ field/ ‘group’: 
! ‘Strontium ranelate’ for criterion 1!
Press ‘view’ 
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Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1 [not like “0”], d1, c2, d2, 
c3 
Run query 5 (query ‘Patient prescribed 
strontium ranelate’) 
Export data to Microsoft Excel®and check 
manually if they are prescribed 2g PO daily.  
Create new query by using design view 
Select table ‘Postmenopausal Osteoporosis’ 
and query ‘Patient prescribed strontium 
ranelate’ 
Link tables via ‘patientKeys’ 
Apply patient keys 
Run query 6 
Apply ‘patientKey’  
! prescribed 2g PO daily and 
postmenopausal woman with 
osteoporosis= Yes 
! not prescribed 2g PO daily or not 
postmenopausal woman with 
osteoporosis= No(U) 
! recorded data not clear=IDS 
! No(J)=0… there is no justification for 
prescribing another dose or prescribing 
to another patient group 
 
 
Step 7 
!
Identify patients 
prescribed daily 
60mg PO raloxifene  
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘drug’ field/ ‘group’: 
! ‘Raloxifene’ for criterion 1 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1 [not like “0”], d1, c2, d2, 
c3 
Run query 7 (query ‘Patient prescribed 
raloxifene’) 
Export data to Microsoft Excel®and check 
manually if they are prescribed 60mg PO daily.  
Create new query by using ‘design view’ 
Select table ‘Postmenopausal Osteoporosis’ 
and query ‘Patient prescribed raloxifene’ 
Link tables via ‘patientKey’ 
Apply ‘patientKey’ 
Run query 8 
! prescribed 60mg PO daily and 
postmenopausal woman with 
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osteoporosis= Yes 
! not prescribed 60mg PO daily or not 
postmenopausal woman with 
osteoporosis= No(U) 
! recorded data not clear=IDS 
 
 
Step 8 
!
Identify patients 
prescribed 
teriparatide (20 
micrograms daily, 
for a maximum 
duration of 
treatment of 18 
months) 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘drug’ field/ ‘group’: 
! ‘Teriparatide’ for criterion 1 
Press ‘view’ 
Create new query by using ‘design view’ 
Select tbl_temp 
Apply ‘patientKey’, c1 [not like “0”], d1, c2, d2, 
c3 
Run Query 9 (Query ‘Patient prescribed 
teriparatide’) 
Export data to Microsoft Excel®and check 
manually if they are prescribed 20 micrograms 
daily, for a maximum duration of treatment of 
18 months.  
Create new query by using design view 
Select Table ‘Patients: NHS Read codes_QOF 
and MAT data items_tbl’ and Query ‘Patient 
prescribed teriparatide’ 
Link tables via patient keys 
Apply ‘patient keys’ and ‘mat data item’ [male] 
Run Query 10 
! prescribed 20 micrograms daily, for a 
maximum duration of treatment of 18 
months and not male = Yes 
! not prescribed 20 micrograms daily, for a 
maximum duration of treatment of 18 
months or male= No(U) 
! recorded data not clear=IDS 
 
 
Step 9 
!
Identify patients 
prescribed 
calcitonin (200 units 
daily intranasally)!
 
Use form ‘Query maker’ in Microsoft Access® 
Select in drug field/ group: 
! Calcitonin for criterion 1 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1 [not like “0”], d1, c2, d2, 
c3 
Run query 11 (query ‘Patient prescribed 
calcitonin’) 
Export data to Microsoft Excel®and check 
manually if they are prescribed 200 units 
intranasally.  
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Create new query by using ‘design view’ 
Select table ‘Postmenopausal Osteoporosis’ 
and query ‘Patient prescribed calcitonin’ 
Link tables via ‘patientKey’ 
Apply ‘patientKey’ 
Run query 12 
! prescribed 200 units intranasally and 
postmenopausal woman with 
osteoporosis= Yes 
! not prescribed 200 units intranasally or 
not postmenopausal woman with 
osteoporosis= No(U) 
! recorded data not clear=IDS 
 
Step 10  
!
Identify patients 
prescribed  a 
standard dose 
regimen for 
bisphophonates!
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘drug’ field/ ‘group’: 
! BP 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ and ‘Patients: NHS Read 
codes_QOF and MAT data items_tbl’ 
Apply ‘patientKey’, c1, c2, c3,d3 (‘tbl_temp’) 
and mat data item [male] (table ‘Patients: NHS 
Read codes_QOF and MAT data items_tbl’) 
Run query 13 
Export results to Microsoft Excel® and check 
manually if patients are prescribed the correct 
dose regimen: 
! Alendronic acid: 10mg po. Justification 
for not being prescribed 
10mg:glucocorticoid induced 
osteoporosis and prescribed 5mg po 
! Disodium etidronate: 400mg for 14 days 
PO, 1.25g calcium carbonate for 76 days 
PO (only if glucocorticoid induced 
osteoporosis) 
! Risedronate sodium 5mg daily PO (only 
if glucocorticoid induced osteoporosis) 
 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ and ‘Patients: NHS Read 
codes_QOF and MAT data items_tbl’ 
Apply ‘patientKey’, c1, c2, c3,d3 (‘tbl_temp’) 
and mat data item [female] (table ‘Patients: 
NHS Read codes_QOF and MAT data 
items_tbl’) 
Run query 14 
Export results to Microsoft Excel® and check 
manually if patients are prescribed the correct 
dose regimen: 
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! Alendronic acid: 10mg po daily, or 70 mg 
one weekly PO. Justification for not 
being prescribed 10mg or 70 mg once 
weekly PO: glucocorticoid induced 
osteoporosis or osteopenia and 
prescribed 5mg PO. 
! Disodium etidronate: 400mg for 14 days 
PO, 1.25g calcium carbonate for 76 days 
PO  
! Risedronate sodium 5mg daily PO or 35 
mg weekly PO (only if osteoporosis) 
Count only one result per patient. Delete 
results for ibandronic acid. 
 
CRITERION 14- SEARCH 1 (excluding ibandronic acid and 
zoledronic acid because they are not included in the guidelines) 
 
Step What? How? 
 
Step 1 
 
Drugs containing 
bisphosphonates are the 
following: 
 
Alendronic acid (Fosamax®, 
Fosavance®), disodium 
etidronate (Didronel PMO®), 
risedronate sodium (Actonel®) 
 
 
Use form ‘Query maker’ in Microsoft 
Access® 
Select in ‘Read Code’ field 
! ‘Bisphosphonate’ for criterion 
1 
! ‘BP (A)’ for criterion 2 
Press ‘view’ 
Delete patients who are not 
prescribed a bisphosphonate (0)  
Sort patients by alendronate 
Export results to Excel® 
 
 
 
 
 
Patient when started on bisphosphonate therapy!
Was initiated on alendronate 
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CRITERION 14- SEARCH 2 (including ibandronic acid and 
zoledronic acid because they are authorized by BNF but not by the 
guidelines) 
 
Step What? How? 
 
Step 1 
 
Drugs containing 
bisphosphonates are the 
following: 
 
Alendronic acid (Fosamax®, 
Fosavance®), disodium 
etidronate (Didronel PMO®), 
risedronate sodium (Actonel®) 
 
 
Use form ‘Query maker’ in Microsoft 
Access® 
Select in ‘Read Code’ field 
! ‘Bisphosphonate’ for criterion 
1 
! ‘BP (I)’ for criterion 2 
! ‘BP (A) for criterion 3 
Press ‘view’ 
Delete patients who are not 
prescribed a bisphosphonate (0)  
Sort patients by alendronate 
Export results to Excel® 
 
 
 
 
 
 
 
 
 
 
 
A patient with osteoporosis and NOT prescribed any of the following: 
bisphosphonates, raloxifene, strontium ranelate or calcitonin!
has a recorded contraindication to each agent (see below(!
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CRITERION 15 
 
Step What? How? 
 
Step 1 
!
A postmenopausal woman 
diagnosed with 
osteoporosis/osteopenia 
and not treated with 
alendronate isprescribed 
risedronate 
!
 
 
Use form ‘Query maker’ in Microsoft 
Access® 
! Select in ‘Read Code’ field 
‘postmenopausal’ for criterion 1 !
! ‘Osteoporosis’ for criterion 2!
! ‘Osteopenia’ for criterion 3!
! ‘BP(A)’  for criterion 4 !
! ‘BP(R)’  for criterion 5   !
Press ‘view’ 
!
Sort  patients by ‘postmenopausal’ 
Delete patients who are not 
postmenopausal (0) 
Delete patients who are not 
osteoporotic/ osteopenic (0) 
Sort patients by ‘BP(A)’ 
Delete patients who are receiving 
alendronic acid  
Sort patients by ’BP(R)’ 
Patients receiving risedronate  = YES!
 
 
 
 
 
 
A postmenopausal woman diagnosed with osteoporosis/osteopenia and not 
treated with alendronate!
Is prescribed risedronate 
The implementation of a pharmaceutical care tool to guide community pharmacy interventions in osteoporosis !
!189 
CRITERION 16 
 
Step What? How? 
 
Step 1 
!
Identify 
postmenopausal 
women with " 2 
vertebral 
fractures and 
NOT treated with 
alendronate or 
risedronateare 
prescribed 
intermittent 
cyclical etidronate 
!
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
! ‘postmenopausal’ for criterion 1 
! ‘vertebral fractures’ for criterion 2 
! ‘BP(A)’ for criterion 3 
! ‘BP(R)’ for criterion 4 
! ‘BP (E+ca)’ for criterion 5 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1 [1], c2 [1], c3 [0], c4 [0], c5 
Run query 1 
Export results to Microsoft Excel® 
Check manually(in table ‘Patients: NHS Read 
codes_QOF and MAT data items_tbl’) if patients 
have records for 2 or more vertebral fractures and 
note those patients.  
Delete patients who have less than 2 vertebral 
fractures.  
 
 
 
 
 
 
 
 
 
 
Postmenopausal women with " 2 vertebral fractures and NOT treated with 
alendronate or risedronate!
Are prescribed intermittent cyclical etidronate 
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CRITERION 17- SEARCH 1 (excluding ibandronic acid and 
zoledronic acid because they are not included in the guidelines) 
 
 
Step What? How? 
 
Step 1 
!
Identify patients 
who are on long-
term 
glucocorticoid 
therapy  and 
prescribed a 
bisphosphonate!
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
! ‘long-term steroid’ for criterion 1 
! ‘bisphosphonates’ for criterion 2 
Press ‘view’ 
Sort patients by ‘long-term steroids’ 
Delete patients who do not receive a long-term 
treatment with steroids (0) 
Export results to Microsoft Excel 
Inspect on ‘Bisphosphonates’ column: 
! ‘1’= YES 
! ‘0’= NO (possible justification: see criterion 
12 ‘reasons to avoid bisphoshonates) 
 
 
 
 
 
 
 
 
 
 
 
 
Patient who is on long-term glucocorticoid therapy (" 7.5 mg prednisolone or 
equivalents for " 3 months)!
Is prescribed a bisphosphonate 
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CRITERION 17- SEARCH 2 (including ibandronic acid and 
zoledronic acid because they are authorized by BNF but not by the 
guidelines) 
 
Step What? How? 
 
Step 1 
!
Identify patients 
who are on long-
term 
glucocorticoid 
therapy  and 
prescribed a 
bisphosphonate!
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
! ‘long-term steroid’ for criterion 1 
! ‘bisphosphonates’ for criterion 2 
! ‘Ibandro + Zoledro’ for criterion 3 
Press ‘view’ 
Sort patients by ‘long-term steroids’ 
Delete patients who do not receive a long-term 
treatment with steroids (0) 
Export results to Microsoft Excel 
Inspect on ‘Bisphosphonates’ column and 
‘Ibandro + Zoledro’ column: 
! ‘1’= YES 
! ‘0’= NO (possible justification: see criterion 
12 ‘reasons to avoid bisphoshonates) 
 
 
 
 
 
 
 
 
 
 
 
 
Patient who is on long-term glucocorticoid therapy (" 7.5 mg prednisolone or 
equivalents for " 3 months)!
Is prescribed a bisphosphonate 
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CRITERION 18 
 
 
 
Step What? How? 
 
Step 1 
!
Identify 
postmenopausal 
women diagnosed 
with osteoporosis 
requiring treatment 
for primary 
prevention of 
fractures!
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
! ‘postmenopausal’ for criterion 1!
! ‘osteoporosis’ for criterion 2!
! ‘ All fractures’ for criterion 3!
! ‘strontium ranelate’ for criterion 4!
Press ‘view’ 
Sort patients by ‘postmenopausal’!
Delete those who are not postmenopausal (0)!
Delete patients who are not osteoporotic (0)!
Delete patients with records of fractures !
Export results to Microsoft Excel and import 
document again to create a table (table 
‘Criterion 18 step 1’) 
 
Step 2 Identify 
postmenopausal 
women diagnosed 
with osteoporosis 
requiring treatment 
for primary 
prevention of 
fractures!
who have an 
identifiable reason 
for not being 
prescribed a 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
! Contraindication to bisphosphonates’ 
for criterion 1 
! ‘inab to compl with instr bp’ for criterion 
2 
! ‘intol to bp’ for criterion 3 
Press ‘view’ 
Create a new query by using ‘design view’ 
Link table ‘Criterion 18 step 1’ to ‘tbl_temp’ via 
‘patientKeys’ 
Apply ‘patientKey’, c1, c2, c3 (table ‘Criterion 
A postmenopausal woman diagnosed with osteoporosis requiring treatment for 
primary prevention of fractures who has an identifiable reason for not being 
prescribed a bisphosphonate $
is prescribed strontium ranelate. 
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bisphosphonate and 
are prescribed 
strontium ranelate!
!
18 step 1’) and c1, c2 (‘tbl_temp’) 
Run query 1 
Sort ‘Contraindications to bisphosphonates’ 
Delete patients with no contraindication (0) 
Sort by ‘inab to compl with instr bp’ 
Delete patients with (0) recorded 
Sort by ‘intol to bp’ 
Delete patients with (0) recorded 
Check if remaining patients are prescribed 
strontium ranelate 
 
 
CRITERION 19 
 
Step What? How? 
Step 1 Identify 
postmenopausal 
women diagnosed 
with osteoporosis with 
at least one 
osteoporotic fracture$
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
! ‘postmenopausal’ for criterion 1 
! ‘Osteoporosis’ for criterion 2 
! ‘osteoporotic fractures’ for criterion 3 
! ‘strontium ranelate’ for criterion 4 
! ‘raloxifene’ for criterion 5 
Press ‘view’ 
Sort patients by ‘postmenopausal’ 
Delete patients who are not postmenopausal 
(0) 
Sort patients by ‘Osteoporosis’ 
A postmenopausal woman diagnosed with osteoporosis with at least one 
osteoporotic fracture who has an identifiable reason for not being prescribed a 
bisphosphonate (see below)$
Isprescribed  strontium ranelateor raloxifene 
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Delete patients who are not osteoporotic (0) 
Sort patients by ‘osteoporotic fracture’ 
Delete patients without an osteoporotic 
fracture (0) 
Export results to Microsoft Excel and import 
document again to create a table (table ‘ 
Criterion 19 Step 1’) 
 
Step 2 Identify 
postmenopausal 
women diagnosed 
with osteoporosis with 
at least one 
osteoporotic fracture$
!
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
! ‘Contraindication to bisphosphonates’ 
for criterion 1 
! ‘inab to compl with instr bp’ for 
criterion 2 
! ‘intol to bp’ for criterion 3 
Press ‘view’ 
Create a new query by using ‘design view’ 
Link table ‘Criterion 19 step 1’ to ‘tbl_temp’ 
via ‘patientKey’ 
Apply ‘patientKey’, c1, c2, c3 (table ‘Criterion 
19 step 1’) and c1, c2, c3, c4, c5 (‘tbl_temp’) 
Run query 1 
Sort ‘Contraindications to bisphosphonates’ 
Delete patients with no contraindication (0) 
Sort by ‘inab to compl with instr bp’ 
Delete patients with (0) recorded 
Sort by ‘intol to bp’ 
Delete patients with (0) recorded 
Check if remaining patients are prescribed 
strontium ranelate or raloxifene 
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CRITERION 20 
 
 
Step What? How? 
 
Step 1 
Identify patients prescribed 
teriparatide!
Identify postmenopausal 
women diagnosed with 
osteoporosis with at 
lleastoneosteoporotic fracture 
among patients prescribed 
teriparatide!
Identify whether remaining 
patients present a reason to 
avoid bisphosphonates and 
strontium ranelate and are at 
the required age and present 
the required T-Score as 
indicated above  
 
 
 
Postmenopausal woman diagnosed with osteoporosis and at least one 
osteoporotic fracture!
who has either!
o a reason to avoid bisphosphonates !
o a contraindication to strontium ranelate !
$ pregnancy!
$ breast feeding!
o an intolerance to strontium ranelate!
$ persistent nausea!
$ persistent diarrhoea!
and who is either!
o aged " 65 years with a T-Score # -4 SD!
o aged " 65 years with a T-Score # -3.5 SD and has more than two 
fractures!
o aged 55-64 years with a T-Score # -4 SD and has more than two 
fractures!
!
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CRITERION 21- SEARCH 1(including ibandronic acid and 
zoledronic acid because they are authorized by BNF but not by the 
guidelines) 
 
Step What? How? 
Step 1 Identify postmenopausal 
women with a diagnosis of 
osteoporosis and at least 
one vertebral fracture who 
are prescribed calcitonin$
 
Use form ‘Query maker’ in Microsoft 
Access® 
Select in ‘Read Code’ field: 
! ‘postmenopausal’ for criterion 1 
! ‘Osteoporosis’ for criterion 2 
! ‘osteoporotic fractures’ for 
criterion 3 
! ‘Bisphosphonate’ for criterion 4 
! ‘strontium ranelate’ for criterion 5 
! ‘calcitonin’ for criterion 6 
Press ‘view’ 
 
Delete patients who are not 
postmenopausal (0) 
Delete patients who are not osteoporotic 
(0) 
Delete patients without fractures (0) 
Delete patients who are receiving a 
bisphosphonate, raloxifene, strontium 
ranelate or teriparatide (Mauck and 
Clarke 2006) 
Sort remaining patients by ‘calcitonin’ 
Export results to Microsoft Excel® 
 
Use form ‘Query maker’ in Microsoft 
Access® 
Select in ‘Read Code’ field: 
! ‘postmenopausal’ for criterion 1 
A postmenopausal woman diagnosed with osteoporosis and with at least one 
vertebral fracture; NOT treated with a bisphosphonate, raloxifene, strontium 
ranelate or teriparatide!
Is prescribed calcitonin)!
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! ‘Osteoporosis’ for criterion 2 
! ‘osteoporotic fractures’ for 
criterion 3 
! ‘Bisphosphonate’ for criterion 4 
! ‘raloxifene’ for criterion 5 
! ‘teriparatide’ for criterion 6 
Press ‘view’ 
 
Delete patients who are not 
postmenopausal (0) 
Delete patients who are not osteoporotic 
(0) 
Delete patients without fractures (0) 
Delete patients who are receiving a 
bisphosphonate, raloxifene, strontium 
ranelate or teriparatide (Mauck and 
Clarke 2006) 
Sort remaining patients by ‘calcitonin’ 
Export results to Microsoft Excel® 
 
 
 
 
 
 
 
 
 
 
 
 
CRITERION 21- SEARCH 2 (excluding ibandronic acid 
andzoledronicacid because they are not included in the guidelines) 
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Step What? How? 
Step 1 Identify postmenopausal 
women with a diagnosis of 
osteoporosis and at least 
one vertebralfracture who 
are prescribed calcitonin$
 
Use form ‘Query maker’ in Microsoft 
Access® 
Select in ‘Read Code’ field: 
! ‘postmenopausal’ for criterion 1 
! ‘Osteoporosis’ for criterion 2 
! ‘osteoporotic fractures’ for 
criterion 3 
! ‘Bisphosphonate’ for criterion 4 
! ‘BP (I)’ for criterion 5 
! ‘strontium ranelate’ for criterion 6 
Press ‘view’ 
Delete patients who are not 
postmenopausal (0) 
Delete patients who are not osteoporotic 
(0) 
Delete patients without fractures (0) 
Delete patients who are receiving a 
bisphosphonate, raloxifene, strontium 
ranelate or teriparatide (Mauck and 
Clarke 2006) 
Sort remaining patients by ‘calcitonin’ 
Export results to Microsoft Excel® 
 
Use form ‘Query maker’ in Microsoft 
Access® 
Select in ‘Read Code’ field: 
A postmenopausal woman diagnosed with osteoporosis and with at least one 
vertebral fracture; NOT treated with a bisphosphonate, raloxifene, strontium 
ranelate or teriparatide!
Is prescribed calcitonin. 
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! ‘postmenopausal’ for criterion 1 
! ‘Osteoporosis’ for criterion 2 
! ‘osteoporotic fractures’ for 
criterion 3 
! ‘Bisphosphonate’ for criterion 4 
! ‘raloxifene’ for criterion 5 
! ‘teriparatide’ for criterion 6 
Press ‘view’ 
 
Delete patients who are not 
postmenopausal (0) 
Delete patients who are not osteoporotic 
(0) 
Delete patients without fractures (0) 
Delete patients who are receiving a 
bisphosphonate, raloxifene, strontium 
ranelate or teriparatide 
Sort remaining patients by ‘calcitonin’ 
Export results to Microsoft Excel® 
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APPENDIX 5: INTER RATER RELIABILITY TESTING PRACTICE A 
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Table 28 Inter-rater reliability testing Adherence 
Criterion 1 Student 1 Student 2 
Patient diagnosed with osteoporosis has a recorded DEXA scan. 
Not applicable 16 16 
Yes 77 77 
No(J) 6 6 
No(U) 55 55 
IDQ 0 0 
IDS 0 0 
Adherence% 58,33 58,33 
   
Criterion 2 Student 1 Student 2 
DXE scan is performed at two specific sites 
(anteroposterior spine and hip)     
Not applicable     
Yes 243 243 
No(J) 0 0 
No(U) 67 67 
IDQ 1 1 
IDS 6 6 
Adherence% 76,9 76,9 
   
Criterion 3 Student 1 Student 2 
Patient with osteoporosis is prescribed calcium and 
vitamin D.     
Not applicable 16 16 
Yes 76 76 
No(J) 0 0 
No(U) 62 62 
IDQ 0 0 
IDS 0 0 
Adherence% 55,07 55,07 
   
Criterion 4 Student 1 Student 2 
Patient with osteopenia is prescribed calcium and vitamin 
D.     
Not applicable 138 138 
Yes 9 9 
No(J) 0 0 
No(U) 7 7 
IDQ 0 0 
IDS 0 0 
Adherence% 56,25 56,25 
 .  
Criterion 5 Student 1 Student 2 
Patient with vitamin D deficiency or aged over 64 is 
prescribed vitamin D.     
Not applicable 30 31 
Yes 73 72 
No(J) 0 0 
No(U) 51 51 
IDQ 0 0 
IDS 0 0 
Adherence% 58,87 58,54 
   
Criterion 6 S1 Student 1 Student 2 
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Patient with osteoporosis NOT prescribed 
bisphosphonates, raloxifene, strontium ranelate, calcitonin 
or teriparatide has a contraindication to each agent.     
Not applicable 101 100 
Yes 0 0 
No(J) 0 0 
No(U) 53 54 
IDQ 0 0 
IDS 0 0 
Adherence% 0 0 
   
   
Criterion 6 S2 Student 1 Student 2 
      
Not applicable 101 101 
Yes 0 0 
No(J) 0 0 
No(U) 52 53 
IDQ 0 0 
IDS 0 0 
Adherence% 0 0 
   
Criterion 7 Student 1 Student 2 
Patient prescribed calcium is prescribed a daily dose of 
500-1500 mg.     
Not applicable 69 69 
Yes 84 84 
No(J) 0 0 
No(U) 1 1 
IDQ 0 0 
IDS 0 0 
Adherence% 98,82 98,82 
   
Criterion 8 Student 1 Student 2 
Patient prescribed vitamin D is prescribed a daily dose of 
400-800 IU.     
Not applicable 76 76 
Yes 77 77 
No(J) 0 0 
No(U) 1 1 
IDQ 0 0 
IDS 0 0 
Adherence% 98,72 98,72 
   
Criterion 9 S1 Student 1 Student 2 
Patient with osteoporosis and NOT prescribed 
bisphosphonates, raloxifene, stronium ranelate or 
calcitonin is prescribed >=1000 mg calcium plus 800 IU 
vitamin D per day.     
Not applicable 100 100 
Yes 10 11 
No(J) 0 0 
No(U) 43 42 
IDQ 0 0 
IDS 0 1 
Adherence% 18,52 20,37 
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Criterion 9 S2 Student 1 Student 2 
Not applicable 101 101 
Yes 10 11 
No(J) 0 0 
No(U) 42 41 
IDQ 0 0 
IDS 1 1 
Adherence% 18,87 20,75 
   
Criterion 10 S1 Student 1 Student 2 
Patient with osteoporosis is prescribed an oral 
bisphosphonate as first-line therapy.     
Not applicable 16 16 
Yes 81 81 
No(J) 0 0 
No(U) 57 57 
IDQ 0 0 
IDS 0 0 
Adherence% 58,7 58,7 
   
   
Criterion 10 S2 Student 1 Student 2 
Not applicable 16 16 
Yes 82 82 
No(J) 0 0 
No(U) 56 56 
IDQ 0 0 
IDS 0 0 
Adherence% 59,42 59,42 
   
Criterion 11 Bergmann Doblhammer 
Patient with osteopenia is prescribed an oral 
bisphosphonate as first-line therapy.     
Not applicable 138 138 
Yes 9 9 
No(J) 0 0 
No(U) 7 7 
IDQ 0 0 
IDS 0 0 
Adherence% 56,25 56,25 
   
Criterion 12 S1 Student 1 Student 2 
Patient prescribed a bisphosphonate has no reason to 
avoid them.     
Not applicable 63 63 
Yes 75 75 
No(J) 0 0 
No(U) 0 0 
IDQ 0 0 
IDS 16 16 
Adherence% 82,42 82,42 
   
Criterion 12 S2 Student 1 Student 2 
Not applicable 62 62 
Yes 75 75 
No(J) 0 0 
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No(U) 0 0 
IDQ 0 0 
IDS 14 14 
Adherence% 81,52 81,52 
   
Criterion 13 Student 1 Student 2 
Patient receiving osteoporosis/osteopenia treatment is 
prescribed a standard dose regimen.     
Not applicable 60 60 
Yes 81 84 
No(J) 0 0 
No(U) 10 10 
IDQ 0 0 
IDS 3 0 
Adherence% 86,17 89,36 
   
Criterion 14 S1 Student 1 Student 2 
Postmenopausal when started on bisphosphonate was 
initiated on alendronate.     
Not applicable 63 63 
Yes 79 79 
No(J) 0 0 
No(U) 12 12 
IDQ 0 0 
IDS 0 0 
Adherence% 86,81 86,81 
   
   
Criterion 14 S2 Student 1 Student 2 
Not applicable 62 62 
Yes 79 79 
No(J) 0 0 
No(U) 13 13 
IDQ 0 0 
IDS 0 0 
Adherence% 85,87 85,87 
   
Criterion 15 Student 1 Student 2 
Postmenopausal woman with osteoporosis/osteopenia and 
NOT treated with alendronate is prescribed risedronate.     
Not applicable 89 89 
Yes 8 8 
No(J) 0 0 
No(U) 57 57 
IDQ 0 0 
IDS 0 0 
Adherence% 12,31 12,31 
   
Criterion 16 Student 1 Student 2 
Postmenopausal woman with at least two vertebral 
fractures and NOT treated with alendronate or risedronate 
is prescribed intermittent cyclical etidronate.     
Not applicable 152 152 
Yes 0 0 
No(J) 0 0 
No(U) 2 2 
IDQ 0 0 
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IDS 0 0 
Adherence% 0 0 
   
Criterion 17 Student 1 Student 2 
Patient on long-term oral steroid therapy is prescribed a 
bisphosphonate.     
Not applicable no result no result 
Yes no result no result 
No(J) no result no result 
No(U) no result no result 
IDQ no result no result 
IDS no result no result 
Adherence% no result no result 
   
Criterion 18 Student 1 Student 2 
Postmenopausal woman with osteoporosis with a reason 
for not being prescribed a bisphosphonate is prescribed 
strontium ranelate.     
Not applicable 153 153 
Yes 0 0 
No(J) 0 0 
No(U) 1 1 
IDQ 18 20 
IDS 0 0 
adherent 0 0 
   
Criterion 19 Student 1 Student 2 
Postmenopausal woman with osteoporosis with at least 
one vertebral fracture and a reason for not being 
prescribed a bisphosphonate is prescribed strontium 
ranelate or raloxifene.     
Not applicable 153 153 
Yes 0 0 
No(J) 0 0 
No(U) 1 1 
IDQ 5 6 
IDS 0 0 
Adherence% 0 0 
   
   
Criterion 20 Student 1 Student 2 
Postmenopausal woman with osteoporosis and at least 
one vertebral fracture who has either a reason to avoid 
BPs OR an intolerance to strontium ranelate AND who is 
either older than 54 with a T-Score <= -4 SD OR older than 
64 with a T-Score <= - 3,5 and more than two fractures OR 
55-64 years with a T-Score <= - 4 SD and more than two 
fractures is prescribed teriparatide.     
Not applicable no result no result 
Yes no result no result 
No(J) no result no result 
No(U) no result no result 
IDQ no result no result 
IDS no result no result 
Adherence% no result no result 
   
Criterion 21 Student 1 Student 2 
Postmenopausal woman with osteoporosis, at least one     
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vertebral fracture and NOT treated with BPs, raloxifene or 
strontium ranelate is prescribed calcitonin. 
Not applicable 150 150 
Yes 0 0 
No(J) 0 0 
No(U) 4 4 
IDQ 0 0 
IDS 0 0 
Adherence% 0 0 
 
 
 
Table 29 Inter-rater reliability testing Applicability
Criterion Applicability 1 Applicability 2 Percentage of Discrepancy 
Percentage of 
Agreement 
1 40,2 40,2 0 100 
2 30,8 27,6 10,4 89,6 
3 50 50 0 100 
4 56,3 56,3 0 100 
5 59,1 58,8 0,5 99,5 
6 0 0 0 100 
7 99,2 99,2 0 100 
8 98,2 97,3 0,9 99,1 
9 22,6 23,5 3,8 96,2 
10 56 56 0 100 
11 56,3 56,3 0 100 
12 85,9 85,9 0 100 
13 82,1 84,1 2,4 97,6 
14 86,1 86,1 0 100 
15 12,4 12,4 0 100 
16 nr nr 0 100 
17 nr nr 0 100 
18 0 0 0 100 
19 0 0 0 100 
20 nr nr 0 100 
21 0 0 0 100 
  Mean% 0,86 99,14 
 
 
Table 30 Inter-rater reliability testing Yes-results 
 
Criterion Yes 1 Yes 2 Percentage of Discrepancy 
Percentage of 
Agreement 
1 78 78 0 100 
2 32 32 0 100 
3 100 100 0 100 
4 9 9 0 100 
5 101 100 1,0 99,0 
6 0 0 0 100 
7 118 118 0 100 
8 109 109 0 100 
9 19 20 5 95 
10 112 112 0 100 
11 9 9 0 100 
12 116 116 0 100 
13 119 122 2,5 97,5 
14 105 105 0 100 
15 12 12 0 100 
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16 0 0 0 100 
17 0 0 0 100 
18 0 0 0 100 
19 0 0 0 100 
20 0 0 0 100 
21 0 0 0 100 
Mean%   0,4 99,6 
 
 
 
 
 
 
Table 31 Inter-rater reliability testing Justified non-adherence 
 
Criterion No(J) 1 No(J) 2 Percentage of Discrepancy Percentage of Agreement 
1 6 6 0 100 
2 0 0 0 100 
3 0 0 0 100 
4 0 0 0 100 
5 0 0 0 100 
6 0 0 0 100 
7 0 0 0 100 
8 0 0 0 100 
9 0 0 0 100 
10 0 0 0 100 
11 0 0 0 100 
12 0 0 0 100 
13 0 0 0 100 
14 0 0 0 100 
15 0 0 0 100 
16 0 0 0 100 
17 0 0 0 100 
18 0 0 0 100 
19 0 0 0 100 
20 0 0 0 100 
21 0 0 0 100 
Mean%   0 100 
 
 
 
Table 32 Inter-rater reliability testing Unjustified non-adherence 
 
 
Criterion No(U) 1 No(U) 2 Percentage of Discrepancy Percentage of Agreement 
1 109 109 0 100 
2 56 56 0 100 
3 100 100 0 100 
4 7 7 0 100 
5 70 70 0 100 
6 84 85 1,2 98,8 
7 1 1 0 100 
8 3 3 0 100 
9 65 64 1,5 98,5 
10 88 88 0 100 
11 7 7 0 100 
12 0 0 0 100 
13 15 15 0 100 
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14 17 17 0 100 
15 85 85 0 100 
16 2 2 0 100 
17 0 0 0 100 
18 33 33 0 100 
19 1 1 0 100 
20 0 0 0 100 
21 9 9 0 100 
Mean%   0,1 99,9 
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APPENDIX 6: MAT DATA ITEMS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 33 MAT Data items 
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 Data item 
H/O: peptic ulcer Contraindications to bisphosphonates 
Oesophageal stricture or achalasia Contraindications to bisphosphonates 
Inability to remain upright for >30 min after 
ingestion 
Contraindications to bisphosphonates 
Hypocalcaemia Contraindications to bisphosphonates/calcitonin 
Osteomalacia (Etidronate) Contraindications to bisphosphonates 
Moderate renal impairment (CrCl < 35ml/min) Contraindications to bisphosphonates 
Pregnancy and breast feeding Contraindications to 
bisphosphonates/raloxifene/strontium ranelate 
DVT - Deep vein thrombosis Contraindication to raloxifene 
Liver function tests abnormal Contraindication to raloxifene 
Chronic liver disease NOS Contraindication to raloxifene 
[D]Abnormal liver function test Contraindication to raloxifene 
Dysfunctional uterine bleeding Contraindication to raloxifene 
[V] Personal history DVT- deep vein thrombosis Contraindication to raloxifene 
Chronic renal failure Contraindication to raloxifene 
Past and present venous thromboembolic events  Contraindication to raloxifene 
Hepatic impairment Contraindication to raloxifene 
Cholestasis Contraindication to raloxifene 
Severe renal impairment (CrCl<10ml/min) Contraindication to raloxifene 
Endometrial cancer Contraindication to raloxifene 
Pregnancy and breast feeding Contraindications to 
bisphosphonates/raloxifene/strontium ranelate 
Hypersensitivity Contraindications to strontium ranelate/calcitonin 
Hypocalcaemia Contraindications to bisphosphonates/calcitonin 
DEXA - Dual energy X-ray photon absorptiometry DEXA 
Dual energy X-ray photon absorptiometry DEXA 
Hip DXA scan DEXA 
Hip DXA scan result normal DEXA 
Hip DXA scan result osteopenic DEXA 
Hip DXA scan result osteoporotic DEXA 
Lumbar DXA scan DEXA 
Lumbar DXA scan result normal DEXA 
Lumbar DXA scan result osteopenic DEXA 
Lumbar DXA scan result osteoporotic DEXA 
Lumbar spine DXA scan DEXA 
Bone density scan DEXA IDS 
Body Mass Index low K/M Independent clinical risk factor/ indicator of low 
BMD 
Alcohol dependence syndrom Independent clinical risk factor/ indicator of low 
BMD 
Alcohol intake of 4 or more units per day Independent clinical risk factor/ indicator of low 
BMD  
H/O: rheumatoid arthritis Independent clinical risk factor/ indicator of low 
BMD 
Rheumatoid Arthritis Independent clinical risk factor/ indicator of low 
BMD 
Rheumatoid lung Independent clinical risk factor/ indicator of low 
BMD 
Irritable bowel syndrome Independent clinical risk factor/ indicator of low 
BMD 
Crohn’s disease Independent clinical risk factor/ indicator of low 
BMD 
BMI less than 22 kg/m2 Independent clinical risk factor/ indicator of low 
BMD 
Ankylosing spondylitis Independent clinical risk factor/ indicator of low 
BMD 
Parental history of hip fracture Independent clinical risk factor/ indicator of low 
BMD 
CKD follow-up Renal impairment IDS 
CKD Monitoring Defaulter Renal impairment IDS 
Chronic kidney disease stage 3 Renal impairment IDS 
Serum creatinine raised Renal impairment IDS 
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Renal Monitoring Defaulter Renal impairment IDS 
Vitamin D deficiency Vitamin D deficiency 
Oesophageal ulceration Intolerance to bisphosphonates 
Erosion or stricture Intolerance to bisphosphonates 
Severe lower GI symptoms Intolerance to bisphosphonates 
Persistent nausea Intolerance to strontium ranelate 
Persistent diarrhoea Intolerance to strontium ranelate 
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APPENDIX 7: INTERVIEW QUESTIONS 
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‘From a public health perspective, what are the challenges regarding osteoporosis?’ !
 
 
1 
 
Do you think that the population has sufficient knowledge about the disease and the risk 
factors? 
 
Is there enough information provided about the disease?  
Do you think that the community pharmacy is providing enough information? Is this done 
actively or passively through e.g. leaflets? Would more information encourage more people to 
refer themselves to a doctor for diagnosis? 
 
For better treatment of those already diagnosed, do you think an assessment of patients’ 
knowledge would help to improve the outcomes of treatment?  
 
 
2 
 
Do you think that there is enough awareness of the disease in the population?  
 
Is it already the subject of public health awareness campaigns? 
What can the public do for themselves to identify their vulnerability to the disease? 
Might it be worth it to mount a mass public health campaign like the one for smoking? Or to 
develop a special service for osteoporosis?  
If yes, what do you think pharmacists have to offer in such a campaign/service? 
Is there already such a service? 
 
 
3 
 
Do you think pharmacists are aware enough of the risk of osteoporosis to e.g. advise a patient 
who has been prescribed long-term oral steroid therapy that he/she should be considered for 
bisphosphonate therapy? 
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4 
 
How are people without diagnosis diagnosed? 
 
What do you think about the FRAX®? Do you use it? Do you think it is a helpful tool to identify 
candidates for primary prevention? Do you think it might be feasible to use it in community 
pharmacies for access to the public on a large scale? 
 
 
5 
 
Pharmacists provide dietary and smoking advice in general. 
 
Do you think they focus sufficiently on the connection between diet, smoking, exercise etc and 
osteoporosis? 
Do you think they currently give health education and health recommendations relevant to 
osteoporosis? 
 
 
6 
 
As the instructions for use of e.g. bisphosphonates are complicated but should be complied 
with, there is a recognised need to support medicines compliance for osteoporosis therapy. 
 
Do you think general medical practitioners provide sufficient help to target the problem of 
compliance in osteoporosis treatment? 
 
Do you think community pharmacists provide sufficient help to target the problem of 
compliance in osteoporosis treatment?  
 
Do you think they are aware enough of e.g. patients not taking the prescribed calcium? If no, 
might it be useful and feasible to create a standard procedure for patients receiving 
osteoporosis treatment in order to increase the numbers of compliant patients? 
 
 
7 
 
Falls in elderly people with osteoporosis are a major health problem and the effect of 
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concomitant medicines taken by a patient can increase the risk of falling.  
 
Do you think that community pharmacists can help to reduce the risk of falling by 
systematically reviewing a patient’s medication?  
 
 
8 
 
Do you think patients are aware of programmes such as the Home Falls Prevention 
Programme (HFPP) and local support groups?  
 
Do you think pharmacists give enough information about how to access these programmes 
and support groups?  
 
Do you think pharmacists themselves are sufficiently aware and active in these programmes? 
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Is adherence to clinical guidelines in osteoporosis treatment an important problem in your 
view? 
 
For patients diagnosed with osteoporosis and just started on bisphosphonate treatment 
 
a. Is there a follow up service through community pharmacies to monitor 
adherence to the guidelines? 
 
b. Is there a follow up service through community pharmacies to monitor patient 
compliance? 
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Do you think that there is a need for more collaboration between general practitioners and 
community pharmacists?  
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If yes, can you give any specific examples? 
 
Do you have any further comments? 
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